[go: up one dir, main page]

EP0450060A1 - Dna sequencing - Google Patents

Dna sequencing

Info

Publication number
EP0450060A1
EP0450060A1 EP19910900474 EP91900474A EP0450060A1 EP 0450060 A1 EP0450060 A1 EP 0450060A1 EP 19910900474 EP19910900474 EP 19910900474 EP 91900474 A EP91900474 A EP 91900474A EP 0450060 A1 EP0450060 A1 EP 0450060A1
Authority
EP
European Patent Office
Prior art keywords
dna molecule
complementary dna
incorporated
subject
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910900474
Other languages
German (de)
French (fr)
Inventor
Roger Y. Tsien
Pepi Ross
Margaret Fahnestock
Allan J. Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
Original Assignee
SRI International Inc
Stanford Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc, Stanford Research Institute filed Critical SRI International Inc
Publication of EP0450060A1 publication Critical patent/EP0450060A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor

Definitions

  • This invention relates to DNA sequencing. More particularly, it relates to methods and apparatus for determining the sequence of deoxyribonucleotides within DNA molecules .
  • DNA sequencing is an important tool.
  • a current goal of the biological community in general is the determination of the complete structure of the DNA of a number of organisms, including man. This information will aid in the understanding, diagnosis, prevention and treatment of disease.
  • the DNA to be sequenced is enzymatically copied by the Klenow fragment of DNA polymerase I or by a similar polymerase enzyme such as Taq polymerase or SequenaseTM .
  • the enzymatic copying is carried out in quadruplicate.
  • a low concentration of a chain terminating dideoxynucleotide is present, a different dideoxynucleotide being present in each of the four reactions (ddATP, ddCTP, ddGTP and ddTTP) .
  • the polymerase reaction is terminated, again producing sets of nested fragments. Again, the nested fragments have to be separated from one another by electrophoresis to determine the sequence.
  • the present invention provides methods and apparatus for determining the sequence of deoxyribonucleotides in a DNA molecule.
  • a key characteristic of this invention is that it determines the DNA sequence without recourse to electrophoresis or other size-based separation techniques.
  • the present invention provides a method for determining the deoxyribonucleotide sequence, of a single stranded DNA subject molecule.
  • This method involves synthesizing, in the presence of a multitude of identical copies of the subject DNA, the DNA molecule which is complementary to it.
  • This synthesis is carried out using deoxyribonucleotide triphosphates (dNTP) in a stepwise serial manner so as to simultaneously build Up numerous copies of the complementary molecule, dNTP by dNTP.
  • dNTP deoxyribonucleotide triphosphates
  • this invention provides apparatus for carrying out the above-described method.
  • this method and apparatus for carrying it out can take many different configurations.
  • This invention can be carried out in a single reaction zone with multiple differentiable reporters or in multiple reaction zones with a single reporter in each zone. It can be carried out by detecting the incremental signal change after addition of reporters or by noting each added reporter separately. The various reporters can be measured in the reaction zones while attached to the growing molecule or they can be separated from the molecule and then measured.
  • the invention can be practiced to create the growing complementary DNA chain without interruption or it can be practiced in stages wherein a portion of the complementary chain is created and its sequence determined; this portion of the chain is then removed; a sequence corresponding to a region of the removed chain is separately synthesized and used to prime the template chain for subsequent chain growth. The latter method can be repeated as needed to grow out in portions the complete complementary chain.
  • Figures 1A and IB are schematic diagrams of the process of this invention on a molecular level.
  • Figure 2 is a schematic representation of one form of apparatus for practising the invention.
  • the DNA growth takes place in a single reaction zone.
  • This embodiment uses separate, distinguishable reporters associated with each of the four nucleotides incorporated into the growing molecule. The four different reporters are measured after each addition to detect which base has just been added to that position of the complementary chain.
  • Figure 3 is a schematic representation of another form of apparatus for practising the invention.
  • This embodiment employs four reaction zones in which the molecular growth is carried out in quadruplicate. In each of the four zones, a different one of the four nucleotides is associated with a reporter (with the remaining three being unlabeled) so that the identity of the nucleotide incorporated at each stage can be determined.
  • Figure 4 is a schematic representation of an adoption of the apparatus for practising the invention particularly adapted for carrying out the invention to grow a series of portions of the complementary molecule as opposed to a single continuous complementary molecule.
  • Figures 5 through 8 are pictorial representations of chemical reaction sequences which can be used to synthesize representative labeled nucleotide building blocks for use in the practice of this invention.
  • dNTPs of these materials are abbreviated as dATP, dCTP, dGTP and dTTP. When these materials are blocked in their 3'-OH position they are shown as 3 'blockeddATP, 3'blockeddCTP, 3 'blockeddGTP and 3 'bl ⁇ ckeddTTP. Similarly, when they are each tagged or labeled with a common reporter group, such as a single fluorescent group, they are represented as dA'TP, dC'TP, dG'TP and dT'TP.
  • a solid support 1 is illustrated with a reactive group A attached to its surface via tether 2. This attachment can be covalent, ionic or the like.
  • a second reactive group. X capable of bonding to group A, again via a covalent, ionic or the like bond, is attached to the 5' end of a DNA primer 4.
  • This primer has a known DNA sequence. When coupled to the substrate via the A-X bond it forms immobilized primer 5.
  • Primer 5 is then hybridized to template DNA strand 6 which is made up of an unknown region 7 inserted between regions 8 and 8 ' . Regions 8 and 8' are located at the 5' and 3' ends of the unknown region and have known sequences.
  • the 8' region's known sequence is complementary to the sequence of primer 4 so that those regions hybridize to form immobilized template DNA 9. Therefore the individual dNTPs are serially added to form the DNA sequence complementary to the unknown region of the template. 11 and 12 represent the first two such dNTPs incorporated into the growing molecule. These in turn provide the identity of their complements 11' and 12' respectively. This growth continues until the entire complementary DNA molecule has been constructed. Completion can be noted by identifying the sequence corresponding to the 8 region of template 6. Turning to Figure IB, a variation of this chemistry is shown in that the template 6* carries the reactive group X which bonds to the substrate via the A-X bond to form an immobilized template 5*.
  • Device 13 for carrying out the invention is shown schematically.
  • Device 13 includes a reaction zone 14 which carries inside it a surface 15.
  • a plurality of copies of a subject primed single stranded DNA are immobilized on this surface 15. This is the strand of DNA for which the sequence is desired.
  • the immobilized DNA is depicted fancifully on surface 15 as if it were present as a series of separately visible attached strands. As will be appreciated, this is not in fact the case and is only done to guide the reader as to the location of the DNA strands .
  • the reaction zone 14 may be configured to permit direct reading of reporter signals emanating from within. Examples of this configuration include equipping the reaction zone to permit measuring fluorescence or luminescence through one or more transparent walls or detecting radionuclide decay.
  • Reaction zone 14 is fitted with inlet 16 for the addition of polymerase or another suitable enzyme capable of moderating the templat ⁇ e-directing coupling of nucleotides to one another.
  • the reaction zone is ⁇ also accessed by inlet lines, 18a-18d for four differently labeled blocked dNTPs, that is 3'blockeddA'TP, 3 'blockeddC' 'TP, 3 'blockeddG' ' 'TP, and 3'blockeddT' ' ' 'TP. These materials can be added in four separate lines, as shown, or can be premixed, if desired, and added via a single line. Buffer and other suitable reaction medium components are added via line 20.
  • the polymerase and the four labeled dNTPs are added to the reaction zone 14 under conditions adequate to permit the enzyme to bring about addition of the one, and only the one, of the four labeled blocked dNTPs which is complementary to the first available template nucleotide following the primer.
  • the blocking group present on the 3 '-hydroxyl position of the added dNTP prevents inadvertent multiple additions .
  • the liquid in reaction zone 14 is drained through line 22 either to waste, or if desired to storage for reuse.
  • the reaction zone and the surface 15 are rinsed as appropriate to remove unreacted, uncoupled labeled blocked dNTPs.
  • the first member of the complementary chain is now in place associated with the subject chain attached to surface 15.
  • the identity of this first nucleotide can be determined by detecting and identifying the label attached to it.
  • This detection and identification can be carried out in the case of a fluorescent label by irradiating the surface with a fluorescence-exciting beam from light source 24 and detecting the resulting fluorescence with detector 26.
  • the detected florescence is then correlated to the fluorescence properties of the four different labels present on the four different deoxynucleotide triphosphates to identify exactly which one of the four materials was incorporated at the first position of the complementary chain. This identity is then noted.
  • a reaction is carried out to remove the blocking group and label from the 3' position on the first deoxynucleotide triphosphate.
  • This reaction is carried out in reaction zone 14.
  • a deblocking solution is added via line 28 to remove the 3' hydroxyl labeled blocking group. This then generates an active 3' hydroxyl position on the first nucleotide present in the complementary chain and makes it available for coupling to the 5' position of the second nucleotide.
  • removal of the deblocking solution via line 22 and rinsing as needed the four blocked, labeled deoxynucleotide triphosphates, buffer and polymerase are again added and the appropriate second member is then coupled into the growing complementary chain.
  • the second member of the chain can be identified based on its label. This process is then repeated as needed until the complementary chain has been completed.
  • the sequence of incorporated deoxynucleotides is known, and therefore so is the sequence of the complement which is the subject chain. It will be appreciated that this process is easily automated. It is a series of fluid additions and removals from a reaction zone. This can be easily accomplished by a series of timer-controlled valves and the like. This technology has been well developed in the area of oligonucleotide synthesizers, peptide synthesizers, and the like. In such an automated system, the timing can be controlled by a microprocessor or, in most cases, by a simple programmable timer. The rate and " extent of reaction can be monitored by measurement of the reporter concentration at various stages .
  • the labels present in the blocked dNTPs can be incorporated in one of several manners. For one, they can be incorporated directly and irremovably in the deoxynucleotide triphosphate unit itself. Thus, as the complementary chain grows there is a summing of signals and one identifies each added nucleotide by noting the change in signal observed after each nucleotide is added.
  • the label is incorporated within the blocking group or is otherwise incorporated in a way which allows it to be removed between each addition. This permits the detection to be substantially simpler in that one is noting the presence of one of the four reporter groups after each addition rather than a change in the sum of a group of reporter groups .
  • the presence of reporter signal is noted directly in the reaction zone 14 by the analytical system noted as source 24 and detector 26. It will be appreciated, however, that in embodiments where the reporter group is removed during each cycle, it is possible to read or detect the reporter at a remote site after it has been carried out of the reaction zone 14.
  • drain line 22 could be valved to a sample collector (not shown) which would isolate and store the individual delabeling product solutions for subsequent reading.
  • the various removed labels could be read as they flowed out of the reaction zone by equipping line 22 with an in-line measurement cell such as source 24' and detector 26' or the like.
  • a second embodiment of this invention employs four separate parallel reaction zones. This method has the advantage of requiring only one type of labeling and being able to use it with all four dNTPs.
  • Figure 3 shows a schematic representation of a device 30 which has the four reaction zone configuration. In this configuration there are four reaction zones 32a through 32d, each of which resembles the reaction zone 14 in Figure 2. In these cases each of the four reaction zones contains a surface 34a-d to which is immobilized numerous copies of a primed subject single stranded DNA. Each reaction zone is supplied with polymerase via lines 36a-d. Each zone is supplied with suitable reaction medium via lines 38a-38d. The four dNTPs are supplied in blocked form to each zone, as well.
  • zone 32a one of the blocked dNTPs is labeled, for example "A'"; in zone 32b a second dNTP is labeled, for example "C”; in zone 32c a third dNTP is labeled, for example "G'”; and in 32d the fourth labeled dNTP "T' M is present.
  • These labeled materials are supplied via lines 40a through 40d respectively.
  • Unlabeled blocked dNTPs are supplied via lines 42a-d so that each of the four reaction zones contains three unlabeled blocked dNTPs and one labeled blocked dNTP.
  • the various labeled and unlabeled dNTP ' s can be premixed. These premixed materials can be added to the various reaction zones via single addition lines.
  • the single stranded DNA hybridized to a primer and attached to each of surfaces 34a-34d is contacted with polymerase (supplied via lines 36a-36d), buffer (supplied via lines 38a-38d) and the four bases in each of the four reaction zones .
  • the blocked dNTP which complements the first base on the subject chain couples.
  • this base is labeled.
  • this label is incorporated into the growing chain, one can determine the identity of the dNTP which is incorporated at the first position. This determination of the identity of the first unit of the chain can be carried out using signal sources and detectors such as 44a-44d and 46a-46d, respectively.
  • Deblocking is carried out by adding deblocking solution to the reaction zone through lines 48a-48d.
  • Lines 50a-50d are drain lines for removing material from the reaction zones following each step.
  • all of the variations noted with reference to the device described in Figure 2 can also be used including cumulating reporter signals and generating reporter signals away from the reaction zone by removing the reporter groups as part of each of the sequential couplings.
  • this embodiment can be readily automated, as well.
  • One obvious potential shortcoming of the present invention is that it employs a long sequence of serial reactions. Even if the efficiency and yield of each of these reactions are relatively high, the overall yield becomes the product of a large number of numbers, each of which is somewhat less than 1.00, and thus can become unacceptably low. For example if the yield of a given addition step is 98% and the deblocking is 98% as well, the overall yield after 15 additions is 48 , after 30 additions it is 23% and after 60 additions it is 5.3%.
  • This limitation can be alleviated by periodically halting the DNA molecule growth and using the sequence data obtained prior to halting the growth to externally recreate a portion of the molecule which can then be used as a primer for renewed DNA fabrication. This process is illustrated in Figure 4.
  • FIG 4 shows a schematic of an automated sequencer 52 employing the present invention.
  • Sequencer 52 has a single reaction zone 14 combining the subject primed DNA, immobilized therein such as on surface 15.
  • the four 3-blocked DNTP's are fed to the reaction zone through line 18.
  • Polymerase and buffers are added via lines 16 and 20, respectively.
  • the dNTP 's, polymerase and buffer can be recycled from step to step via lines 54 and 56 and holding vessel 58. All of the valves admitting and removing fluids from reaction zone 14 can be controlled by central computer 60 which functions as a valve control clock.
  • This computer 60 can also control the addition of deblocker from line 28, deblocking eluent with cleaved labels (as obtained when the label is present in the blocking group) is removed via line 22 and detected via detector system 24/26 reading label values in detector vessel 62.
  • This embodiment illustrates the use of a fluorescent label system and shows the addition of fluorescent sensitizer (flooder) via line 64 to the fluorescent detection zone 62.
  • the deblocking solution and detected label are discarded via line 66.
  • the signal presented by the label identified by detector 26 is passed to analog/digital converter 68 and therein to a memory in central computer 60 where it is stored.
  • the memory in computer 60 contains the sequence of an initial portion of the complementary DNA molecule which has been constructed in association with the subject or target DNA molecule contained within reactor 14. After some number of units have been assembled - typically 25 to 300, or more; preferably 50 to 300, or more; and more preferably 100 to 300, or more - the growing complementary DNA molecule is stripped from the immobilized subject DNA molecule and discarded. This stripping (denaturing) can be done by art-known methods such as by warming the reaction zone to 75°C or higher (preferably 90-95°C) for a few (1-15) minutes.
  • the sequence information stored in computer 60 is used to drive DNA synthesizer 70 to externally create a new DNA primer corresponding to at least a portion of the discarded DNA molecule. (The sequence can also be read on printer 72, if desired.)
  • This newly constructed DNA primer molecule is fed through line 74 to reaction zone 14 under hybridization conditions so as to join to the complementary region of the subject DNA molecule as a new primer.
  • the length of the primer must be adequate to. unambiguously and strongly hybridize with a single region of the subject DNA. As is known in the hybridization art, this can depend upon factors such as the sequence, environmental conditions, and the length of the subject DNA. For efficiency of operation, the primer should ideally be as short as possible.
  • Primer lengths typically range from about 10 bases to about 30 bases, although shorter primers would certainly be attractive if they met the above criteria, and longer primers could be used albeit with an increase in cost and time. Good results generally are achieved with primers from 12 to 20 bases long. This gives the molecular growth reaction a "new start" with a large number of properly primed identical molecules. This allows a strong signal to be generated when the next dNTP is coupled.
  • the coupling process employed in this invention to incorporate each of the blocked deoxynucleotide triphosphates into the growing complementary chain is an enzyme moderated process.
  • Each member of the complementary DNA chain is added using a suitable template-dependent enzyme.
  • One enzyme which can be used is Sequenase TM enzyme (an enzyme derived from bacteriophage 7 DNA polymerase that is modified to improve its sequencing properties - see Tabor and
  • Sequenase TM examples include but are not limited to
  • the coupling conditions which are employed are those known in the art for these enzymes.
  • these include temperatures in the range of from about room temperature to about 45 C; a buffer of pH 7 to 8 and preferably pH 7.3 to 7.7; an enzyme concentration of from about 0.01 units per microliter to about 1 unit per microliter and a reaction time of from about 1 to about 20 minutes and preferable 1 to 5 minutes.
  • a typical buffer for use with Sequenase TM is made up of
  • these typical conditions include temperatures in the range of from about 10 C to about 45 C and preferably from about 15°C to about 40°C; a buffer of pH 6.8 to 7.4 and preferably pH 7.0 to 7.4; an enzyme concentration of from about 0.01 units per microliter to about 1 unit per microliter and preferably from about 0.02 to about 0.15 units per microliter and a reaction time of from about 1 to about 40 minutes.
  • a typical buffer for use with Klenow fragment of DNA polymerase I is made up of
  • 3 '-blocking groups include: (l) the ability of a polymerase enzyme to accurately and efficiently incorporate the dNTPs carrying the 3 '-blocking groups into the cDNA chain,
  • the 3 '-blocking group carries a reporter group, it is desirable that the reporter permit sensitive detection either when part of the cDNA chain before deblocking or subsequent to deblocking in the reaction eluant.
  • 3 '-blocked dNTPs are used that can be incorporated in a template-dependent fashion and easily deblocked to yield a viable 3 ' -OH terminus.
  • the most common 3 '-hydroxyl blocking groups are esters and ethers.
  • ester blocking groups such as lower (1-4 carbon) alkanoic acid and substituted lower alkanoic acid esters, for example formyl, acetyl, isopropanoyl, alpha fluoro- and alpha chloroacetyl esters and the like; ether blocking groups such as alkyl ethers; phosphate blocking groups; carbonate blocking groups such as 2-nitrobenzyl; 2,4-dinitrobenzene-sulfenyl and tetrahydrothiofuranyl ether blocking groups.
  • Blocking groups can be modified to incorporate reporter moieties, if desired, including radiolabels (tritium, C 14 or F ⁇ ** 2 , for example), enzymes, fluorophores and chromophores .
  • selectively-removable amine protection groups include carbamate ⁇ cleavable by acid hydrolysis [t-butyl, 2-(biphenyl)isopropyl] and certain amides susceptible to acid cleavage (formamide, trichloroacetamide) (Greene, 1981) .
  • nucleotide derivatives protection of the primary amino groups is performed prior to phosphonation.
  • standard amino protecting groups cleavable by ammonolysis may be used.
  • the sequencing scheme After successfully incorporating a 3 '-blocked nucleotide into the DNA chain, the sequencing scheme requires the blocking group to be removed to yield a viable 3 '-OH site for continued chain synthesis.
  • the deblocking method should:
  • the exact deblocking chemistry selected will, of course, depend to a large extent upon the blocking group employed. For example, removal of ester blocking groups from the 3 'hydroxyl function is usually achieved by base hydrolysis. The ease of removal varies widely; generally, the greater the electro-negativity of substituents on the carbonyl carbon, the greater the ease of removal. For example, the highly electronegative group trifluoroacetate is cleaved rapidly from 3' hydroxyls in methanol at pH 7 (Cramer et al. , 1963) and thus would not be stable during coupling at that pH.
  • Phenoxyacetate groups are cleaved in less than one minute but require substantially higher pH such as is achieved with NH-/ methanol (Reese and Steward, 1968).
  • the ester deblocking rate is advantageously selected so as to exhibit a deblocking rate of less than 10 -3s-1 during the incorporation, and at least 10 ⁇ s during the deblocking stage. Ideally, this rate change is achieved by changing the buffer pH from 7 to about 10, but care must be taken not to denature the DNA.
  • hydroxyl blocking groups are cleaved selectively using chemical procedures other than base hydrolysis.
  • 2,4-Dinitrobenzenesulfenyl groups are cleaved rapidly by treatment with nucleophiles such as thiophenol and thiosulfate (Letsinger et al., 1964).
  • Allyl ethers are cleaved by treatment with Hg(II) in acetone/water (Gigg and Warren, 1968) .
  • Tetrahydrothiofuranyl ethers are removed under neutral conditions using Ag(I) or Hg(II) (Cohen and Steele, 1966; Cruse et al . , 1978).
  • These protecting groups which are stable to the conditions used in the synthesis of dNTP analogues and in the sequence incorporation steps, have some advantages over groups cleavable by base hydrolysis - deblocking occurs only when the specific deblocking reagent is present and premature deblocking during incorporation is minimized.
  • Photochemical deblocking can be used with photochemically-cleavable blocking groups.
  • Several blocking groups are available for such an approach.
  • the use of o-nitrobenzylethers as protecting groups for 2 '-hydroxyl functions of ribonucleosides is known and demonstrated (Ohtsuka et al. , 1978); removal occurs by irradiation at 260 nm.
  • Alkyl o-nitrobenzyl carbonate protecting groups are also cleaved by irradiation at pH 7 (Cama and Christensen, 1978).
  • Enzymatic deblocking of 3 '-OH blocking groups is also possible. It has been demonstrated that T4 polynucleotide kinase can convert 3 '-phosphate termini to 3 '-hydroxyl termini that can then serve as primers for DNA polymerase I (Henner et al . , 1983). This 3 '-phosphatase activity is used to remove the 3 '-blocking group of those dNTP analogues that contain a phosphate as the blocking group; the radioactive label enables the incorporation of the nucleotide analogue and the removal of the phosphate group to be followed easily. . If the use of radioisotopes represents too great a drawback, it is possible to use unlabeled phosphate monoesters with a cleavable fluorescent label (see below).
  • each dNTP into the complementary chain is noted by detecting a label or reporter group present in or associated with the incorporated dNTP.
  • the labels or markers are "innocuous".
  • An "innocuous marker or label or reporter” refers to a radioactive, fluorescent, or the like marker or reporter which has physical and chemical properties which do not interfere with either the enzymatic addition of the marked nucleotide to the cDNA, or the subsequent deblocking to yield a viable 3 '-OH terminus .
  • One simple labeling approach is to incorporate a radioactive species within the blocking group or in some other location of the dNTP units. This can be done easily by C 14 labeling or P32 labeling.
  • Another labeling approach employs fluorescent labels. These can be attached to the dNTP's via the 3 '0H- blocking groups or attached in other positions. There are two general routes available using fluorescent tags:
  • the first route is fairly straightforward and can employ a range of known fluorophores such as rhodamines, fluoresceins and the like, typically including those fluorophores known as useful in labeling dNTP's and the like.
  • fluorophores such as rhodamines, fluoresceins and the like, typically including those fluorophores known as useful in labeling dNTP's and the like.
  • the second route can employ a fluorophore where only a fragment is attached to the dNTP. This can reduce size and minimize steric interference. In the second route, rapid reaction of a normally nonfluorescent probe or molecule with specific functional group(s) found only on the label fragment leads to the formation of a fluorescent addition product. This leads to a signal only when the particular label
  • Blocking groups or other label fragment groups containing free thiol functions can be used for this approach.
  • the blocking group or other label fragment can contain a metal-binding ligand, e.g. a carboxylic acid group which will react with added rare earth metal ions such as europium or terbium ions to yield a fluorescent species.
  • This dNTP can be incorporated and the fluorescence measured and removed according to the methods described below.
  • One method involves the use of a fluorescent tag attached to the base moiety.
  • the tag may be chemically cleaved (either separately from or simultaneously with the deblocking step) and measured either in the reaction zone before deblocking or in the reaction eluant after cleavage.
  • the fluorescent moiety or other innocuous label can be attached to the dNTP through a spacer or tether.
  • the tether can be cleavable if desired to release the fluorophore or other label on demand.
  • Typical tethers are from about 2 to about 20, and preferably from about 3 to about 10 atoms in length.
  • the C-8 position of the purine structure presents an ideal position for attachment of a label.
  • Sarfati et al . (1987) describes a derivatization of deoxyadenosine at C-8 of the purine to prepare, ultimately, an 8-substituted biotin aldylamino dATP.
  • the Sarfati et al . (1987) approach can be used to prepare the appropriate fluorescent, rather than biotinylated, analogues.
  • a number of approaches are possible to produce fluorescent derivatives of thymidine and deoxycytidine.
  • One quite versatile scheme is based on an approach used by Prober et al . (1987) to prepare ddNTPs with fluorescent tags. Structures A, B, C and D below illustrate the type of fluorescent dNTPs that result from these synthetic approaches.
  • the synthetic routes have a great flexibility in that the linker can be varied with respect to length or functionality.
  • the terminal fluorescent moiety can also be varied according to need.
  • the labels so incorporated in the growing cDNA chain are detected by conventional analytical methods .
  • increased detection sensitivity is a major advantage of the present method.
  • the signal is based on a low level of fluorophores and is superimposed on a background of scatter from the gel and glass plates. This decreases sensitivity and often constrains current methods to the use of laser illumination to maximize sensitivity (Smith et al., 1986; Prober et al . , 1987; Ansorge et al . , 1986) .
  • Detection of fluorophores is readily achievable in commercial non-excited spectrofluorometers , such as are sold by Perkin-Elmer.
  • LED light- emitting diodes
  • Typical LEDs include:
  • Red LED emitting at approximately 650 nm
  • Green LED emitting at approximately 540 nm
  • Blue LED emitting at approximately 450 nm
  • the solution containing cleaved blocking groups or nucleotides is directly injected into a field ionization mass spectrometer. Identification of the particular nucleotide incorporated or cleaved is achieved by monitoring the relative abundance of molecular ion peaks corresponding to the specific nucleotides or blocking groups; for example, four distinct acetyl blocking groups differing by one mass unit (replacement of 0 to 3 hydrogens by deuterium) could be detected by monitoring a small “window. "
  • Immobilization of Subject DNA In the present invention, single stranded subject DNA or its primer is immobilized.
  • One approach to this immobilization is to attach the DNA to a solid substrate.
  • DNA and RNA are commonly attached noncovalently through ionic interactions along their length to various types of membranes (Southern, 1975; Maniatis, Fritsch, and Sambrook, 1982; Chuvpilp and Kravchenko, 1984).
  • polynucleotides are covalently attached along their length to membranes (Goldberg, et al . , 1979), resins (Seed, 1982; Arndt-Jovin, et al .
  • the inner quartz or glass surface can be advantageously functionalized using silanizing reagents such as triethoxysilylpropylamine or dichlorodi ethylsilane. This is followed by covalent attachment of a long-chain alkylamine to these functionalizing groups.
  • the single stranded subject DNA is attached to the long chain amine.
  • immobilization is carried out by attaching the subject DNA to a plastic surface.
  • a thin polypropylene chamber wall designed to pass Cer'enkov radiation from 32P, for example, can serve as a suitable substrate for DNA immobilization.
  • a plastic surface it is preferable to use the method of Kremsky et al .
  • the reaction zone has one or more openings covered with a membrane such as an ultrafiltration membrane, for example, Amicon's PM-5 or PM-10 membranes which have nominal molecular weight cut offs of 5000 and 10,000 respectively.
  • a membrane such as an ultrafiltration membrane, for example, Amicon's PM-5 or PM-10 membranes which have nominal molecular weight cut offs of 5000 and 10,000 respectively.
  • the single stranded DNA is suspended in liquid in the reaction zone.
  • the labeled and unlabeled dNTPs and other coupling reagents are flowed into the zone. Materials are removed from the zone through such a filter which retains the DNA chains.
  • the polymerase or other enzyme which is used to effect coupling is generally of a size to be retained by the membrane. This scheme works for chemical but not enzymatic deblocking, since in enzymatic deblocking the polymerase and phosphatase must be cycled separately through the cell.
  • the DNA can be immobilized on particles of resin or polymer microspheres and these particles retained within the chamber.
  • the filter material is unimportant as long as the DNA is attached to resin particles which are of a size that cannot penetrate the filter pores .
  • oligonucleotides or polynucleotides are linked through their 5' end to cellulose (Gilha , 1968; Clerici et al . 1979), Sephacryl (Langdale and Malcolm, 1985), or latex microspheres (Kremsky et al., 1987).
  • the DNA is available for interactions with other nucleic acids or proteins .
  • the DNA is coupled covalently to streptavidin-agarose beads by an alkylbiotinylated oligonucleotide (Kremsky et al., 1987).
  • the single-stranded DNA is coupled to DBM paper such as a filter in the presence of a protecting strand. After coupling, the protecting strand is released, leaving the immobilized template and priming site free for successive enzymatic reactions (Hansen et al . , 1987) .
  • This method and the other single-point methods described above are useful for immobilizing DNA while leaving it free for interactions with enzymes used in DNA sequencing- Examples
  • the organic layer is separated and the aqueous layer washed with 2 x 200 ml CH 2 C1 2
  • the combined CH-Cl- extracts are dried over magnesium sulfate (MgSO.), filtered and evaporated to dryness under vacuum at room temperature.
  • the crude 5 '-dimethoxytrityl-3 'thymidine H-phosphonate II is then treated with 2% benzenesulfonic acid in CH ⁇ Cl- -.methanol (MeOH) (7:3) (200 ml) for one hour.
  • the solution is washed with 10% sodium bicarbonate (NaHCO-) and water, dried over magnesium sulfate and evaporated to dryness.
  • the crude 3 '-thymidine- H-phosphonate III is recrystallized from ethanol/ether.
  • the mixtu-re is stirred for 12 hours at 4 C, neutralized with NaHCO.. solution,- and added to 150 ml water.
  • the aqueous solution is washed with benzene (2 x 100 ml) and ether ( 2 x 100 ml), and diluted to 0.8 liters with water and charged on a 2.5 x 50 cm column of DEAE-cellulose.
  • the products are eluted using a linear gradient of pH 8.5 ammonium bicarbonate solution (0.05 to 0.25 M) .
  • the fractions collected are analyzed by HPLC to determine the desired product-containing fractions, and these are evaporated to dryness under vacuum. The residue is repeatedly re-evaporated with water to remove salts .
  • the 5 '-monophosphate IV (16 mmole) is then dissolved in 30 ml of dimethylformamide (DMF) and treated with N,N'-carbonyldiimidazole (30 mmole) at room temperature for one hour.
  • the reaction is quenched by addition of 5 ml methanol, and 60 ml of a 0.5M solution of bis (tri-n-butyl-ammonium) pyrophosphate in DMF is added dropwise over 10 minutes.
  • the solution is diluted with water to 1 liter and treated with 100 ml of a solution of 0.1 M iodine (I-.) in 5% pyridine/water. After one hour, the solution is deposited on a DEAE-cellulose column from Sigma (5x50cm) or Sephradex from Pharmacia. The column is washed with water and eluted with triethylammonium bicarbonate solution
  • the 5 '-triphosphate-3 '-phosphate thymidine product V is obtained by evaporation of the appropriate fractions collected.
  • Example 3 Quartz Surface Immobilization of Subject DNA Four 25 microliter volume quartz cuvette reaction chambers are prepared. These chambers are configured like chamber 32 in Figure 3 with the exception that they use their inner walls as the surface to which the DNA is affixed. The inner surfaces are cleaned and dried.
  • Triethoxysilylpropylamine (5 microliter in 20 microliter CHC1-.) is added and held at 5°C for 120 minutes under anhydrous conditions . This couples the triethoxysilylpropylamine to the surface and gives an amine character to the surface.
  • the subject DNA is then attached to the amine surface.
  • This is carried out by first attaching a long chain alkyl amine (n-octylamine) to the base at the 5' end of the subject DNA molecule or to the base at the 5 ' end of a suitable primer, such as an M13 primer for example the 17-mer dGTAAAACGACGGCCAGT, and then joining the alkylamine to the aminopropyl ⁇ ilane surface groups by reaction with glutaraldehyde (1.5 equivalents, 25°C, 120 minutes).
  • a suitable primer such as an M13 primer for example the 17-mer dGTAAAACGACGGCCAGT
  • Other functional groups pendant to the base moiety or attached to the 5' position can also be used [for example: aldehydes or carboxylic acids (Kremsky et al) ] for covalent immobilization on derivatized quartz or glass surfaces.
  • Example 4 Incorporation of Labeled Nucleotide Analogs into DNA
  • the 25 microliter reaction zones are charged with a reaction mixture which contains three Units of Sequenase TM enzyme.
  • the reaction mixture also contains an appropriate buffer for this enzyme (20 mM Tris-HCl pH 7.5, 10 mM MgCl, 25 mM NaCl, 0.01 M dithiothreitol), the i single-stranded primed subject DNA is present at a concentration of approximately 0.1 M attached to the surface of the reaction chamber at its 5' end, (see Example 3), three unlabeled, 3 '-blocked deoxynucleotide triphosphate (dNTP) analogs at a concentration of 1.5 micromolar each, and one 3 '-blocked, fluorescently labeled dNTP analog of Example 2 at a concentration of 30 micromolar are each present in each of the four reaction zones. In each zone a different one of the four dNTPs is labeled.
  • the reaction
  • the identity of the added dNTP is determined by exciting the fluorophores present in the one cuvette which incorporated its fluorescently-labeled dNTP.
  • the fluorescent group is removed before measurement.
  • the 2 ,4-dinitrobenzenesulfenyl fluorescent blocking groups are removed with a deblocking reagent which consists of 0.1 M pyridine/pyridinium chloride buffer (pH 7.8) containing thiourea 0.05 M.
  • the deblocking reaction is allowed to proceed for one minute at 40 C-
  • the reaction chamber is then drained and washed twice with 100 mM Tris-HCl buffer, pH 6.5.
  • the release of the fluorescent blocking group is measured in the initial eluate from the reaction chamber using a flow-through cell. Depending on the cell in which the fluorescent group is present, the identity of the nucleotide which has been added to the DNA chain is determined.
  • the blocking group were a dansylcadaverine type ester such as in reaction scheme 4 , it could be removed by treatment with 50% methanol/50% water pH 10.0 for one minute.
  • Example 6 Enzymatic Deblocking
  • the blocking group can also be removed enzymaticall .
  • the deblocker fed into the reaction chamber contains 100 mM Tris-HCl (pH 6.5) 10 mM MgCl-, 5 mM 2-mercaptoethanol, and one Unit T4 polynucleotide kinase.
  • the reaction proceeds for one minute at a temperature of 37 C.
  • the 3 ' -phosphatase activity of T4 polynucleotide kinase converts 3 '-phosphate termini to 3 '-hydroxyl termini which then serve as primers for further synthesis.
  • a simple clock mechanism or microprocessor driven timer circuit can be used to actuate a plurality of electrically controlled valves in. sequence to add the various reagents for adding building blocks, deblocking and the like with the result that the sequence of the target DNA single strand can be obtained with minimum involvement of lab personnel .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Instrument et procédé permettant de déterminer la séquence de nucléotides se trouvant dans une molécule d'ADN, sans l'emploi d'une étape d'électrophorèse sur gel. Le procédé emploie une séquence d'ADN monocaténaire amorçée inconnue, laquelle est immobilisée ou piégée à l'intérieur d'une chambre à l'aide d'une polymérase, de sorte que l'ADN complémentaire formé de manière séquentielle peut être contrôlé à chaque addition d'un nucléotide bloqué, par mesure de la présence d'un marqueur inoffensif sur des désoxyribonucléotides spécifiés. L'invention concerne également un procédé de détermination de la séquence de nucléotides d'ADN inconnue à l'aide de désoxynucléotides bloqués. Le dNTP (désoxyribonucléotide-triphosphate) bloqué comporte un marqueur inoffensif, de sorte que son identité peut être facilement déterminée. L'instrument et les procédés de l'invention permettent d'obtenir une détermination précise et rapide d'une séquence de nucléotides d'ADN sans électrophorèse sur gel.Instrument and method for determining the nucleotide sequence found in a DNA molecule, without the use of a gel electrophoresis step. The method employs an unknown primed single-stranded DNA sequence, which is immobilized or trapped inside a chamber using a polymerase, so that the complementary DNA formed sequentially can be checked each time addition of a blocked nucleotide, by measuring the presence of a harmless marker on specified deoxyribonucleotides. The invention also relates to a method for determining the unknown DNA nucleotide sequence using blocked deoxynucleotides. The blocked dNTP (deoxyribonucleotide-triphosphate) has a harmless marker, so its identity can be easily determined. The instrument and methods of the invention make it possible to obtain an accurate and rapid determination of a DNA nucleotide sequence without gel electrophoresis.

Description

DNA SEQUENCING
Background Of The Invention
Field of the Invention
This invention relates to DNA sequencing. More particularly, it relates to methods and apparatus for determining the sequence of deoxyribonucleotides within DNA molecules .
Description of Background Art
DNA sequencing is an important tool. A current goal of the biological community in general is the determination of the complete structure of the DNA of a number of organisms, including man. This information will aid in the understanding, diagnosis, prevention and treatment of disease.
Current DNA sequencing methods employ either chemical or enzymatic procedures to produce labeled fragments of DNA molecules. In the chemical method, reactions are performed that specifically modify certain of the nucleotide bases present in the end-labeled DRΛ. These reactions are carried out only partially to completion so that only a portion of the bases present in the molecules are reacted. These modified bases are then treated with piperidine, to cleave the DNA chains at the modified bases producing four sets of nested fragments. These fragments are then separated from one another according to size by electrophoresis in polyacrylamide gels. The fragments can then be visualized in the gels by eans of radioactive labels. The position of the fragments in the gel indicates the identity of the last nucleotide in each fragment so that on the gel a "ladder" of fragments, with each step identified, is assembled to provide the overall sequence.
In the enzymatic method, the DNA to be sequenced is enzymatically copied by the Klenow fragment of DNA polymerase I or by a similar polymerase enzyme such as Taq polymerase or Sequenase™ . The enzymatic copying is carried out in quadruplicate. In each of the four reactions a low concentration of a chain terminating dideoxynucleotide is present, a different dideoxynucleotide being present in each of the four reactions (ddATP, ddCTP, ddGTP and ddTTP) . Whenever a dideoxynucleotide is incorporated, the polymerase reaction is terminated, again producing sets of nested fragments. Again, the nested fragments have to be separated from one another by electrophoresis to determine the sequence.
Recently, new advances in sequencing technology have introduced automated methods. Applied Biosystems has developed an instrument based on the use of fluorescent labels and a laser-and computer-based detection system (Smith et al. , 1986; Smith, 1987). An automated system developed by E.E. du Pont de Nemours & Company, Inc. (Prober et al. , 1987) is similar to the Applied Biosystems instrument but uses fluorescently labeled ddNTPs to terminate the reaction instead of fluorescent primers . Hitachi (Japan) and EMBL (West Germany) have developed similar systems (Ansorge et al . , 1986) . Other approaches involve multiplexing technology (Church and
Kieffer-Higgins , 1988), detection of radioactively labeled DNA fragments by sensitive Beta-detectors (EG&G), automated gel readers (BioRad), and automated liquid handlers (Beckman Instruments; Seiko; Goodenow, University of California, Berkeley) . The need to rely on electrophoresis and a separation according to size as part of the analytical scheme is a severe limitation. The gel electrophoresis is a time-consuming step and requires very highly trained skilled personnel to carry it out correctly. The present invention provides methods and apparatus for sequencing DNA which do not require electrophoresis or similar separation according to size as part of their methodology.
References of Interest
The following articles and patents relate to the general field of DNA sequencing and are provided as a general summary of the background art. From time to time reference will be made to these items for their teaching of synthetic methods, coupling and detection methodologies, and the like. In these cases, they will generally be referred to by author and year.
W.B. Ansorge, et al . , (1987) Nucleic Acid Research, 15:4593-4602. W.B. Ansorge, et al . , (1986) Journal of
Biochemical and Biophysical Methods, 13:325-323.
J. T. Arndt-Jovin, et al . , (1975) European Journal of Biochemistry, 54:411-413.
H. Bunemann, et al . (1982) Nucleic Acids Research, 10:7163-7180.,
L.D. Cama, et al . , (1978) Journal of the American Chemical Society, 100:8006.
G. M. Church, et al . , (1988) Science 240:185-188. s.A. Chuvpilo, et al . , (1984) "A Simple and
Rapid Method for Sequencing DNA," FEBS 179:34-36.
L.F. Clerici, et al . , (1979) Nucleic Acids Research, 6:247-258.
L.A. Cohen, et al . , (1966) Journal of Organic Chemistry, 31:2333. B.A. Connolly, (1987) Nucleic Acids Research, 15:3131-3139.
C.G. Cruse, et al . , (1978) Journal of Organic Chemistry, 43:3548-3553. P.T. Englund, et al. , (1969) Journal of
Biological Chemistry, 244:3038-3044.
B.C. Froehler, et al. , (1986) Nucleic Acids Research, 14:5399-5407.
R. Gigg, et al. , (1968) Journal of the Chemical Society, C14 : 1903-1911.
P.T. Gilham, (1968) Biochemistry, 7:2809-2813.
M.L. Goldberg, et al. , (1979) Methods in Enzymology, 68:206-220.
T. Goldkorn, et al . , (1986) Nucleic Acids Research 14:9171-9191.
T.W. Greene, (1981) Protective Groups in Organic Synthesis, John Wiley and Sons, Inc., New York, New York.
E. Hansbury, et al. , (1970) Biochemical & Biophysical Acta, 199:322-329. C. Hansen, et al., (1987) Analytical
Biochemistry, 162:130-136.
W.D. Henner, et al. , (1983) Journal of Biological Chemistry, 258:151198-15205.
J.A. Huberman, et al. , (1970) Journal of Biological Chemistry, 245:5326-5334.
Y. Kanaoka, (1977), Angewante Chemie International Edition English, 16:137-147.
A. Kornberg,. (1974), DNA Synthesis, W. H. Freeman and Company, San Francisco. A.A. Kraevskii, et al . , (1987) Molecular
Bioloσy, 21:25-29-
A. . Kraevsky, et al . , (1987) Biophosphates and Their Analogues--Synthesis , Structure, Metabolism and Activity, K.S. Bruzik and W.J. Stec (Eds.), Elsevier, Amsterdam, pp. 379-390 (and references therein). J.N. Kremsky, et al., (1987) Nucleic Acids Research, 15:2891-2909.
T.V. Kutateladze, et al . , (1987) Molecular Biology, 20:222-231'. J.A. Langdale, et al . , (1985) Gene 36:201-210.
R.T. Letsinger, et al. (1964) Journal of Organic Chemistry, 29:2615-2618.
J.K. Mackey, et al . , (1971) Nature, 233:551-553.
T. Maniatis, et al . , (1982) Molecular Cloning, A Laboratory Handbook, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
A. M. Maxam, et al. , (1980) Methods in Enzymology, 65:499-560.
E. Ohtsuka, et al . , (1978) Journal of the American Chemical Society, 100:8210-8213.
A.V. Papchikhin, et al . , (1985) Bioorganic Chemistry, 11:716-727.
S. Pochet, et al . , (1987), Tetrahedron, 43:3481-3490. R. Polsky-Cynkin, et al . , (1985) Clinical
Chemistry, 31:1438-1443.
J.M. Prober, et al . , (1987) Science, 238:336-341.
C.B. Reese, et al. (1968) Tetrahedron Letters, 40:4273-4276.
T.A. Rezovskaya, et al. , (1977) Molecular Biology, 11:455-466.
F. Sanger, et al . , (1977) Proceedings of the National Academy of Science USA, 74:5463-5467. S.R. Sarfati, et al . (1987) Tetrahedron Letters,
43:3491-3497.
B. Seed, (1982) Nucleic Acids Research, 10:1799-1810.
A.J.H. Smith, (1980) Methods in Enzymology, 65:560-580. L.M. Smith, et al . , (1986) Nature, 321:674-679.
L.M. Smith, (1987) Science, 235:G89.
E.M. Southern, (1975) Journal of Molecular Biology, 98:503-517. S. Tabor, et al., (1987) Proceedings of the
National Academy of Sciences USA, 84:4767-4771.
R.I. Zhdanov, et al . , (1975) Synthesis, 1975:222-245.
Additional references of interest are:
N. Dattagupta, U.S. Patent No. 4,670,380 issued June 2, 1987.
W.J. Martin, European Patent Application No. 0187699, published July 16, 1986. Japan.Kokai Tokyo Kobo JP 58/87,452 (May 25,
1983); Chem. Abs, Vol. 99, No. 172376n.
R. Lewis, "Computerizing Gene Analyses" High Technology, December 1986, p. 4.6 ff.
C. Connell, et al. "Automated DNA Sequence Analysis", BioTechniques, Vol. 5, No. 4, p. 342 ff. (1987) .
J.F.M. De Rooiz, et al. , Journal of Chromotography, Vol. 177, p. 380-384 (1987).
Statement of the Invention
The present invention provides methods and apparatus for determining the sequence of deoxyribonucleotides in a DNA molecule. A key characteristic of this invention is that it determines the DNA sequence without recourse to electrophoresis or other size-based separation techniques.
In one aspect, the present invention provides a method for determining the deoxyribonucleotide sequence, of a single stranded DNA subject molecule. This method involves synthesizing, in the presence of a multitude of identical copies of the subject DNA, the DNA molecule which is complementary to it. This synthesis is carried out using deoxyribonucleotide triphosphates (dNTP) in a stepwise serial manner so as to simultaneously build Up numerous copies of the complementary molecule, dNTP by dNTP. As each dNTP is added to the growing complementary molecules, it is identified by way of an appropriate label (i.e., reporter group). By noting the identity of the bases present in this complementary molecule and using standard rules of DNA complementation, one can translate from the complementary molecule to the corresponding original subject molecule and thus obtain the deoxyribonucleotide sequence of the subject molecule. In an additional aspect, this invention provides apparatus for carrying out the above-described method.
As will be seen in the Detailed Description of the Invention which follows, this method and apparatus for carrying it out can take many different configurations. A key to all of them, however, is the fact that the DNA sequence is determined not by generating a series of nested fragments which must be separated according to size but rather by direct identification of the dNTPs as they are incorporated into the growing complementary DNA chain. This invention can be carried out in a single reaction zone with multiple differentiable reporters or in multiple reaction zones with a single reporter in each zone. It can be carried out by detecting the incremental signal change after addition of reporters or by noting each added reporter separately. The various reporters can be measured in the reaction zones while attached to the growing molecule or they can be separated from the molecule and then measured.
The invention can be practiced to create the growing complementary DNA chain without interruption or it can be practiced in stages wherein a portion of the complementary chain is created and its sequence determined; this portion of the chain is then removed; a sequence corresponding to a region of the removed chain is separately synthesized and used to prime the template chain for subsequent chain growth. The latter method can be repeated as needed to grow out in portions the complete complementary chain.
Detailed Description of the invention
Brief Description of the Drawings
The invention will be further described with reference being made to the accompanying drawings in which:
Figures 1A and IB are schematic diagrams of the process of this invention on a molecular level.
Figure 2 is a schematic representation of one form of apparatus for practising the invention. In this embodiment the DNA growth takes place in a single reaction zone. This embodiment uses separate, distinguishable reporters associated with each of the four nucleotides incorporated into the growing molecule. The four different reporters are measured after each addition to detect which base has just been added to that position of the complementary chain.
Figure 3 is a schematic representation of another form of apparatus for practising the invention. This embodiment employs four reaction zones in which the molecular growth is carried out in quadruplicate. In each of the four zones, a different one of the four nucleotides is associated with a reporter (with the remaining three being unlabeled) so that the identity of the nucleotide incorporated at each stage can be determined. Figure 4 is a schematic representation of an adoption of the apparatus for practising the invention particularly adapted for carrying out the invention to grow a series of portions of the complementary molecule as opposed to a single continuous complementary molecule. Figures 5 through 8 are pictorial representations of chemical reaction sequences which can be used to synthesize representative labeled nucleotide building blocks for use in the practice of this invention.
Organization of this Section This Detailed Description of the Invention is organized as follows:
First, several terms are defined in a Nomenclature section.
Second, a series of Representative Apparatus Configurations and Process Embodiments for carrying out the invention are described.
Third, Materials and Reagents and Methods of Use employed in the process of the invention are set forth, including; Enzymes and Coupling Conditions,
Blocking Groups and Methods for Incorporation, Deblocking Methods,
Reporter Groups , their Incorporation and Detection, and Immobilization of Subject DNA.
Thereafter, a series of nonlimiting EXAMPLES is provided.
Nomenclature A number of related and generally conventional abbreviations and defined term? appear in this specification and claims . The four nucleotides are at times referred to in shorthand by way of their nucleoside bases, adenosine, cytidine, guanosine and thymidine, or "A", "C", "G" and "T". Deoxynucleotide triphosphates
"dNTPs" of these materials are abbreviated as dATP, dCTP, dGTP and dTTP. When these materials are blocked in their 3'-OH position they are shown as 3 'blockeddATP, 3'blockeddCTP, 3 'blockeddGTP and 3 'blσckeddTTP. Similarly, when they are each tagged or labeled with a common reporter group, such as a single fluorescent group, they are represented as dA'TP, dC'TP, dG'TP and dT'TP. When they are each tagged or labeled with different reporter groups, such as different fluorescent groups, they are represented as dA'TP, dC'TP, dG' ' 'TP and dT' *' 'TP. As will be explained in more detail below, the fact that the indication of labeling appears associated with the "nucleoside base part" of these abbreviations does not imply that this is the sole place where labeling can occur. Labeling could occur as well in other parts of the molecule.
Representative Apparatus Configurations and Process Embodiments
In the specification and claims, reference is made to a "subject" DNA or "template" DNA to define the DNA for which the sequence is desired. In practice, this material is contained within a vector of known sequence. A primer, which is complementary to the known sequence of the vector is used to start the growth of the unknown complementary chain. Two embodiments of this process are illustrated on a molecular level in Figures 1A and IB.
In Figure 1A, a solid support 1 is illustrated with a reactive group A attached to its surface via tether 2. This attachment can be covalent, ionic or the like. A second reactive group. X, capable of bonding to group A, again via a covalent, ionic or the like bond, is attached to the 5' end of a DNA primer 4. This primer has a known DNA sequence. When coupled to the substrate via the A-X bond it forms immobilized primer 5. Primer 5 is then hybridized to template DNA strand 6 which is made up of an unknown region 7 inserted between regions 8 and 8 ' . Regions 8 and 8' are located at the 5' and 3' ends of the unknown region and have known sequences. The 8' region's known sequence is complementary to the sequence of primer 4 so that those regions hybridize to form immobilized template DNA 9. Therefore the individual dNTPs are serially added to form the DNA sequence complementary to the unknown region of the template. 11 and 12 represent the first two such dNTPs incorporated into the growing molecule. These in turn provide the identity of their complements 11' and 12' respectively. This growth continues until the entire complementary DNA molecule has been constructed. Completion can be noted by identifying the sequence corresponding to the 8 region of template 6. Turning to Figure IB, a variation of this chemistry is shown in that the template 6* carries the reactive group X which bonds to the substrate via the A-X bond to form an immobilized template 5*. This is then hybridized with primer 3* to give the immobilized, primed template 9* upon which the desired adding of dNTPs takes place to add units 11 and 12 and thus identify the sequence and identity of units 11' and 12' . While in the chemistry illustrated in Figure IB reference is made to coupling template DNA 6* via an X group on its 3' end to the A group on the substrate, it will be appreciated that the template DNA 6* could just as well be coupled through its 5' end. The chemistry for such an attachment is known in the art.
Referring now to Figure 2, a device 13 for carrying out the invention is shown schematically. In this schematic representation, and the representation provided, in Figure 2 , many components such as mixers, valves and the like are omitted to facilitate a clear focus on the invention. Device 13 includes a reaction zone 14 which carries inside it a surface 15. A plurality of copies of a subject primed single stranded DNA are immobilized on this surface 15. This is the strand of DNA for which the sequence is desired. The immobilized DNA is depicted fancifully on surface 15 as if it were present as a series of separately visible attached strands. As will be appreciated, this is not in fact the case and is only done to guide the reader as to the location of the DNA strands . The reaction zone 14 may be configured to permit direct reading of reporter signals emanating from within. Examples of this configuration include equipping the reaction zone to permit measuring fluorescence or luminescence through one or more transparent walls or detecting radionuclide decay. Reaction zone 14 is fitted with inlet 16 for the addition of polymerase or another suitable enzyme capable of moderating the templat¬ e-directing coupling of nucleotides to one another. The reaction zone is^also accessed by inlet lines, 18a-18d for four differently labeled blocked dNTPs, that is 3'blockeddA'TP, 3 'blockeddC' 'TP, 3 'blockeddG' ' 'TP, and 3'blockeddT' ' ' 'TP. These materials can be added in four separate lines, as shown, or can be premixed, if desired, and added via a single line. Buffer and other suitable reaction medium components are added via line 20.
In practice, the polymerase and the four labeled dNTPs are added to the reaction zone 14 under conditions adequate to permit the enzyme to bring about addition of the one, and only the one, of the four labeled blocked dNTPs which is complementary to the first available template nucleotide following the primer. The blocking group present on the 3 '-hydroxyl position of the added dNTP prevents inadvertent multiple additions . After this first addition reaction is complete, the liquid in reaction zone 14 is drained through line 22 either to waste, or if desired to storage for reuse. The reaction zone and the surface 15 are rinsed as appropriate to remove unreacted, uncoupled labeled blocked dNTPs. At this point the first member of the complementary chain is now in place associated with the subject chain attached to surface 15. The identity of this first nucleotide can be determined by detecting and identifying the label attached to it.
This detection and identification can be carried out in the case of a fluorescent label by irradiating the surface with a fluorescence-exciting beam from light source 24 and detecting the resulting fluorescence with detector 26. The detected florescence is then correlated to the fluorescence properties of the four different labels present on the four different deoxynucleotide triphosphates to identify exactly which one of the four materials was incorporated at the first position of the complementary chain. This identity is then noted.
In the next step, a reaction is carried out to remove the blocking group and label from the 3' position on the first deoxynucleotide triphosphate. This reaction is carried out in reaction zone 14. A deblocking solution is added via line 28 to remove the 3' hydroxyl labeled blocking group. This then generates an active 3' hydroxyl position on the first nucleotide present in the complementary chain and makes it available for coupling to the 5' position of the second nucleotide. After completion of the deblocking, removal of the deblocking solution via line 22 and rinsing as needed, the four blocked, labeled deoxynucleotide triphosphates, buffer and polymerase are again added and the appropriate second member is then coupled into the growing complementary chain. Following rinsing, the second member of the chain can be identified based on its label. This process is then repeated as needed until the complementary chain has been completed. At the completion of the construction of the complementary chain, the sequence of incorporated deoxynucleotides is known, and therefore so is the sequence of the complement which is the subject chain. It will be appreciated that this process is easily automated. It is a series of fluid additions and removals from a reaction zone. This can be easily accomplished by a series of timer-controlled valves and the like. This technology has been well developed in the area of oligonucleotide synthesizers, peptide synthesizers, and the like. In such an automated system, the timing can be controlled by a microprocessor or, in most cases, by a simple programmable timer. The rate and "extent of reaction can be monitored by measurement of the reporter concentration at various stages .
The labels present in the blocked dNTPs can be incorporated in one of several manners. For one, they can be incorporated directly and irremovably in the deoxynucleotide triphosphate unit itself. Thus, as the complementary chain grows there is a summing of signals and one identifies each added nucleotide by noting the change in signal observed after each nucleotide is added. Alternatively, and in many cases preferably, the label is incorporated within the blocking group or is otherwise incorporated in a way which allows it to be removed between each addition. This permits the detection to be substantially simpler in that one is noting the presence of one of the four reporter groups after each addition rather than a change in the sum of a group of reporter groups .
In the embodiment shown in Figure 2 , the presence of reporter signal is noted directly in the reaction zone 14 by the analytical system noted as source 24 and detector 26. It will be appreciated, however, that in embodiments where the reporter group is removed during each cycle, it is possible to read or detect the reporter at a remote site after it has been carried out of the reaction zone 14. For example, drain line 22 could be valved to a sample collector (not shown) which would isolate and store the individual delabeling product solutions for subsequent reading. Alternatively, if the nature of the label permitted, the various removed labels could be read as they flowed out of the reaction zone by equipping line 22 with an in-line measurement cell such as source 24' and detector 26' or the like.
A second embodiment of this invention employs four separate parallel reaction zones. This method has the advantage of requiring only one type of labeling and being able to use it with all four dNTPs. Figure 3 shows a schematic representation of a device 30 which has the four reaction zone configuration. In this configuration there are four reaction zones 32a through 32d, each of which resembles the reaction zone 14 in Figure 2. In these cases each of the four reaction zones contains a surface 34a-d to which is immobilized numerous copies of a primed subject single stranded DNA. Each reaction zone is supplied with polymerase via lines 36a-d. Each zone is supplied with suitable reaction medium via lines 38a-38d. The four dNTPs are supplied in blocked form to each zone, as well. In zone 32a one of the blocked dNTPs is labeled, for example "A'"; in zone 32b a second dNTP is labeled, for example "C"; in zone 32c a third dNTP is labeled, for example "G'"; and in 32d the fourth labeled dNTP "T'M is present. These labeled materials are supplied via lines 40a through 40d respectively. Unlabeled blocked dNTPs are supplied via lines 42a-d so that each of the four reaction zones contains three unlabeled blocked dNTPs and one labeled blocked dNTP. Again, as noted with reference to Figure 2, the various labeled and unlabeled dNTP ' s can be premixed. These premixed materials can be added to the various reaction zones via single addition lines.
Using the same general methodology described with reference to Figure 2, the single stranded DNA hybridized to a primer and attached to each of surfaces 34a-34d is contacted with polymerase (supplied via lines 36a-36d), buffer (supplied via lines 38a-38d) and the four bases in each of the four reaction zones . The blocked dNTP which complements the first base on the subject chain couples. In one of the four reaction zones, this base is labeled. By noting in which of the four zones this label is incorporated into the growing chain, one can determine the identity of the dNTP which is incorporated at the first position. This determination of the identity of the first unit of the chain can be carried out using signal sources and detectors such as 44a-44d and 46a-46d, respectively. Deblocking is carried out by adding deblocking solution to the reaction zone through lines 48a-48d. Lines 50a-50d are drain lines for removing material from the reaction zones following each step. In this second configuration, all of the variations noted with reference to the device described in Figure 2 can also be used including cumulating reporter signals and generating reporter signals away from the reaction zone by removing the reporter groups as part of each of the sequential couplings. Clearly, this embodiment can be readily automated, as well.
One obvious potential shortcoming of the present invention is that it employs a long sequence of serial reactions. Even if the efficiency and yield of each of these reactions are relatively high, the overall yield becomes the product of a large number of numbers, each of which is somewhat less than 1.00, and thus can become unacceptably low. For example if the yield of a given addition step is 98% and the deblocking is 98% as well, the overall yield after 15 additions is 48 , after 30 additions it is 23% and after 60 additions it is 5.3%. This limitation can be alleviated by periodically halting the DNA molecule growth and using the sequence data obtained prior to halting the growth to externally recreate a portion of the molecule which can then be used as a primer for renewed DNA fabrication. This process is illustrated in Figure 4. Figure 4 shows a schematic of an automated sequencer 52 employing the present invention. Sequencer 52 has a single reaction zone 14 combining the subject primed DNA, immobilized therein such as on surface 15. The four 3-blocked DNTP's, suitably detachably labeled, are fed to the reaction zone through line 18. Polymerase and buffers are added via lines 16 and 20, respectively. Additionally, the dNTP 's, polymerase and buffer can be recycled from step to step via lines 54 and 56 and holding vessel 58. All of the valves admitting and removing fluids from reaction zone 14 can be controlled by central computer 60 which functions as a valve control clock. This computer 60 can also control the addition of deblocker from line 28, deblocking eluent with cleaved labels (as obtained when the label is present in the blocking group) is removed via line 22 and detected via detector system 24/26 reading label values in detector vessel 62.
This embodiment illustrates the use of a fluorescent label system and shows the addition of fluorescent sensitizer (flooder) via line 64 to the fluorescent detection zone 62.
Following detection of the label in vessel 62, the deblocking solution and detected label are discarded via line 66.
The signal presented by the label identified by detector 26 is passed to analog/digital converter 68 and therein to a memory in central computer 60 where it is stored. After a number of iterations, the memory in computer 60 contains the sequence of an initial portion of the complementary DNA molecule which has been constructed in association with the subject or target DNA molecule contained within reactor 14. After some number of units have been assembled - typically 25 to 300, or more; preferably 50 to 300, or more; and more preferably 100 to 300, or more - the growing complementary DNA molecule is stripped from the immobilized subject DNA molecule and discarded. This stripping (denaturing) can be done by art-known methods such as by warming the reaction zone to 75°C or higher (preferably 90-95°C) for a few (1-15) minutes. Other equivalent methods can be used. The sequence information stored in computer 60 is used to drive DNA synthesizer 70 to externally create a new DNA primer corresponding to at least a portion of the discarded DNA molecule. (The sequence can also be read on printer 72, if desired.) This newly constructed DNA primer molecule is fed through line 74 to reaction zone 14 under hybridization conditions so as to join to the complementary region of the subject DNA molecule as a new primer. The length of the primer must be adequate to. unambiguously and strongly hybridize with a single region of the subject DNA. As is known in the hybridization art, this can depend upon factors such as the sequence, environmental conditions, and the length of the subject DNA. For efficiency of operation, the primer should ideally be as short as possible. Primer lengths typically range from about 10 bases to about 30 bases, although shorter primers would certainly be attractive if they met the above criteria, and longer primers could be used albeit with an increase in cost and time. Good results generally are achieved with primers from 12 to 20 bases long. This gives the molecular growth reaction a "new start" with a large number of properly primed identical molecules. This allows a strong signal to be generated when the next dNTP is coupled.
This restarting of the growth can be carried out as often as needed to assure a strong consistent label signal . Materials and Reagents and Methods of Use
Enzymes and Coupling Conditions
The coupling process employed in this invention to incorporate each of the blocked deoxynucleotide triphosphates into the growing complementary chain is an enzyme moderated process. Each member of the complementary DNA chain is added using a suitable template-dependent enzyme. One enzyme which can be used is Sequenase TM enzyme (an enzyme derived from bacteriophage 7 DNA polymerase that is modified to improve its sequencing properties - see Tabor and
Richarson, Proc. Nat. Acad. Sci. USA, 84:4767-4771
(1987)—sold by United States Biochemical Corporation, Cleveland, Ohio) . Other polymerases which can be used instead of Sequenase TM include but are not limited to
Klenow fragment of DNA polymerase I, AMV reverse transcriptase, and Taq polymerase.
Typically the coupling conditions which are employed are those known in the art for these enzymes. In the case of Sequenase TM these include temperatures in the range of from about room temperature to about 45 C; a buffer of pH 7 to 8 and preferably pH 7.3 to 7.7; an enzyme concentration of from about 0.01 units per microliter to about 1 unit per microliter and a reaction time of from about 1 to about 20 minutes and preferable 1 to 5 minutes. A typical buffer for use with Sequenase TM is made up of
0.040 M Tris HCl (pH 7.5) 0.050 M sodium chloride
0.010 M magnesium chloride
0-010 M dithiothreitol
In the case of Klenow fragment of DNA polymerase
I, these typical conditions include temperatures in the range of from about 10 C to about 45 C and preferably from about 15°C to about 40°C; a buffer of pH 6.8 to 7.4 and preferably pH 7.0 to 7.4; an enzyme concentration of from about 0.01 units per microliter to about 1 unit per microliter and preferably from about 0.02 to about 0.15 units per microliter and a reaction time of from about 1 to about 40 minutes. A typical buffer for use with Klenow fragment of DNA polymerase I is made up of
0.05 M Tris chloride, pH 7.5 0.05 M magnesium chloride 0.05 M sodium chloride • 0.010 M dithiothreitol
These conditions are representative. When other enzymes are employed, one should use the conditions optimal for them since it is generally desirable to run the addition reaction as quickly as possible. To this end, it is often desirable to use temperatures of 42 C for reverse transcriptase; 24 C for Klenow polymerase; 37 C with Sequenase TM and 72oC with Taq polymerase. In addition, to force the reaction, especially with derivatized dNTP's it may often be helpful to use substantial excesses (over εtoichiometry) of the dNTP's, or to modify other conditions such as the salt concentration.
Blocking Groups and Methods for Incorporation The coupling reaction generally employs
3 'hydroxyl-blocked dNTPs to prevent inadvertent extra additions .
The criteria for the successful use of
3 '-blocking groups include: (l) the ability of a polymerase enzyme to accurately and efficiently incorporate the dNTPs carrying the 3 '-blocking groups into the cDNA chain,
(2) the availability of mild conditions for rapid and quantitative deblocking, and (3) the ability of a polymerase enzyme' to reinitiate the cDNA synthesis subsequent to the deblocking stage.
In addition, if the 3 '-blocking group carries a reporter group, it is desirable that the reporter permit sensitive detection either when part of the cDNA chain before deblocking or subsequent to deblocking in the reaction eluant.
For the present invention, 3 '-blocked dNTPs are used that can be incorporated in a template-dependent fashion and easily deblocked to yield a viable 3 ' -OH terminus. The most common 3 '-hydroxyl blocking groups are esters and ethers. Other blocking modifications to the 3'-OH position of dNTPs include the introduction of groups such as -F, -NH2, -OCH- , -N-., -OP03 =, -NHCOCH-, 2- nitrobenzene carbonate, 2 ,4-dinitrobenzene sulfenyl and tetrahydrofuranyl ether. Incorporation and chain termination have been demonstrated with dNTPs containing many of these blocking groups (Kraevskii et al . , 1987) . Presently preferred embodiments focus on the ester blocking groups such as lower (1-4 carbon) alkanoic acid and substituted lower alkanoic acid esters, for example formyl, acetyl, isopropanoyl, alpha fluoro- and alpha chloroacetyl esters and the like; ether blocking groups such as alkyl ethers; phosphate blocking groups; carbonate blocking groups such as 2-nitrobenzyl; 2,4-dinitrobenzene-sulfenyl and tetrahydrothiofuranyl ether blocking groups. Blocking groups can be modified to incorporate reporter moieties, if desired, including radiolabels (tritium, C 14 or F~**2 , for example), enzymes, fluorophores and chromophores .
These blocking materials in their fundamental forms have all been described in the literature as has their use as blockers in chemical DNA synthesis settings. Two representative blockers, esters and phosphate, can be incorporated into dNTP's as follows: The general procedure for synthesis of 3 ' -O-acyl dNTPs is outlined in Reaction Scheme 1 set forth in Figure 5 for 3'-0-acetyl TTP. 5 '-Dimethoxytrityl (DMT) thymidine 2_ is prepared from thymidine 1 by reaction with DMT chloride in pyridine, followed by acetylation of the 3 '-OH function using acetic anhydride in pyridine to yield _3 (Zhdanov and Zhenodarova, 1975) . Treatment of the 5'-DMT group with 2% benzene-sulfonic acid yields 4^, which is converted into the phosphomonoester 5_ by reaction with POC1-. in trimethyl phosphate (Papchikhin et al., 1985) and by purification using chromatograph . The 5'- monophosphate is converted into the 5 '-triphosphate (5 by activation with N,N'-carbonyldiimidazole, followed by pyrophosphorylation with tri(n-butylammonium) pyrophosphate (Papchikhin et al. , 1985) and purification by chromatography.
Preparation of 3'-0-acetyl derivatives of dATP, dCTP, and dGTP follows the same general scheme, with additional steps to protect and deprotect the primary amino functions (see below). Because 5 '-triphosphate derivatives of nucleosides are often unstable, the final preparative steps outlined above may be optionally carried out just before introducing the dNTPs into the reaction cell. If radiolabeled acetic anhydride is used, this serves to introduce a label into the ester blocking group. When carrying out this ester-blocking of the 3'- OH group it should be borne in mind that the primary amino residues in cytosine, adenine, and guanine are also susceptible to attack by electrophilic reagents such as acetic anhydride and may be advantageously protected. In chemical oligonucleotide synthesis (phosphotriester or phosphoramidite approaches . , various N-acyl groups are commonly used for protection of the primary amine (Papchikhin et al . , 1985) . Because the N-acyls are stable in acidic and neutral solutions, removal is typically effected by ammonolysis. These conditions are likely to cleave 3'-0-acyl blocking groups and other blocking groups hydrolyzable under basic conditions, so alternative N-protection should be used if it is desired to selectively remove the amino group protection. Several selectively-removable amine protection groups include carbamateε cleavable by acid hydrolysis [t-butyl, 2-(biphenyl)isopropyl] and certain amides susceptible to acid cleavage (formamide, trichloroacetamide) (Greene, 1981) . The synthesis of 3 '-monophosphate dNTPs is outlined in Reaction Scheme 2 set forth in Figure 6 for TTP and is a modification of reported procedures for chemical oligonucleotide synthesis using the H-phosphonate method (Froehler et al . , 1986) . 5 ' -DMT-3 '-thymidine H-phosphonate 1_ is prepared by reaction of 5'-DMT thymidine 2_ with phosphorous trichloride, 1 , 2 , 4-triazole, and N-methylmorpholine . Removal of the 5 '-protecting group and formation of the 5 '-triphosphate moiety (7 to 11) is achieved as shown in Scheme 1. The 3 '-OH phosphonate TTP VI is converted to the 3 '-O-monophosphate 12 by oxidation with iodine in basic solution.
For other nucleotide derivatives, protection of the primary amino groups is performed prior to phosphonation. In this preparation, standard amino protecting groups cleavable by ammonolysis may be used.
Deblocking Methods
After successfully incorporating a 3 '-blocked nucleotide into the DNA chain, the sequencing scheme requires the blocking group to be removed to yield a viable 3 '-OH site for continued chain synthesis. The deblocking method should:
(a) proceed rapidly,
(b) yield a viable 3 '-OH function in high yield, and, (c) not interfere with future enzyme function or denature the DNA strand.
(d) the exact deblocking chemistry selected will, of course, depend to a large extent upon the blocking group employed. For example, removal of ester blocking groups from the 3 'hydroxyl function is usually achieved by base hydrolysis. The ease of removal varies widely; generally, the greater the electro-negativity of substituents on the carbonyl carbon, the greater the ease of removal. For example, the highly electronegative group trifluoroacetate is cleaved rapidly from 3' hydroxyls in methanol at pH 7 (Cramer et al. , 1963) and thus would not be stable during coupling at that pH. Phenoxyacetate groups are cleaved in less than one minute but require substantially higher pH such as is achieved with NH-/ methanol (Reese and Steward, 1968). To prevent significant premature deblocking and DNA degradation, the ester deblocking rate is advantageously selected so as to exhibit a deblocking rate of less than 10 -3s-1 during the incorporation, and at least 10~ s during the deblocking stage. Ideally, this rate change is achieved by changing the buffer pH from 7 to about 10, but care must be taken not to denature the DNA.
A wide variety of hydroxyl blocking groups are cleaved selectively using chemical procedures other than base hydrolysis. 2,4-Dinitrobenzenesulfenyl groups are cleaved rapidly by treatment with nucleophiles such as thiophenol and thiosulfate (Letsinger et al., 1964). Allyl ethers are cleaved by treatment with Hg(II) in acetone/water (Gigg and Warren, 1968) .
Tetrahydrothiofuranyl ethers are removed under neutral conditions using Ag(I) or Hg(II) (Cohen and Steele, 1966; Cruse et al . , 1978). These protecting groups, which are stable to the conditions used in the synthesis of dNTP analogues and in the sequence incorporation steps, have some advantages over groups cleavable by base hydrolysis - deblocking occurs only when the specific deblocking reagent is present and premature deblocking during incorporation is minimized.
Photochemical deblocking can be used with photochemically-cleavable blocking groups. Several blocking groups are available for such an approach. The use of o-nitrobenzylethers as protecting groups for 2 '-hydroxyl functions of ribonucleosides is known and demonstrated (Ohtsuka et al. , 1978); removal occurs by irradiation at 260 nm. Alkyl o-nitrobenzyl carbonate protecting groups are also cleaved by irradiation at pH 7 (Cama and Christensen, 1978).
Enzymatic deblocking of 3 '-OH blocking groups is also possible. It has been demonstrated that T4 polynucleotide kinase can convert 3 '-phosphate termini to 3 '-hydroxyl termini that can then serve as primers for DNA polymerase I (Henner et al . , 1983). This 3 '-phosphatase activity is used to remove the 3 '-blocking group of those dNTP analogues that contain a phosphate as the blocking group; the radioactive label enables the incorporation of the nucleotide analogue and the removal of the phosphate group to be followed easily. . If the use of radioisotopes represents too great a drawback, it is possible to use unlabeled phosphate monoesters with a cleavable fluorescent label (see below).
This method is improved by increasing the efficiency and speed of each step. Upon selection of the optimal methodology for incorporation and deblocking, other nonchemical assistance may be used to accelerate chemical deblocking. This may include, for example applying controlled ultrasonic irradiation of the reaction chamber to increase the rate of the deblocking step if mass transport limitations are significant and raising the reaction temperature up to about 50 C for a short period. Reporter Groups, their Incorporation and Detection
As part of this invention, the incorporation of each dNTP into the complementary chain is noted by detecting a label or reporter group present in or associated with the incorporated dNTP. The labels or markers are "innocuous". An "innocuous marker or label or reporter" refers to a radioactive, fluorescent, or the like marker or reporter which has physical and chemical properties which do not interfere with either the enzymatic addition of the marked nucleotide to the cDNA, or the subsequent deblocking to yield a viable 3 '-OH terminus .
One simple labeling approach is to incorporate a radioactive species within the blocking group or in some other location of the dNTP units. This can be done easily by C 14 labeling or P32 labeling.
Another labeling approach employs fluorescent labels. These can be attached to the dNTP's via the 3 '0H- blocking groups or attached in other positions. There are two general routes available using fluorescent tags:
(1) the use of a labeling group that is itself fluorescent and detected either before or after deblocking, and
(2) the use of a nonfluorescent labeling group that is detected by its fluorescent interaction with a nonfluorescent probe or other moiety.
The first route is fairly straightforward and can employ a range of known fluorophores such as rhodamines, fluoresceins and the like, typically including those fluorophores known as useful in labeling dNTP's and the like. One caution however, is to try to select fluorophores which are not so large and bulky that the labeled dNTP can not be incorporated readily into the growing DNA chain by a polymerase or similarly functioning enzyme. The second route can employ a fluorophore where only a fragment is attached to the dNTP. This can reduce size and minimize steric interference. In the second route, rapid reaction of a normally nonfluorescent probe or molecule with specific functional group(s) found only on the label fragment leads to the formation of a fluorescent addition product. This leads to a signal only when the particular labeling group is present.
One system that is applicable to this scheme is the thiol/maleimide interaction:
NONFLUORESCENT FLUORESCENT
Certain N-substituted maleimides which are normally nonfluorescent react readily with various thiols to form fluorescent products (Kanaoka, 1977). Blocking groups or other label fragment groups containing free thiol functions, such as -COCH2SH, can be used for this approach. Alternatively, the blocking group or other label fragment can contain a metal-binding ligand, e.g. a carboxylic acid group which will react with added rare earth metal ions such as europium or terbium ions to yield a fluorescent species.
While the above-described approaches to labeling focus on incorporating the label into the 3'-hydroxyl blocking group, there are a number of alternatives - particularly the formation of a 3'-blocked dNTP analogue containing a label such as a fluorescent group coupled to a remote position such as the base. This dNTP can be incorporated and the fluorescence measured and removed according to the methods described below. One method involves the use of a fluorescent tag attached to the base moiety. The tag may be chemically cleaved (either separately from or simultaneously with the deblocking step) and measured either in the reaction zone before deblocking or in the reaction eluant after cleavage. This method is included because a number of base moiety derivatized dNTP analogues have been reported to exhibit enzymatic competence. Sarfati et al, (1987) demonstrates the incorporation of biotinylated dATP in nick translations, and other biotinylated derivatives such as 5-biotin (19)-dUTP (Calbiochem) are incorporated by polymerases and reverse transcriptase. Prober et al .
(1987) show enzymatic incorporation of fluorescent ddNTPs by reverse transcriptase and Sequenase TM
In another type of remote labeling the fluorescent moiety or other innocuous label can be attached to the dNTP through a spacer or tether. The tether can be cleavable if desired to release the fluorophore or other label on demand. There are several cleavable tethers that permit removing the fluorescent group before the next successive nucleotide is added—for example, silyl ethers are suitable tethers which are cleavable by base or fluoride, allyl ethers are cleavable by Hg(II), or 2 ,4-dinitrophenylsulfenyls are cleavable by thiols or thiosulfate. Cleavages using acidic conditions are undesirable because DNA is more labile in acid than in base. Long tethers ma}7 be used so that the large fluorescent groups are spaced sufficiently far away from the base and triphosphate moieties and do not interfere with the binding of the dNTP to the polymerase or with proper base pairing during complementary chain growth. Typical tethers are from about 2 to about 20, and preferably from about 3 to about 10 atoms in length.
The C-8 position of the purine structure presents an ideal position for attachment of a label. Sarfati et al . (1987) describes a derivatization of deoxyadenosine at C-8 of the purine to prepare, ultimately, an 8-substituted biotin aldylamino dATP. The Sarfati et al . (1987) approach can be used to prepare the appropriate fluorescent, rather than biotinylated, analogues. A number of approaches are possible to produce fluorescent derivatives of thymidine and deoxycytidine. One quite versatile scheme is based on an approach used by Prober et al . (1987) to prepare ddNTPs with fluorescent tags. Structures A, B, C and D below illustrate the type of fluorescent dNTPs that result from these synthetic approaches. The synthetic routes have a great flexibility in that the linker can be varied with respect to length or functionality. The terminal fluorescent moiety can also be varied according to need.
The labels so incorporated in the growing cDNA chain are detected by conventional analytical methods . In many cases, particularly with fluorescent labels, increased detection sensitivity is a major advantage of the present method. When the fluorescent signal is detected in sequencing gels, the signal is based on a low level of fluorophores and is superimposed on a background of scatter from the gel and glass plates. This decreases sensitivity and often constrains current methods to the use of laser illumination to maximize sensitivity (Smith et al., 1986; Prober et al . , 1987; Ansorge et al . , 1986) . Detection of fluorophores is readily achievable in commercial non-excited spectrofluorometers , such as are sold by Perkin-Elmer. In these devices, the requirement for a laser light source is eliminated (although one can of course be used if desired) allowing use of light- emitting diodes (LED) or a conventional xenon arc lamp, the choice being dictated primarily by the fluorochromes decided upon and the excitation frequency they require. Typical LEDs include:
(1) Red LED, emitting at approximately 650 nm
2 with a radiance of 40 mw/cm /steradian;
(2) Green LED, emitting at approximately 540 nm; and (3) Blue LED, emitting at approximately 450 nm.
Although fluorescent and radioactive detection methods form the basis of the preferred approaches, other detection procedures are contemplated. Chemiluminescence can be used as the detection method. Interaction of specific (cleaved) blocking groups with immobilized lumiυol derivatives could also be detected spectroelectrochemically.
In another approach, using mass spectrometric detection, the solution containing cleaved blocking groups or nucleotides is directly injected into a field ionization mass spectrometer. Identification of the particular nucleotide incorporated or cleaved is achieved by monitoring the relative abundance of molecular ion peaks corresponding to the specific nucleotides or blocking groups; for example, four distinct acetyl blocking groups differing by one mass unit (replacement of 0 to 3 hydrogens by deuterium) could be detected by monitoring a small "window. "
Immobilization of Subject DNA. In the present invention, single stranded subject DNA or its primer is immobilized. One approach to this immobilization is to attach the DNA to a solid substrate. Many of the techniques of modern molecular biology involve immobilization of DNA onto a solid support. DNA and RNA are commonly attached noncovalently through ionic interactions along their length to various types of membranes (Southern, 1975; Maniatis, Fritsch, and Sambrook, 1982; Chuvpilp and Kravchenko, 1984). Similarly, polynucleotides are covalently attached along their length to membranes (Goldberg, et al . , 1979), resins (Seed, 1982; Arndt-Jovin, et al . , 1975), or plastic (Polsky-Cynkin, et al. , 1985). These methods may be employed subject to the caution that this multipoint attachment may, in some cases, introduce interference with the subsequent synthesis of the complementary DNA strand. A single-point covalent attachment of DNA to a solid polymer or glass support is possible. Such single-point methods are preferred for immobilizing the subject DNA, since this leaves the chain free for interactions with the polymerase and similar enzymes used herein.
To effect a single point coupling of DNA to glass or quartz it is often preferred to treat the glass or quartz to assure an inert bond and prevent loss of the DNA during the reactions and rinses carried out in the present method. Pochet et al . (1987) have shown that' a very efficient immobilization of DNA occurred on a silanized glass surface. Therefore, the inner quartz or glass surface can be advantageously functionalized using silanizing reagents such as triethoxysilylpropylamine or dichlorodi ethylsilane. This is followed by covalent attachment of a long-chain alkylamine to these functionalizing groups. The single stranded subject DNA is attached to the long chain amine. The attached single stranded DNA then serves as the template for the formation of the complementary chain. In another embodiment, immobilization is carried out by attaching the subject DNA to a plastic surface. A thin polypropylene chamber wall designed to pass Cer'enkov radiation from 32P, for example, can serve as a suitable substrate for DNA immobilization. With a plastic surface, it is preferable to use the method of Kremsky et al .
(1987), wherein the surface is coated with streptavidin, to which an alkylbiotinylated oligonucleotide will bind. The immobilized oligonucleotide is annealed to the template DNA as a primer. In addition to retaining the subject single strand DNA by means of immobilizing it to a surface, the subject DNA can also be entrapped by the use of membranes which retain it. In this embodiment, the reaction zone has one or more openings covered with a membrane such as an ultrafiltration membrane, for example, Amicon's PM-5 or PM-10 membranes which have nominal molecular weight cut offs of 5000 and 10,000 respectively. That is, they are capable of passing materials having molecular weights of less than 5,000 and 10,000 respectively while retaining materials above these sizes. Other ultrafiltration or dialysis membranes such as those marketed by Dow or Abcor can also be used. In this embodiment, the single stranded DNA is suspended in liquid in the reaction zone. The labeled and unlabeled dNTPs and other coupling reagents are flowed into the zone. Materials are removed from the zone through such a filter which retains the DNA chains. In this method, the polymerase or other enzyme which is used to effect coupling is generally of a size to be retained by the membrane. This scheme works for chemical but not enzymatic deblocking, since in enzymatic deblocking the polymerase and phosphatase must be cycled separately through the cell.
In an alternative embodiment the DNA can be immobilized on particles of resin or polymer microspheres and these particles retained within the chamber. In this embodiment, the filter material is unimportant as long as the DNA is attached to resin particles which are of a size that cannot penetrate the filter pores . There are several methods that couple DNA to resins through the 5' terminus (Pochet, 1987; Polysky-Cynkin, 1985). For example, oligonucleotides or polynucleotides are linked through their 5' end to cellulose (Gilha , 1968; Clerici et al . 1979), Sephacryl (Langdale and Malcolm, 1985), or latex microspheres (Kremsky et al., 1987). In these methods, the DNA is available for interactions with other nucleic acids or proteins . Of particular interest for our application is the method of Goldkorn and Prockop (1986) for covalent coupling of DNA to oligo(dT)-cellulose. Alternatively, the DNA is coupled covalently to streptavidin-agarose beads by an alkylbiotinylated oligonucleotide (Kremsky et al., 1987).
In yet another embodiment, the single-stranded DNA is coupled to DBM paper such as a filter in the presence of a protecting strand. After coupling, the protecting strand is released, leaving the immobilized template and priming site free for successive enzymatic reactions (Hansen et al . , 1987) . This method and the other single-point methods described above are useful for immobilizing DNA while leaving it free for interactions with enzymes used in DNA sequencing- Examples
Example 1 Synthesis of 3'-P0-,f 32P] Thymidine Triphosphate: To a stirred solution of phosphorus trichloride ( 32P) (75 mmole) and N-methyl morpholine (750 mmole,
Aldrich) in 750 ml dry methylene chloride (CH2C12 is added 1,2 , 4-triazole (250 mmole) at room temperature. The reaction mixture is stirred one hour, cooled to 0 C and 15 mmole of 5 '-dimethoxytrityl thymidine I (Sigma) in 200 ml of anhydrous acetonitrile is added dropwise over 30 minutes. (See Reaction Scheme 3 given in Figure 7) . The solution is stirred an additional 30 minutes, and poured into 600 ml of 1M triethylammonium bicarbonate (TEAB, pH, 8.5) . The organic layer is separated and the aqueous layer washed with 2 x 200 ml CH2C12 The combined CH-Cl- extracts are dried over magnesium sulfate (MgSO.), filtered and evaporated to dryness under vacuum at room temperature. The crude 5 '-dimethoxytrityl-3 'thymidine H-phosphonate II is then treated with 2% benzenesulfonic acid in CH^Cl- -.methanol (MeOH) (7:3) (200 ml) for one hour. The solution is washed with 10% sodium bicarbonate (NaHCO-) and water, dried over magnesium sulfate and evaporated to dryness. The crude 3 '-thymidine- H-phosphonate III is recrystallized from ethanol/ether. To a solution of 1 ml of phosphorus oxytrichloride (POC1-.) in 30 ml of triethylphosphate at 0 C is added 10 mmole of the 3 '-thymidine H-phosphonate. The mixtu-re is stirred for 12 hours at 4 C, neutralized with NaHCO.. solution,- and added to 150 ml water. The aqueous solution is washed with benzene (2 x 100 ml) and ether ( 2 x 100 ml), and diluted to 0.8 liters with water and charged on a 2.5 x 50 cm column of DEAE-cellulose. The products are eluted using a linear gradient of pH 8.5 ammonium bicarbonate solution (0.05 to 0.25 M) . The fractions collected are analyzed by HPLC to determine the desired product-containing fractions, and these are evaporated to dryness under vacuum. The residue is repeatedly re-evaporated with water to remove salts .
The 5 '-monophosphate IV (16 mmole) is then dissolved in 30 ml of dimethylformamide (DMF) and treated with N,N'-carbonyldiimidazole (30 mmole) at room temperature for one hour. The reaction is quenched by addition of 5 ml methanol, and 60 ml of a 0.5M solution of bis (tri-n-butyl-ammonium) pyrophosphate in DMF is added dropwise over 10 minutes. After stirring for 24 hours, the solution is diluted with water to 1 liter and treated with 100 ml of a solution of 0.1 M iodine (I-.) in 5% pyridine/water. After one hour, the solution is deposited on a DEAE-cellulose column from Sigma (5x50cm) or Sephradex from Pharmacia. The column is washed with water and eluted with triethylammonium bicarbonate solution
(0.05 to 0.5M) . The 5 '-triphosphate-3 '-phosphate thymidine product V is obtained by evaporation of the appropriate fractions collected.
Example 2
Synthesis of 3 '-labelled (fluorescent) thymidine triphosphate
A solution of 5-dimethoxytrityl thymidine I (2.5 mmole) in 10 ml dry pyridine is treated with succinic anhydride (8 mmole) at 4°C for 24 hours. Cold water
(150ml) is added, and after 30 minutes the solution is filtered. The washed, dried, precipitate is taken up in
30 ml CH-C1-, extracted with water (2 x 25ml), dried over MgSO^ and evaporated to dryness. (See Reaction Scheme 4 shown in Figure 8. )
The 5 '-dimethoxytrityl-thymidine 3'-succinate VI
(2mmole) is dissolved in 15 ml dry CH. _-_.C1.__,., cooled to 0°C and treated with a fivefold excess of N,N' -dicyclohexyl- carbodiimide and N-hydroxybenzotriazole. After one hour, an equivalent amount of the fluorescent labeling group containing a pendant amino function, dansylcadaverine, is added and the solution stirred for 8 hours at 10 C. The solution is then washed with water (2 x 10 ml). The CH2C1 layer is dried over MgS04 and evaporated to dryness to yield the product VII. Removal of the dimethoxytrityl protecting group and conversion to the 5 'triphosphate VIII is accomplished in the same manner as described for the 3 '-phosphate thymidine triphosphate V. This reaction is carried out in similar fashion using the other three nucleosides to give the corresponding labeled materials.
Example 3 Quartz Surface Immobilization of Subject DNA Four 25 microliter volume quartz cuvette reaction chambers are prepared. These chambers are configured like chamber 32 in Figure 3 with the exception that they use their inner walls as the surface to which the DNA is affixed. The inner surfaces are cleaned and dried.
Triethoxysilylpropylamine (5 microliter in 20 microliter CHC1-.) is added and held at 5°C for 120 minutes under anhydrous conditions . This couples the triethoxysilylpropylamine to the surface and gives an amine character to the surface.
The subject DNA is then attached to the amine surface. This is carried out by first attaching a long chain alkyl amine (n-octylamine) to the base at the 5' end of the subject DNA molecule or to the base at the 5 ' end of a suitable primer, such as an M13 primer for example the 17-mer dGTAAAACGACGGCCAGT, and then joining the alkylamine to the aminopropylεilane surface groups by reaction with glutaraldehyde (1.5 equivalents, 25°C, 120 minutes). Other functional groups pendant to the base moiety or attached to the 5' position can also be used [for example: aldehydes or carboxylic acids (Kremsky et al) ] for covalent immobilization on derivatized quartz or glass surfaces.
Example 4 Incorporation of Labeled Nucleotide Analogs into DNA The 25 microliter reaction zones are charged with a reaction mixture which contains three Units of Sequenase TM enzyme. The reaction mixture also contains an appropriate buffer for this enzyme (20 mM Tris-HCl pH 7.5, 10 mM MgCl, 25 mM NaCl, 0.01 M dithiothreitol), the i single-stranded primed subject DNA is present at a concentration of approximately 0.1 M attached to the surface of the reaction chamber at its 5' end, (see Example 3), three unlabeled, 3 '-blocked deoxynucleotide triphosphate (dNTP) analogs at a concentration of 1.5 micromolar each, and one 3 '-blocked, fluorescently labeled dNTP analog of Example 2 at a concentration of 30 micromolar are each present in each of the four reaction zones. In each zone a different one of the four dNTPs is labeled. The reaction proceeds at room temperature for one minute. Then the reaction zones are drained and rinsed with buffers.
In one embodiment the identity of the added dNTP is determined by exciting the fluorophores present in the one cuvette which incorporated its fluorescently-labeled dNTP. Alternatively, the fluorescent group is removed before measurement.
Example 5 Chemical Deblocking
The 2 ,4-dinitrobenzenesulfenyl fluorescent blocking groups are removed with a deblocking reagent which consists of 0.1 M pyridine/pyridinium chloride buffer (pH 7.8) containing thiourea 0.05 M. The deblocking reaction is allowed to proceed for one minute at 40 C- The reaction chamber is then drained and washed twice with 100 mM Tris-HCl buffer, pH 6.5. The release of the fluorescent blocking group is measured in the initial eluate from the reaction chamber using a flow-through cell. Depending on the cell in which the fluorescent group is present, the identity of the nucleotide which has been added to the DNA chain is determined. Similarly, if the blocking group were a dansylcadaverine type ester such as in reaction scheme 4 , it could be removed by treatment with 50% methanol/50% water pH 10.0 for one minute.
Example 6 Enzymatic Deblocking The blocking group can also be removed enzymaticall . For enzymatic deblocking, the deblocker fed into the reaction chamber contains 100 mM Tris-HCl (pH 6.5) 10 mM MgCl-, 5 mM 2-mercaptoethanol, and one Unit T4 polynucleotide kinase. The reaction proceeds for one minute at a temperature of 37 C. The 3 ' -phosphatase activity of T4 polynucleotide kinase converts 3 '-phosphate termini to 3 '-hydroxyl termini which then serve as primers for further synthesis.
While in these examples, the invention has been shown as practiced in a manual manner with each step being carried out sequentially, it can readily be appreciated that this process can be easily automated. A simple clock mechanism or microprocessor driven timer circuit can be used to actuate a plurality of electrically controlled valves in. sequence to add the various reagents for adding building blocks, deblocking and the like with the result that the sequence of the target DNA single strand can be obtained with minimum involvement of lab personnel .
While only a few embodiments of the invention have been shown and described herein, it will become apparent to those skilled in the art that various modifications and changes can be made in the present invention to methods to determine the sequence of deoxyribonucleotides in a deoxyribonucleotide chain (DNA) without the use of a sequencing gel without departing from the spirit and scope of the present invention.

Claims

What is Claimed:
1. A method for determining the sequence of deoxyribonucleotides in a subject single stranded deoxyribonucleic acid (DNA) molecule comprising: synthesizing, in the presence of the subject DNA molecule, the complementary DNA molecule, the synthesizing being carried out in a stepwise serial manner in which the identity of each deoxynucleotide triphosphate incorporated into the complementary DNA molecule is determined subsequent to its incorporation.
2. The method of claim 1 wherein the synthesizing of the complementary DNA molecule is carried out enzymatically.
3. The method of claim 1 wherein the synthesizing of the complementary DNA molecule is carried out with addition occurring at the 3'-OH position of the complementary DNA molecule.
4. The method of claim 3 wherein each deoxynucleotide triphosphate as incorporated into the complementary DNA molecule is modified to contain a blocking group at its 3'-OH position.
5. The method of claim 4 wherein the blocking group is removed from each deoxynucleotide triphosphate after it has been incorporated into the complementary DNA molecule.
6 - The method of claim 1 wherein the identity of each deoxynucleotide triphosphate incorporated into the complementary DNA molecule is determined by identifying at least one reporter group associated with at least one of the four deoxynucleotide triphosphates.
7. The method of claim 1 wherein the synthesizing of the complementary DNA molecule includes contacting the subject single stranded DNA molecule with all four deoxynucleotide triphosphates under conditions such that the deoxynucleotide triphosphate complementary to the next deoxynucleotide in the subject strand is uniquely incorporated into the complementary DNA molecule.
8. The method of claim 7 wherein the contacting is carried out in a single reaction zone.
9. The method of claim 7 wherein the subject single stranded DNA is contacted with all four deoxynucleotide triphosphates. -
10. The method of claim 7 wherein the subject single stranded DNA is simultaneously contacted with all four deoxynucleotide triphosphates .
11. The method of claim 10 wherein the contacting is carried out in a single reaction zone.
12. The method of claim 10 wherein the contacting is carried out with each of the four deoxynucleotide triphosphates associated with reporter groups distinguishing one from another and wherein the determination of the particular deoxynucleotide triphosphate incorporated is accomplished by identifying the particular reporter group associated therewith.
13. The method of claim 12 wherein the contacting is carried out in a single reaction zone.
14 - The method of claim 13 wherein the reporter group remains associated with the deoxynucleotide triphosphate after the deoxynucleotide triphosphate is incorporated into the complementary DNA molecule such that as each deoxynucleotide triphosphate is incorporated the cumulative reporter signals increase.
15. The method of claim 14 wherein the synthesizing of the complementary DNA molecule is carried out enzymatically with addition occurring at the 3'-OH position of the complementary DNA molecule.
16. The method of claim 15 wherein the subject single stranded DNA molecule and the growing complementary DNA molecule are immobilized in the reaction zone.
17. The method of claim 16 wherein the immobilization of the subject single stranded DNA molecule and the growing complementary DNA molecule is accomplished by enclosing the molecules with porous membranes having porej which are too small for the molecules to pass through.
18. The method of claim 16 wherein the immobilization of the subject single stranded DNA molecule and the growing complementary DNA molecule is accomplished by attaching the molecules to a surface within the reaction zone.
19. The method of claim 13 wherein the reporter group is disassociated from the complementary DNA molecule prior to.the addition of the next deoxynucleotide triphosphate such that the reporter signal noted when said next deoxynucleotide triphosphate is added is uniquely related to said next deoxynucleotide triphosphate.
20. The method of claim 19 wherein the synthesizing of the complementary DNA molecule is carried out enzymatically with addition occurring at the 3'-OH position of the complementary DNA molecule.
21. The method of claim 20 wherein the subject single-stranded DNA molecule and the growing complementary
DNA molecule are immobilized in the reaction zone.
22. The method of claim 21 wherein the immobilization of the subject single stranded DNA molecule and the growing complementary DNA molecule is accomplished by enclosing the molecules with porous membranes having pores which are too small for the molecules to pass throug .
23. The method of claim 22 wherein the immobilization of the subject single stranded DNA molecule and the growing complementary DNA molecule is accomplished by attaching the molecules to a surface within the reaction zone.
24. The method of claim 19 wherein each deoxynucleotide triphosphate as incorporated into the complementary DNA molecule is modified to contain a blocking group at its 3'-OH position and the blocking group is removed from each deoxynucleotide triphosphate after it has been incorporated into the complementary DNA molecule.
25. The method of claim 24 wherein the reporter group is associated with the blocking group.
26. The method of claim 25 wherein the reporter group is a radiolabel .
27. The method of claim 25 wherein the reporter group is a fluorolabel.
28. The method of claim 25 wherein the reporter group is identified while associated with the complementary DNA molecule.
29. The method of claim 25 wherein the reporter group is identified after being dissociated from the complementary DNA molecule.
30. The method of claim 7 wherein the synthesizing is carried out in four parallel reaction zones, each having the four deoxynucleotide triphosphates contained therein and each having a different one of the four deoxynucleotide triphoshates associated with a reporter group.
31. The method of claim 30 wherein the reporter groups with which the four deoxynucleotide triphosphates are associated are from one to four different reporter groups -
32. The method of claim 30 wherein the reporter groups with which the four deoxynucleotide triphosphates are associated are a single reporter group.
33. The method of claim 32 wherein the reporter group remains associated with the deoxynucleotide triphosphate after the deoxynucleotide triphosphate is incorporated into the complementary DNA molecule such that as each deoxynucleotide triphosphate is incorporated the cumulative reporter signals increase.
34. The method of claim 33 wherein the synthesizing of the complementary DNA molecule is carried out enzymatically with addition occurring at the ' -OH position of the complementary DNA molecule.
35. The method of claim 34 wherein the subject single stranded DNA molecule and the growing complementary DNA molecule are immobilized in the reaction zone.
36. The method of claim 35 wherein the immobilization of the subject single stranded DNA molecule and the growing complementary DNA molecule is accomplished by enclosing the molecules with porous membranes having pores which are too small for the molecules to pass through.
37. The method of claim 35 wherein the immobilization of the subject single strand DNA molecule and the growing complementary DNA molecule is accomplished by attaching the molecules to a surface within the reaction zone.
38. The method of claim 32 wherein the reporter group is disassociated from the complementary DNA molecule prior to the addition of the next deoxynucleotide triphosphate such that the reporter signal noted when said next deoxynucleotide triphosphate is added is uniquely related to said next deoxynucleotide triphosphate.
39. The method of claim 38 wherein the synthesizing of the complementary DNA molecule is carried out enzymatically with addition occurring at the 3 '-OH position of the complementary DNA molecule.
40. The method of claim 39 wherein the subject single stranded DNA molecule and the growing complementary DNA molecule are immobilized in the reaction zone.
41. The method of claim 0 wherein the immobilization of the subject single stranded DNA molecule and the growing complementary DNA molecule is accomplished by enclosing the molecules with porous membranes having pores which are too small for the molecules to pass through.
42. The method of claim 41 wherein the immobilization of the subject single stranded DNA molecule and the growing complementary DNA molecule is accomplished by attaching the molecules to a surface within the reaction zone.
43. The method of claim 38 wherein each deoxynucleotide triphosphate as incorporated into the complementary DNA molecule is modified to contain a blocking group at its 3'-OH position and the blocking group is removed from each deoxynucleotide triphosphate after it has been incorporated into the complementary DNA molecule.
44. The method of claim 43 wherein the reporter group is associated with the blocking group.
45. The method of claim 44 wherein the reporter group is a radiolabel.
46. The method of claim 44 wherein the reporter group is a fluorolabel.
47. The method of claim 44 wherein the reporter group is .identified while associated with the complementary DNA molecule.
48. The method of claim 44 wherein the reporter group is identified after being dissociated from the complementary DNA molecule.
49. A method for determining the sequence of deoxyribonucleotides in a subject single stranded deoxyribonucleotide (DNA) molecule comprising:
(a) synthesizing, in the presence of the subject DNA molecule, the complementary DNA molecule, the synthesizing being carried out in a stepwise serial manner in which the identity of each deoxynucleotide triphosphate incorporated into the complementary DNA molecule is determined subsequent to its incorporation; (b) translating the identity of each deoxynucleotide triphosphate incorporated into the complementary molecule to the identity of its corresponding complement present in the subject molecule; and (c) tabulating the identities of the corresponding complements thereby giving rise to the deoxyribonucleotide sequence of the subject DNA.
50. A method for determining the sequence of deoxyribonucleotides in a subject single stranded deoxyribonucleotide (DNA) molecule comprising:
(a) synthesizing, in the presence of the subject DNA molecule an initial region of the complementary DNA molecule, the synthesizing being carried out in a stepwise serial manner in which the identity of each deoxyribonucleotide triphosphate incorporated into the complementary DNA molecule is determined subsequent to its incorporation;
(b) tabulating the identities of the deoxyribonucleotides incorporated into the initial region of the complementary DNA molecule;
(c) removing the initial region of the complementary DNA molecule for the subject single stranded DNA molecule; (d) separately synthesizing a DNA primer molecule corresponding in sequence to at least a part of the initial region of the complementary DNA molecule;
(e) annealing the DNA primer molecule to the subject single stranded DNA molecule;
(f) synthesizing, from the DNA primer molecule the next region of the complementary DNA molecule;
(g) tabulating the identities of the deoxyribonucleotides incorporated into the next region of the complementary DNA molecule; and
(h) repeating steps c, d, e, f and g as needed to determine the entire structure of the subject single stranded DNA molecule.
EP19910900474 1989-10-26 1990-10-26 Dna sequencing Withdrawn EP0450060A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42732189A 1989-10-26 1989-10-26
US427321 1999-10-26

Publications (1)

Publication Number Publication Date
EP0450060A1 true EP0450060A1 (en) 1991-10-09

Family

ID=23694359

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910900474 Withdrawn EP0450060A1 (en) 1989-10-26 1990-10-26 Dna sequencing

Country Status (3)

Country Link
EP (1) EP0450060A1 (en)
CA (1) CA2044616A1 (en)
WO (1) WO1991006678A1 (en)

Families Citing this family (718)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
WO1992016657A1 (en) * 1991-03-13 1992-10-01 E.I. Du Pont De Nemours And Company Method of identifying a nucleotide present at a defined position in a nucleic acid
AU1999092A (en) * 1991-05-24 1992-12-30 Walter Gilbert Method and apparatus for rapid nucleic acid sequencing
US5516633A (en) * 1991-08-15 1996-05-14 Amersham Life Science, Inc. DNA sequencing with a T7-type gene 6 exonuclease
GB9208733D0 (en) * 1992-04-22 1992-06-10 Medical Res Council Dna sequencing method
GB9210168D0 (en) * 1992-05-12 1992-06-24 Cemu Bioteknik Ab Method of sequencing dna
US5795714A (en) 1992-11-06 1998-08-18 Trustees Of Boston University Method for replicating an array of nucleic acid probes
US6194144B1 (en) 1993-01-07 2001-02-27 Sequenom, Inc. DNA sequencing by mass spectrometry
EP0689610B1 (en) * 1993-03-19 2002-07-03 Sequenom, Inc. Dna sequencing by mass spectrometry via exonuclease degradation
FR2703052B1 (en) * 1993-03-26 1995-06-02 Pasteur Institut New method of nucleic acid sequencing.
US6153379A (en) * 1993-06-22 2000-11-28 Baylor College Of Medicine Parallel primer extension approach to nucleic acid sequence analysis
US7001722B1 (en) 1993-06-22 2006-02-21 Baylor College Of Medicine Parallel primer extension approach to nucleic acid sequence analysis
US6401267B1 (en) 1993-09-27 2002-06-11 Radoje Drmanac Methods and compositions for efficient nucleic acid sequencing
PL180521B1 (en) * 1993-09-27 2001-02-28 Arch Dev Corp Methods and kits for identifying nucleotide sequences in a target nucleic acid PL PL PL PL PL PL PL
GB9401200D0 (en) * 1994-01-21 1994-03-16 Medical Res Council Sequencing of nucleic acids
FR2718753B1 (en) * 1994-04-15 1996-07-19 Pasteur Institut Method for counting repeated mono-, di- and trinucleotides in a eukaryotic genome and kit allowing the implementation of this method.
US5604097A (en) 1994-10-13 1997-02-18 Spectragen, Inc. Methods for sorting polynucleotides using oligonucleotide tags
USRE43097E1 (en) 1994-10-13 2012-01-10 Illumina, Inc. Massively parallel signature sequencing by ligation of encoded adaptors
SE9500342D0 (en) * 1995-01-31 1995-01-31 Marek Kwiatkowski Novel chain terminators, the use thereof for nucleic acid sequencing and synthesis and a method of their preparation
WO1996027025A1 (en) * 1995-02-27 1996-09-06 Ely Michael Rabani Device, compounds, algorithms, and methods of molecular characterization and manipulation with molecular parallelism
US5830655A (en) 1995-05-22 1998-11-03 Sri International Oligonucleotide sizing using cleavable primers
EP0745686A1 (en) 1995-06-01 1996-12-04 Roche Diagnostics GmbH The use of DNA polymerase 3'-intrinsic editing activity
EP0745688B1 (en) * 1995-06-01 2007-02-14 Roche Diagnostics GmbH The use of DNA polymerase having 3'-intrinsic editing activity
GB9620209D0 (en) 1996-09-27 1996-11-13 Cemu Bioteknik Ab Method of sequencing DNA
US6133436A (en) * 1996-11-06 2000-10-17 Sequenom, Inc. Beads bound to a solid support and to nucleic acids
ATE375403T1 (en) 1996-11-06 2007-10-15 Sequenom Inc DNA DIAGNOSTICS USING MASS SPECTROMETRY
GB9626815D0 (en) 1996-12-23 1997-02-12 Cemu Bioteknik Ab Method of sequencing DNA
US7622294B2 (en) 1997-03-14 2009-11-24 Trustees Of Tufts College Methods for detecting target analytes and enzymatic reactions
US20030027126A1 (en) 1997-03-14 2003-02-06 Walt David R. Methods for detecting target analytes and enzymatic reactions
ATE269908T1 (en) * 1997-04-01 2004-07-15 Manteia S A METHOD FOR SEQUENCING NUCLEIC ACIDS
JP2002503954A (en) * 1997-04-01 2002-02-05 グラクソ、グループ、リミテッド Nucleic acid amplification method
EP0985142A4 (en) 1997-05-23 2006-09-13 Lynx Therapeutics Inc System and apparaus for sequential processing of analytes
RU2198221C2 (en) * 1997-07-28 2003-02-10 Медикал Биосистемз Лтд. Method of polynucleotide sequencing and device for its realization
EP1082458A1 (en) 1998-05-01 2001-03-14 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and dna molecules
US7875440B2 (en) * 1998-05-01 2011-01-25 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
US6780591B2 (en) * 1998-05-01 2004-08-24 Arizona Board Of Regents Method of determining the nucleotide sequence of oligonucleotides and DNA molecules
AR021833A1 (en) 1998-09-30 2002-08-07 Applied Research Systems METHODS OF AMPLIFICATION AND SEQUENCING OF NUCLEIC ACID
WO2000029444A1 (en) 1998-11-16 2000-05-25 Genway Biotech, Inc. Generation of antibodies using polynucleotide vaccination in avian species
AU2180200A (en) 1998-12-14 2000-07-03 Li-Cor Inc. A heterogeneous assay for pyrophosphate detection
NO986133D0 (en) 1998-12-23 1998-12-23 Preben Lexow Method of DNA Sequencing
PT1159453E (en) * 1999-03-10 2008-08-29 Asm Scient Inc A method for direct nucleic acid sequencing
WO2000058507A1 (en) * 1999-03-30 2000-10-05 Solexa Ltd. Polynucleotide sequencing
US20060275782A1 (en) 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US6620584B1 (en) 1999-05-20 2003-09-16 Illumina Combinatorial decoding of random nucleic acid arrays
US6818395B1 (en) 1999-06-28 2004-11-16 California Institute Of Technology Methods and apparatus for analyzing polynucleotide sequences
US7501245B2 (en) 1999-06-28 2009-03-10 Helicos Biosciences Corp. Methods and apparatuses for analyzing polynucleotide sequences
US6908736B1 (en) 1999-10-06 2005-06-21 Medical Biosystems, Ltd. DNA sequencing method
GB9923644D0 (en) 1999-10-06 1999-12-08 Medical Biosystems Ltd DNA sequencing
EP1244782A2 (en) * 1999-12-23 2002-10-02 Axaron Bioscience AG Method for carrying out the parallel sequencing of a nucleic acid mixture on a surface
US7611869B2 (en) 2000-02-07 2009-11-03 Illumina, Inc. Multiplexed methylation detection methods
US7582420B2 (en) 2001-07-12 2009-09-01 Illumina, Inc. Multiplex nucleic acid reactions
JP3442338B2 (en) 2000-03-17 2003-09-02 株式会社日立製作所 DNA analyzer, DNA base sequencer, DNA base sequence determination method, and reaction module
EP1182267B1 (en) 2000-03-30 2012-01-18 Toyota Jidosha Kabushiki Kaisha Method of determining base sequence of single nucleic acid molecule
AU2001254771A1 (en) * 2000-04-03 2001-10-15 Axaron Bioscience Ag Novel method for the parallel sequencing of a nucleic acid mixture on a surface
GB0016472D0 (en) * 2000-07-05 2000-08-23 Amersham Pharm Biotech Uk Ltd Sequencing method and apparatus
EP3034627B1 (en) 2000-10-06 2019-01-30 The Trustees of Columbia University in the City of New York Massive parallel method for decoding dna and rna
US9708358B2 (en) 2000-10-06 2017-07-18 The Trustees Of Columbia University In The City Of New York Massive parallel method for decoding DNA and RNA
EP1354064A2 (en) 2000-12-01 2003-10-22 Visigen Biotechnologies, Inc. Enzymatic nucleic acid synthesis: compositions and methods for altering monomer incorporation fidelity
AR031640A1 (en) 2000-12-08 2003-09-24 Applied Research Systems ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS IN A SOLID SUPPORT
JP2004523243A (en) 2001-03-12 2004-08-05 カリフォルニア インスティチュート オブ テクノロジー Method and apparatus for analyzing polynucleotide sequences by asynchronous base extension
US6653082B2 (en) 2001-05-17 2003-11-25 Baylor College Of Medicine Substrate-bound cleavage assay for nucleic acid analysis
GB0129012D0 (en) 2001-12-04 2002-01-23 Solexa Ltd Labelled nucleotides
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
AU2003249681A1 (en) 2002-05-31 2003-12-19 Diversa Corporation Multiplexed systems for nucleic acid sequencing
JP4106977B2 (en) 2002-06-21 2008-06-25 株式会社日立製作所 Analysis chip and analyzer
US7074597B2 (en) 2002-07-12 2006-07-11 The Trustees Of Columbia University In The City Of New York Multiplex genotyping using solid phase capturable dideoxynucleotides and mass spectrometry
EP3795577A1 (en) 2002-08-23 2021-03-24 Illumina Cambridge Limited Modified nucleotides
US11008359B2 (en) 2002-08-23 2021-05-18 Illumina Cambridge Limited Labelled nucleotides
US7414116B2 (en) 2002-08-23 2008-08-19 Illumina Cambridge Limited Labelled nucleotides
DE60327649D1 (en) 2002-08-23 2009-06-25 Illumina Cambridge Ltd MARKED NUCLEOTIDE
US8637650B2 (en) 2003-11-05 2014-01-28 Genovoxx Gmbh Macromolecular nucleotide compounds and methods for using the same
US7169560B2 (en) 2003-11-12 2007-01-30 Helicos Biosciences Corporation Short cycle methods for sequencing polynucleotides
CA2557177A1 (en) 2004-02-19 2005-09-01 Stephen Quake Methods and kits for analyzing polynucleotide sequences
US7622279B2 (en) 2004-03-03 2009-11-24 The Trustees Of Columbia University In The City Of New York Photocleavable fluorescent nucleotides for DNA sequencing on chip constructed by site-specific coupling chemistry
JP2008512084A (en) 2004-05-25 2008-04-24 ヘリコス バイオサイエンシーズ コーポレイション Methods and devices for nucleic acid sequencing
US7476734B2 (en) 2005-12-06 2009-01-13 Helicos Biosciences Corporation Nucleotide analogs
US7315019B2 (en) * 2004-09-17 2008-01-01 Pacific Biosciences Of California, Inc. Arrays of optical confinements and uses thereof
US7220549B2 (en) 2004-12-30 2007-05-22 Helicos Biosciences Corporation Stabilizing a nucleic acid for nucleic acid sequencing
US7482120B2 (en) 2005-01-28 2009-01-27 Helicos Biosciences Corporation Methods and compositions for improving fidelity in a nucleic acid synthesis reaction
AU2006211150A1 (en) * 2005-01-31 2006-08-10 Pacific Biosciences Of California, Inc. Use of reversible extension terminator in nucleic acid sequencing
EP2239342A3 (en) 2005-02-01 2010-11-03 AB Advanced Genetic Analysis Corporation Reagents, methods and libraries for bead-based sequencing
EP2241637A1 (en) 2005-02-01 2010-10-20 AB Advanced Genetic Analysis Corporation Nucleic acid sequencing by performing successive cycles of duplex extension
US9169510B2 (en) 2005-06-21 2015-10-27 The Trustees Of Columbia University In The City Of New York Pyrosequencing methods and related compositions
US7805081B2 (en) 2005-08-11 2010-09-28 Pacific Biosciences Of California, Inc. Methods and systems for monitoring multiple optical signals from a single source
GB0517097D0 (en) 2005-08-19 2005-09-28 Solexa Ltd Modified nucleosides and nucleotides and uses thereof
US7666593B2 (en) 2005-08-26 2010-02-23 Helicos Biosciences Corporation Single molecule sequencing of captured nucleic acids
US7405281B2 (en) 2005-09-29 2008-07-29 Pacific Biosciences Of California, Inc. Fluorescent nucleotide analogs and uses therefor
US7763423B2 (en) 2005-09-30 2010-07-27 Pacific Biosciences Of California, Inc. Substrates having low density reactive groups for monitoring enzyme activity
US8796432B2 (en) 2005-10-31 2014-08-05 The Trustees Of Columbia University In The City Of New York Chemically cleavable 3'-o-allyl-DNTP-allyl-fluorophore fluorescent nucleotide analogues and related methods
US7982029B2 (en) 2005-10-31 2011-07-19 The Trustees Of Columbia University In The City Of New York Synthesis of four color 3′O-allyl, modified photocleavable fluorescent nucleotides and related methods
GB0522310D0 (en) 2005-11-01 2005-12-07 Solexa Ltd Methods of preparing libraries of template polynucleotides
GB0524069D0 (en) 2005-11-25 2006-01-04 Solexa Ltd Preparation of templates for solid phase amplification
US7998717B2 (en) 2005-12-02 2011-08-16 Pacific Biosciences Of California, Inc. Mitigation of photodamage in analytical reactions
US7715001B2 (en) 2006-02-13 2010-05-11 Pacific Biosciences Of California, Inc. Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources
US7995202B2 (en) 2006-02-13 2011-08-09 Pacific Biosciences Of California, Inc. Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources
US7692783B2 (en) 2006-02-13 2010-04-06 Pacific Biosciences Of California Methods and systems for simultaneous real-time monitoring of optical signals from multiple sources
US7397546B2 (en) 2006-03-08 2008-07-08 Helicos Biosciences Corporation Systems and methods for reducing detected intensity non-uniformity in a laser beam
US8975216B2 (en) 2006-03-30 2015-03-10 Pacific Biosciences Of California Articles having localized molecules disposed thereon and methods of producing same
US7563574B2 (en) 2006-03-31 2009-07-21 Pacific Biosciences Of California, Inc. Methods, systems and compositions for monitoring enzyme activity and applications thereof
WO2007135368A2 (en) 2006-05-18 2007-11-29 Solexa Limited Dye compounds and the use of their labelled conjugates
US8889348B2 (en) 2006-06-07 2014-11-18 The Trustees Of Columbia University In The City Of New York DNA sequencing by nanopore using modified nucleotides
CA2662521C (en) 2006-09-01 2016-08-09 Pacific Biosciences Of California, Inc. Substrates, systems and methods for analyzing materials
US8207509B2 (en) 2006-09-01 2012-06-26 Pacific Biosciences Of California, Inc. Substrates, systems and methods for analyzing materials
WO2008042067A2 (en) 2006-09-28 2008-04-10 Illumina, Inc. Compositions and methods for nucleotide sequencing
US7883869B2 (en) 2006-12-01 2011-02-08 The Trustees Of Columbia University In The City Of New York Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators
WO2008093098A2 (en) 2007-02-02 2008-08-07 Illumina Cambridge Limited Methods for indexing samples and sequencing multiple nucleotide templates
US11940413B2 (en) 2007-02-05 2024-03-26 IsoPlexis Corporation Methods and devices for sequencing nucleic acids in smaller batches
US8551704B2 (en) 2007-02-16 2013-10-08 Pacific Biosciences Of California, Inc. Controllable strand scission of mini circle DNA
US7901889B2 (en) 2007-07-26 2011-03-08 Pacific Biosciences Of California, Inc. Molecular redundant sequencing
EP2201021A4 (en) 2007-08-29 2012-01-25 Applied Biosystems Llc Alternative nucleic acid sequencing methods
WO2009045344A2 (en) 2007-09-28 2009-04-09 Pacific Biosciences Of California, Inc. Error-free amplification of dna for clonal sequencing
US7960116B2 (en) 2007-09-28 2011-06-14 Pacific Biosciences Of California, Inc. Nucleic acid sequencing methods and systems
US20110014611A1 (en) 2007-10-19 2011-01-20 Jingyue Ju Design and synthesis of cleavable fluorescent nucleotides as reversible terminators for dna sequences by synthesis
EP2725107B1 (en) 2007-10-19 2018-08-29 The Trustees of Columbia University in the City of New York DNA sequencing with non-fluorescent nucleotide reversible terminators and cleavable label modified ddNTPs and nucleic acid comprising inosine with reversible terminators
US8617811B2 (en) 2008-01-28 2013-12-31 Complete Genomics, Inc. Methods and compositions for efficient base calling in sequencing reactions
WO2009067628A1 (en) 2007-11-20 2009-05-28 Applied Biosystems Inc. Reversible di-nucleotide terminator sequencing
CA2711560A1 (en) 2008-01-10 2009-07-16 Pacific Biosciences Of California, Inc. Methods and systems for analysis of fluorescent reactions with modulated excitation
CA2715385A1 (en) 2008-02-12 2009-08-20 Pacific Biosciences Of California, Inc. Compositions and methods for use in analytical reactions
US9017973B2 (en) 2008-03-19 2015-04-28 Intelligent Biosystems, Inc. Methods and compositions for incorporating nucleotides
US8628940B2 (en) 2008-09-24 2014-01-14 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
EP4230747A3 (en) 2008-03-28 2023-11-15 Pacific Biosciences Of California, Inc. Compositions and methods for nucleic acid sequencing
US8236499B2 (en) 2008-03-28 2012-08-07 Pacific Biosciences Of California, Inc. Methods and compositions for nucleic acid sample preparation
CA2725239C (en) 2008-05-27 2019-02-26 Trilink Biotechnologies Chemically modified nucleoside 5'-triphosphates for thermally initiated amplification of nucleic acid
US8198023B2 (en) 2008-08-05 2012-06-12 Pacific Biosciences Of California, Inc. Prevention and alleviation of steric hindrance during single molecule nucleic acid synthesis by a polymerase
WO2010027497A2 (en) 2008-09-05 2010-03-11 Pacific Biosciences Of California, Inc Preparations, compositions, and methods for nucleic acid sequencing
US8383345B2 (en) 2008-09-12 2013-02-26 University Of Washington Sequence tag directed subassembly of short sequencing reads into long sequencing reads
DK3629011T3 (en) 2008-09-16 2024-01-29 Pacific Biosciences California Inc INTEGRATED OPTICAL DEVICE
US8921046B2 (en) 2008-09-19 2014-12-30 Pacific Biosciences Of California, Inc. Nucleic acid sequence analysis
US8481264B2 (en) 2008-09-19 2013-07-09 Pacific Biosciences Of California, Inc. Immobilized nucleic acid complexes for sequence analysis
WO2010036287A1 (en) 2008-09-24 2010-04-01 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
US8383369B2 (en) 2008-09-24 2013-02-26 Pacific Biosciences Of California, Inc. Intermittent detection during analytical reactions
WO2010038042A1 (en) 2008-10-02 2010-04-08 Illumina Cambridge Ltd. Nucleic acid sample enrichment for sequencing applications
WO2010048337A2 (en) 2008-10-22 2010-04-29 Illumina, Inc. Preservation of information related to genomic dna methylation
AU2009319907B2 (en) 2008-11-03 2015-10-01 The Regents Of The University Of California Methods for detecting modification resistant nucleic acids
WO2010059206A2 (en) 2008-11-19 2010-05-27 Pacific Biosciences Of California, Inc. Modular nucleotide compositions and uses therefor
US8370079B2 (en) 2008-11-20 2013-02-05 Pacific Biosciences Of California, Inc. Algorithms for sequence determination
US8993230B2 (en) 2008-12-04 2015-03-31 Pacific Biosciences of Californ, Inc. Asynchronous sequencing of biological polymers
US9175338B2 (en) 2008-12-11 2015-11-03 Pacific Biosciences Of California, Inc. Methods for identifying nucleic acid modifications
AU2009325069B2 (en) 2008-12-11 2015-03-19 Pacific Biosciences Of California, Inc. Classification of nucleic acid templates
US20230148447A9 (en) 2008-12-11 2023-05-11 Pacific Biosciences Of California, Inc. Classification of nucleic acid templates
EP2607496B1 (en) 2008-12-23 2014-07-16 Illumina, Inc. Methods useful in nucleic acid sequencing protocols
WO2010111691A2 (en) 2009-03-27 2010-09-30 Life Technologies Corp Conjugates of biomolecules to nanoparticles
AU2010245304B2 (en) 2009-04-27 2015-06-04 Pacific Biosciences Of California, Inc. Real-time sequencing methods and systems
US20100311144A1 (en) 2009-06-05 2010-12-09 Life Technologies Corporation Mutant dna polymerases
US8501406B1 (en) 2009-07-14 2013-08-06 Pacific Biosciences Of California, Inc. Selectively functionalized arrays
US8182994B2 (en) 2009-09-15 2012-05-22 Illumina Cambridge Limited Centroid markers for image analysis of high denisty clusters in complex polynucleotide sequencing
EP2494073B1 (en) 2009-10-26 2017-11-29 AGCT GmbH Nucleotide conjugates and methods of uses thereof
PT2531880T (en) 2010-02-01 2016-10-31 Illumina Inc Focusing methods and optical systems and assemblies using the same
US8518643B2 (en) 2010-02-04 2013-08-27 Pacific Biosciences Of California, Inc. Method to improve single molecule analyses
US8324914B2 (en) 2010-02-08 2012-12-04 Genia Technologies, Inc. Systems and methods for characterizing a molecule
US9605307B2 (en) 2010-02-08 2017-03-28 Genia Technologies, Inc. Systems and methods for forming a nanopore in a lipid bilayer
US9678055B2 (en) 2010-02-08 2017-06-13 Genia Technologies, Inc. Methods for forming a nanopore in a lipid bilayer
CA2790393C (en) 2010-02-19 2019-03-12 Pacific Biosciences Of California, Inc. Integrated analytical system and method
US8994946B2 (en) 2010-02-19 2015-03-31 Pacific Biosciences Of California, Inc. Integrated analytical system and method
WO2011112465A1 (en) 2010-03-06 2011-09-15 Illumina, Inc. Systems, methods, and apparatuses for detecting optical signals from a sample
US20190300945A1 (en) 2010-04-05 2019-10-03 Prognosys Biosciences, Inc. Spatially Encoded Biological Assays
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
CA2794522C (en) 2010-04-05 2019-11-26 Prognosys Biosciences, Inc. Spatially encoded biological assays
US8318094B1 (en) 2010-06-18 2012-11-27 Pacific Biosciences Of California, Inc. Substrate analysis systems
WO2011159942A1 (en) 2010-06-18 2011-12-22 Illumina, Inc. Conformational probes and methods for sequencing nucleic acids
WO2012021733A2 (en) 2010-08-12 2012-02-16 Pacific Biosciences Of California, Inc. Photodamage mitigation compounds and systems
US8465922B2 (en) 2010-08-26 2013-06-18 Pacific Biosciences Of California, Inc. Methods and systems for monitoring reactions
US9029103B2 (en) 2010-08-27 2015-05-12 Illumina Cambridge Limited Methods for sequencing polynucleotides
US8483969B2 (en) 2010-09-17 2013-07-09 Illuminia, Inc. Variation analysis for multiple templates on a solid support
US8759038B2 (en) 2010-09-29 2014-06-24 Illumina Cambridge Limited Compositions and methods for sequencing nucleic acids
EP2633069B1 (en) 2010-10-26 2015-07-01 Illumina, Inc. Sequencing methods
US8575071B2 (en) 2010-11-03 2013-11-05 Illumina, Inc. Reducing adapter dimer formation
EP2635679B1 (en) 2010-11-05 2017-04-19 Illumina, Inc. Linking sequence reads using paired code tags
US9074251B2 (en) 2011-02-10 2015-07-07 Illumina, Inc. Linking sequence reads using paired code tags
WO2012074855A2 (en) 2010-11-22 2012-06-07 The Regents Of The University Of California Methods of identifying a cellular nascent rna transcript
WO2012088339A2 (en) 2010-12-22 2012-06-28 Genia Technologies, Inc. Nanopore-based single dna molecule characterization using speed bumps
US8951781B2 (en) 2011-01-10 2015-02-10 Illumina, Inc. Systems, methods, and apparatuses to image a sample for biological or chemical analysis
US9581563B2 (en) 2011-01-24 2017-02-28 Genia Technologies, Inc. System for communicating information from an array of sensors
US9110478B2 (en) 2011-01-27 2015-08-18 Genia Technologies, Inc. Temperature regulation of measurement arrays
WO2012106081A2 (en) 2011-01-31 2012-08-09 Illumina, Inc. Methods for reducing nucleic acid damage
WO2012106546A2 (en) 2011-02-02 2012-08-09 University Of Washington Through Its Center For Commercialization Massively parallel continguity mapping
WO2012129242A2 (en) 2011-03-23 2012-09-27 Pacific Biosciences Of California, Inc. Isolation of polymerase-nucleic acid complexes and loading onto substrates
WO2012138973A2 (en) 2011-04-06 2012-10-11 The University Of Chicago COMPOSITION AND METHODS RELATED TO MODIFICATION OF 5-METHYLCYTOSINE (5mC)
GB201106254D0 (en) 2011-04-13 2011-05-25 Frisen Jonas Method and product
EP2702171A1 (en) 2011-04-27 2014-03-05 Cherkasov, Dmitry Method and components for detecting nucleic acid chains
DE102012008759A1 (en) 2011-05-04 2012-11-08 Genovoxx Gmbh Nucleoside-triphosphate conjugates and methods for their use
US9624539B2 (en) 2011-05-23 2017-04-18 The Trustees Of Columbia University In The City Of New York DNA sequencing by synthesis using Raman and infrared spectroscopy detection
US8778848B2 (en) 2011-06-09 2014-07-15 Illumina, Inc. Patterned flow-cells useful for nucleic acid analysis
US10152569B2 (en) 2011-09-26 2018-12-11 Gen-Probe Incorporated Algorithms for sequence determinations
US10378051B2 (en) 2011-09-29 2019-08-13 Illumina Cambridge Limited Continuous extension and deblocking in reactions for nucleic acids synthesis and sequencing
US9347900B2 (en) 2011-10-14 2016-05-24 Pacific Biosciences Of California, Inc. Real-time redox sequencing
CA3003082C (en) 2011-10-28 2020-12-15 Illumina, Inc. Microarray fabrication system and method
CA2854023A1 (en) 2011-11-07 2013-05-16 Illumina, Inc. Integrated sequencing apparatuses and methods of use
US9200274B2 (en) 2011-12-09 2015-12-01 Illumina, Inc. Expanded radix for polymeric tags
US9279154B2 (en) 2011-12-21 2016-03-08 Illumina, Inc. Apparatus and methods for kinetic analysis and determination of nucleic acid sequences
US9238836B2 (en) 2012-03-30 2016-01-19 Pacific Biosciences Of California, Inc. Methods and compositions for sequencing modified nucleic acids
WO2013117595A2 (en) 2012-02-07 2013-08-15 Illumina Cambridge Limited Targeted enrichment and amplification of nucleic acids on a support
EP3222627B1 (en) 2012-02-15 2019-08-07 Pacific Biosciences of California, Inc. Polymerase enzyme substrates with protein shield
US8986629B2 (en) 2012-02-27 2015-03-24 Genia Technologies, Inc. Sensor circuit for controlling, detecting, and measuring a molecular complex
NO2694769T3 (en) 2012-03-06 2018-03-03
US20130261984A1 (en) 2012-03-30 2013-10-03 Illumina, Inc. Methods and systems for determining fetal chromosomal abnormalities
JP6159391B2 (en) 2012-04-03 2017-07-05 イラミーナ インコーポレーテッド Integrated read head and fluid cartridge useful for nucleic acid sequencing
US20130274148A1 (en) 2012-04-11 2013-10-17 Illumina, Inc. Portable genetic detection and analysis system and method
WO2013163207A1 (en) 2012-04-24 2013-10-31 Pacific Biosciences Of California, Inc. Identification of 5-methyl-c in nucleic acid templates
US9012022B2 (en) 2012-06-08 2015-04-21 Illumina, Inc. Polymer coatings
JP2015525077A (en) 2012-06-15 2015-09-03 ジェニア・テクノロジーズ・インコーポレイテッド Chip configuration and highly accurate nucleic acid sequencing
US8895249B2 (en) 2012-06-15 2014-11-25 Illumina, Inc. Kinetic exclusion amplification of nucleic acid libraries
US9372308B1 (en) 2012-06-17 2016-06-21 Pacific Biosciences Of California, Inc. Arrays of integrated analytical devices and methods for production
CA2878291A1 (en) 2012-07-03 2014-01-09 Sloan Kettering Institute For Cancer Research Quantitative assessment of human t-cell repertoire recovery after allogeneic hematopoietic stem cell transplantation
WO2014015098A1 (en) 2012-07-18 2014-01-23 Siemens Healthcare Diagnostics Inc. A method of normalizing biological samples
NL2017959B1 (en) 2016-12-08 2018-06-19 Illumina Inc Cartridge assembly
CA3178340C (en) 2012-08-20 2025-10-14 Illumina Inc METHOD AND SYSTEM FOR FLUORESCENCE LIFETIME-BASED SEQUENCING
DK3511423T4 (en) 2012-10-17 2024-07-29 Spatial Transcriptomics Ab METHODS AND PRODUCT FOR OPTIMIZING LOCALIZED OR SPATIAL DETECTION OF GENE EXPRESSION IN A TISSUE SAMPLE
US9181583B2 (en) 2012-10-23 2015-11-10 Illumina, Inc. HLA typing using selective amplification and sequencing
US10206911B2 (en) 2012-10-26 2019-02-19 Memorial Sloan-Kettering Cancer Center Androgen receptor variants and methods for making and using
US9605309B2 (en) 2012-11-09 2017-03-28 Genia Technologies, Inc. Nucleic acid sequencing using tags
US9223084B2 (en) 2012-12-18 2015-12-29 Pacific Biosciences Of California, Inc. Illumination of optical analytical devices
US9683230B2 (en) 2013-01-09 2017-06-20 Illumina Cambridge Limited Sample preparation on a solid support
US9805407B2 (en) 2013-01-25 2017-10-31 Illumina, Inc. Methods and systems for using a cloud computing environment to configure and sell a biological sample preparation cartridge and share related data
US9759711B2 (en) 2013-02-05 2017-09-12 Genia Technologies, Inc. Nanopore arrays
EP2959283B1 (en) 2013-02-22 2022-08-17 Pacific Biosciences of California, Inc. Integrated illumination of optical analytical devices
US9512422B2 (en) 2013-02-26 2016-12-06 Illumina, Inc. Gel patterned surfaces
US9914979B2 (en) 2013-03-04 2018-03-13 Fry Laboratories, LLC Method and kit for characterizing microorganisms
CA2898453C (en) 2013-03-13 2021-07-27 Illumina, Inc. Multilayer fluidic devices and methods for their fabrication
DK3553175T3 (en) 2013-03-13 2021-08-23 Illumina Inc PROCEDURE FOR MAKING A NUCLEIC ACID SEQUENCE LIBRARY
CA2898459C (en) 2013-03-14 2021-02-02 Illumina, Inc. Modified polymerases for improved incorporation of nucleotide analogues
EP2971071B1 (en) 2013-03-15 2018-02-28 Illumina, Inc. Enzyme-linked nucleotides
US20140274747A1 (en) 2013-03-15 2014-09-18 Illumina, Inc. Super resolution imaging
US9193998B2 (en) 2013-03-15 2015-11-24 Illumina, Inc. Super resolution imaging
US10648026B2 (en) 2013-03-15 2020-05-12 The Trustees Of Columbia University In The City Of New York Raman cluster tagged molecules for biological imaging
BR112015022448B1 (en) 2013-03-15 2020-12-08 Illumina Cambridge Limited modified nucleotide or nucleoside molecule, methods for preparing the growth of polynucleotide complementary to single-stranded target polynucleotide in sequencing reaction and to determine the sequence of single-stranded target polynucleotide and kit
WO2014201155A1 (en) 2013-06-11 2014-12-18 Courtagen Life Sciences, Inc. Methods and kits for treating and classifying individuals at risk of or suffering from trap1 change-of-function
US9868979B2 (en) 2013-06-25 2018-01-16 Prognosys Biosciences, Inc. Spatially encoded biological assays using a microfluidic device
CN105431554B (en) 2013-07-01 2019-02-15 Illumina公司 Catalyst-free surface functionalization and polymer grafting
WO2015002789A1 (en) 2013-07-03 2015-01-08 Illumina, Inc. Sequencing by orthogonal synthesis
US9957291B2 (en) 2013-08-05 2018-05-01 Pacific Biosciences Of California, Inc. Protected fluorescent reagent compounds
CA3009218C (en) 2013-08-08 2020-10-27 Illumina, Inc. Fluidic system for reagent delivery to a flow cell
US10508311B2 (en) 2013-08-26 2019-12-17 The Translational Genomics Research Institute Single molecule-overlapping read analysis for minor variant mutation detection in pathogen samples
US9551697B2 (en) 2013-10-17 2017-01-24 Genia Technologies, Inc. Non-faradaic, capacitively coupled measurement in a nanopore cell array
US9567630B2 (en) 2013-10-23 2017-02-14 Genia Technologies, Inc. Methods for forming lipid bilayers on biochips
US10421995B2 (en) 2013-10-23 2019-09-24 Genia Technologies, Inc. High speed molecular sensing with nanopores
US9416414B2 (en) 2013-10-24 2016-08-16 Pacific Biosciences Of California, Inc. Delaying real-time sequencing
US10540783B2 (en) 2013-11-01 2020-01-21 Illumina, Inc. Image analysis useful for patterned objects
CA2930834A1 (en) 2013-11-17 2015-05-21 Quantum-Si Incorporated Integrated device with external light source for probing detecting and analyzing molecules
EP2876166B1 (en) 2013-11-20 2016-12-14 Roche Diagnostics GmbH New compound for sequencing by synthesis
RS60736B1 (en) 2013-12-03 2020-09-30 Illumina Inc Methods and systems for analyzing image data
DK3080585T3 (en) 2013-12-10 2024-02-05 Illumina Inc BIOSENSORS FOR BIOLOGICAL OR CHEMICAL ANALYSIS AND METHODS OF MANUFACTURE THEREOF
DK3083994T3 (en) 2013-12-20 2021-09-13 Illumina Inc Preservation of genomic connectivity information in fragmented genomic DNA samples
KR102333635B1 (en) 2013-12-23 2021-11-30 일루미나, 인코포레이티드 Structured substrates for improving detection of light emissions and methods relating to the same
US10537889B2 (en) 2013-12-31 2020-01-21 Illumina, Inc. Addressable flow cell using patterned electrodes
EP3094742A1 (en) 2014-01-16 2016-11-23 Illumina, Inc. Amplicon preparation and sequencing on solid supports
US9677132B2 (en) 2014-01-16 2017-06-13 Illumina, Inc. Polynucleotide modification on solid support
MY200537A (en) 2014-02-18 2024-01-02 Illumina Inc Methods and compositions for dna profiling
EP3116651B1 (en) 2014-03-11 2020-04-22 Illumina, Inc. Disposable, integrated microfluidic cartridge and methods of making it
FR3020071B1 (en) 2014-04-17 2017-12-22 Dna Script PROCESS FOR THE SYNTHESIS OF NUCLEIC ACIDS, IN PARTICULAR LARGE NUCLEIC ACIDS, USE OF THE METHOD AND KIT FOR IMPLEMENTING THE METHOD
AU2015253299B2 (en) 2014-04-29 2018-06-14 Illumina, Inc. Multiplexed single cell gene expression analysis using template switch and tagmentation
US10570447B2 (en) 2014-05-16 2020-02-25 Illumina, Inc. Nucleic acid synthesis techniques
EP3148697A1 (en) 2014-05-27 2017-04-05 Illumina, Inc. Systems and methods for biochemical analysis including a base instrument and a removable cartridge
DK3152320T3 (en) 2014-06-03 2021-01-11 Illumina Inc Compositions, systems and methods for detecting events using tethers anchored to or adjacent to nanopores
US20150353989A1 (en) 2014-06-09 2015-12-10 Illumina Cambridge Limited Sample preparation for nucleic acid amplification
CA3172086A1 (en) 2014-06-13 2015-12-17 Illumina Cambridge Limited Methods and compositions for preparing sequencing libraries
US10829814B2 (en) 2014-06-19 2020-11-10 Illumina, Inc. Methods and compositions for single cell genomics
US10017759B2 (en) 2014-06-26 2018-07-10 Illumina, Inc. Library preparation of tagged nucleic acid
ES2788949T3 (en) 2014-06-27 2020-10-23 Illumina Inc Modified polymerases for improved incorporation of nucleotide analogs
SG11201610910QA (en) 2014-06-30 2017-01-27 Illumina Inc Methods and compositions using one-sided transposition
WO2016010975A2 (en) 2014-07-15 2016-01-21 Illumina, Inc. Biochemically activated electronic device
CA3176503A1 (en) 2014-07-21 2016-01-28 Illumina, Inc Polynucleotide enrichment using crispr-cas systems
EP3194933B1 (en) 2014-08-08 2024-05-01 Quantum-Si Incorporated Instrument for time resolved reading of fluorescence based assay chip
CA2957546A1 (en) 2014-08-08 2016-02-11 Quantum-Si Incorporated Integrated device with external light source for probing, detecting, and analyzing molecules
EP3471402B1 (en) 2014-08-08 2023-05-31 Quantum-Si Incorporated Integrated device for temporal binning of received photons
GB201414098D0 (en) 2014-08-08 2014-09-24 Illumina Cambridge Ltd Modified nucleotide linkers
US10174363B2 (en) 2015-05-20 2019-01-08 Quantum-Si Incorporated Methods for nucleic acid sequencing
CN107076739B (en) 2014-08-21 2018-12-25 伊卢米纳剑桥有限公司 Reversible surface functionalization
WO2016033207A1 (en) 2014-08-27 2016-03-03 Pacific Biosciences Of California, Inc. Arrays of integrated analyitcal devices
FR3025201B1 (en) 2014-09-02 2018-10-12 Dna Script MODIFIED NUCLEOTIDES FOR THE SYNTHESIS OF NUCLEIC ACIDS, A KIT COMPRISING SUCH NUCLEOTIDES AND THEIR USE FOR GENERATING SYNTHETIC NUCLEIC ACID GENES OR SEQUENCES
WO2016040602A1 (en) 2014-09-11 2016-03-17 Epicentre Technologies Corporation Reduced representation bisulfite sequencing using uracil n-glycosylase (ung) and endonuclease iv
EP3191606B1 (en) 2014-09-12 2020-05-27 Illumina, Inc. Methods for detecting the presence of polymer subunits using chemiluminescence
KR102538753B1 (en) 2014-09-18 2023-05-31 일루미나, 인코포레이티드 Methods and systems for analyzing nucleic acid sequencing data
WO2016054096A1 (en) 2014-09-30 2016-04-07 Illumina, Inc. Modified polymerases for improved incorporation of nucleotide analogues
US9897791B2 (en) 2014-10-16 2018-02-20 Illumina, Inc. Optical scanning systems for in situ genetic analysis
KR102643955B1 (en) 2014-10-17 2024-03-07 일루미나 케임브리지 리미티드 Contiguity preserving transposition
DK3212684T3 (en) 2014-10-31 2020-03-02 Illumina Cambridge Ltd Polymers and DNA copolymer coatings
DK3215616T3 (en) 2014-11-05 2020-03-02 Illumina Cambridge Ltd Reducing DNA damage during sample preparation and sequencing using siderophore chelators
GB201419731D0 (en) 2014-11-05 2014-12-17 Illumina Cambridge Ltd Sequencing from multiple primers to increase data rate and density
HK1243464B (en) 2014-11-11 2019-08-16 Illumina, Inc. Polynucleotide amplification using crispr-cas systems
SG11201703693UA (en) 2014-11-11 2017-06-29 Illumina Cambridge Ltd Methods and arrays for producing and sequencing monoclonal clusters of nucleic acid
CN114438172B (en) 2014-12-15 2025-02-21 亿明达股份有限公司 Compositions and methods for single molecule placement on substrates
US10302972B2 (en) 2015-01-23 2019-05-28 Pacific Biosciences Of California, Inc. Waveguide transmission
US10150872B2 (en) 2015-02-04 2018-12-11 Pacific Biosciences Of California, Inc. Multimeric protected fluorescent reagents
KR20240091073A (en) 2015-02-10 2024-06-21 일루미나, 인코포레이티드 The method and the composition for analyzing the cellular constituent
CN113064236B (en) 2015-03-16 2022-11-01 加利福尼亚太平洋生物科学股份有限公司 Integrated device and system for free space optical coupling
CN107847930B (en) 2015-03-20 2020-06-30 亿明达股份有限公司 Fluid cartridge for use in an upright or substantially upright position
CN119779988A (en) 2015-03-24 2025-04-08 伊鲁米那股份有限公司 Methods, carrier assemblies and systems for imaging samples for biological or chemical analysis
ES2846730T3 (en) 2015-03-31 2021-07-29 Illumina Cambridge Ltd Concatemerization on the surface of molds
WO2016162309A1 (en) 2015-04-10 2016-10-13 Spatial Transcriptomics Ab Spatially distinguished, multiplex nucleic acid analysis of biological specimens
EP3696536A1 (en) 2015-04-14 2020-08-19 Illumina, Inc. A method of manufacturing a substrate and a method of analyzing biomolecules capable of generating light emissions
US10844428B2 (en) 2015-04-28 2020-11-24 Illumina, Inc. Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS)
WO2016179437A1 (en) 2015-05-07 2016-11-10 Pacific Biosciences Of California, Inc. Multiprocessor pipeline architecture
CA2983932C (en) 2015-05-11 2023-07-25 Illumina, Inc. Platform for discovery and analysis of therapeutic agents
CA2984112C (en) 2015-05-12 2021-07-06 Illumina, Inc. Field-effect apparatus and methods for sequencing nucelic acids
BR112017025587B1 (en) 2015-05-29 2022-09-27 Illumina, Inc SAMPLE CARRIER AND ASSAY SYSTEM TO CONDUCT DESIGNATED REACTIONS
US10640809B2 (en) 2015-05-29 2020-05-05 Epicentre Technologies Corporation Methods of analyzing nucleic acids
JP6609641B2 (en) 2015-05-29 2019-11-20 イルミナ ケンブリッジ リミテッド Advanced use of surface primers in clusters
WO2016196755A1 (en) 2015-06-03 2016-12-08 Illumina, Inc. Compositions, systems, and methods for sequencing polynucleotides using tethers anchored to polymerases adjacent to nanopores
CA2989344C (en) 2015-06-12 2023-09-26 Pacific Biosciences Of California, Inc. Integrated target waveguide devices and systems for optical coupling
WO2016205753A1 (en) 2015-06-17 2016-12-22 The Translational Genomics Research Institute Systems and methods for obtaining biological molecules from a sample
EP3878974A1 (en) 2015-07-06 2021-09-15 Illumina Cambridge Limited Sample preparation for nucleic acid amplification
CN107924121B (en) 2015-07-07 2021-06-08 亿明达股份有限公司 Selective Surface Patterning via Nanoimprinting
EP3325648B1 (en) 2015-07-17 2023-03-29 Illumina, Inc. Polymer sheets for sequencing applications
CA3242290A1 (en) 2015-07-27 2017-02-02 Illumina, Inc. Spatial mapping of nucleic acid sequence information
IL255445B (en) 2015-07-30 2022-07-01 Illumina Inc Removal of orthogonal blocking of nucleotides
WO2017030999A1 (en) 2015-08-14 2017-02-23 Illumina, Inc. Systems and methods using magnetically-responsive sensors for determining a genetic characteristic
CN108474805A (en) 2015-08-24 2018-08-31 亿明达股份有限公司 In-line accumulators and flow control systems for biological and chemical assays
CA2997035A1 (en) 2015-08-28 2017-03-09 Illumina, Inc. Nucleic acid sequence analysis from single cells
WO2017037078A1 (en) 2015-09-02 2017-03-09 Illumina Cambridge Limited Systems and methods of improving droplet operations in fluidic systems
US10450598B2 (en) 2015-09-11 2019-10-22 Illumina, Inc. Systems and methods for obtaining a droplet having a designated concentration of a substance-of-interest
WO2017087724A1 (en) 2015-11-17 2017-05-26 Omniome, Inc. Methods for determining sequence profiles
US10676788B2 (en) 2015-11-20 2020-06-09 Pacific Biosciences Of California, Inc. Modified nucleotide reagents
WO2017087975A1 (en) 2015-11-20 2017-05-26 Pacific Biosciences Of California, Inc. Labeled nucleotide analogs, reaction mixtures, and methods and systems for sequencing
CN108472121A (en) 2015-11-20 2018-08-31 加利福尼亚太平洋生物科学股份有限公司 Protected dye-labeled reagents
CN115881230A (en) 2015-12-17 2023-03-31 伊路敏纳公司 Differentiate methylation levels in complex biological samples
DE202017100081U1 (en) 2016-01-11 2017-03-19 Illumina, Inc. Detection device with a microfluorometer, a fluidic system and a flow cell detent module
EP3417277A4 (en) 2016-02-17 2019-10-23 Tesseract Health, Inc. SENSOR AND DEVICE FOR IMAGING AND LIFETIME DETECTION APPLICATIONS
CN110702652A (en) 2016-03-24 2020-01-17 伊鲁米那股份有限公司 Apparatus and compositions for use in luminescence imaging and methods of use thereof
ES2861350T3 (en) 2016-03-28 2021-10-06 Illumina Inc Multi-plane microarrays
WO2017177017A1 (en) 2016-04-07 2017-10-12 Omniome, Inc. Methods of quantifying target nucleic acids and identifying sequence variants
EP3235905A1 (en) 2016-04-20 2017-10-25 QIAGEN GmbH Method for generating a stranded rna library
KR102254451B1 (en) 2016-04-22 2021-05-20 옴니옴 인코포레이티드 Nucleic acid sequencing method and system employing enhanced detection of nucleotide-specific ternary complex formation
IL301735A (en) 2016-04-22 2023-05-01 Illumina Inc Photonic structure-based devices and compositions for use in luminescent imaging of sites in a pixel and methods of using the devices and compositions
US10597643B2 (en) 2016-04-29 2020-03-24 Omniome, Inc. Polymerases engineered to reduce nucleotide-independent DNA binding
AU2017258523B2 (en) 2016-04-29 2020-08-13 Pacific Biosciences Of California, Inc. Method of Nucleic Acid sequence determination
AU2017258619B2 (en) 2016-04-29 2020-05-14 Pacific Biosciences Of California, Inc. Sequencing method employing ternary complex destabilization to identify cognate nucleotides
EP4269611A3 (en) 2016-05-11 2024-01-17 Illumina, Inc. Polynucleotide enrichment and amplification using argonaute systems
EP3458913B1 (en) 2016-05-18 2020-12-23 Illumina, Inc. Self assembled patterning using patterned hydrophobic surfaces
EP3488002B1 (en) 2016-07-22 2021-03-31 Oregon Health & Science University Single cell whole genome libraries and combinatorial indexing methods of making thereof
WO2018034780A1 (en) 2016-08-15 2018-02-22 Omniome, Inc. Sequencing method for rapid identification and processing of cognate nucleotide pairs
KR102230444B1 (en) 2016-08-15 2021-03-23 옴니옴 인코포레이티드 Methods and systems for sequencing nucleic acids
WO2018064116A1 (en) 2016-09-28 2018-04-05 Illumina, Inc. Methods and systems for data compression
CN111781139B (en) 2016-10-14 2023-09-12 亿明达股份有限公司 Clamping box assembly
CN110100009B (en) 2016-10-19 2023-11-21 伊鲁米那股份有限公司 Method for chemical ligation of nucleic acids
WO2018093780A1 (en) 2016-11-16 2018-05-24 Illumina, Inc. Validation methods and systems for sequence variant calls
GB201619458D0 (en) 2016-11-17 2017-01-04 Spatial Transcriptomics Ab Method for spatial tagging and analysing nucleic acids in a biological specimen
KR20240120756A (en) 2016-12-09 2024-08-07 더 브로드 인스티튜트, 인코퍼레이티드 Crispr effector system based diagnostics
KR102512186B1 (en) 2016-12-22 2023-03-20 일루미나, 인코포레이티드 Array comprising a resin film and a patterned polymer layer
AU2017382316B2 (en) 2016-12-22 2023-02-09 Quantum-Si Incorporated Integrated photodetector with direct binning pixel
EP3559262B1 (en) 2016-12-22 2025-04-09 Illumina, Inc. Arrays with quality control tracers
JP7051869B2 (en) 2016-12-22 2022-04-11 イラミーナ インコーポレーテッド Array containing sequencing primers and non-sequencing entities
CA3048415C (en) 2016-12-30 2023-02-28 Omniome, Inc. Method and system employing distinguishable polymerases for detecting ternary complexes and identifying cognate nucleotides
GB201704754D0 (en) 2017-01-05 2017-05-10 Illumina Inc Kinetic exclusion amplification of nucleic acid libraries
WO2018128544A1 (en) 2017-01-06 2018-07-12 Agendia N.V. Biomarkers for selecting patient groups, and uses thereof.
CA3049142A1 (en) 2017-01-06 2018-07-12 Illumina, Inc. Phasing correction
AU2018208462B2 (en) 2017-01-10 2021-07-29 Pacific Biosciences Of California, Inc. Polymerases engineered to reduce nucleotide-independent DNA binding
JP6806909B2 (en) 2017-01-17 2021-01-06 イルミナ インコーポレイテッド Determining tumorigenic splicing variants
EP3571616B1 (en) 2017-01-18 2021-05-19 Illumina, Inc. Methods and systems for generation and error-correction of unique molecular index sets with heterogeneous molecular lengths
AU2017394645B2 (en) 2017-01-20 2020-01-23 Pacific Biosciences Of California, Inc. Genotyping by polymerase binding
WO2018136117A1 (en) 2017-01-20 2018-07-26 Omniome, Inc. Allele-specific capture of nucleic acids
EP3571319A1 (en) 2017-01-20 2019-11-27 Omniome, Inc. Process for cognate nucleotide detection in a nucleic acid sequencing workflow
GB201701689D0 (en) 2017-02-01 2017-03-15 Illumia Inc System and method with fiducials of non-closed shapes
CN109414673B (en) 2017-02-01 2021-09-07 伊鲁米那股份有限公司 System and method having a reference responsive to multiple excitation frequencies
GB201701688D0 (en) 2017-02-01 2017-03-15 Illumia Inc System and method with fiducials in non-recliner layouts
GB201701686D0 (en) 2017-02-01 2017-03-15 Illunina Inc System & method with fiducials having offset layouts
WO2018152162A1 (en) 2017-02-15 2018-08-23 Omniome, Inc. Distinguishing sequences by detecting polymerase dissociation
EP3494235A1 (en) 2017-02-17 2019-06-12 Stichting VUmc Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
EP3783112A1 (en) 2017-02-21 2021-02-24 Illumina, Inc. Tagmentation using immobilized transposomes with linkers
US11021740B2 (en) 2017-03-15 2021-06-01 The Broad Institute, Inc. Devices for CRISPR effector system based diagnostics
EP3596218B1 (en) 2017-03-15 2023-08-23 The Broad Institute, Inc. Crispr effector system based diagnostics for virus detection
US11174515B2 (en) 2017-03-15 2021-11-16 The Broad Institute, Inc. CRISPR effector system based diagnostics
US11104937B2 (en) 2017-03-15 2021-08-31 The Broad Institute, Inc. CRISPR effector system based diagnostics
SG11201908680YA (en) 2017-03-20 2019-10-30 Illumina Inc Methods and compositions for preparing nucleic acid libraries
WO2018175798A1 (en) 2017-03-24 2018-09-27 Life Technologies Corporation Polynucleotide adapters and methods of use thereof
WO2018187013A1 (en) 2017-04-04 2018-10-11 Omniome, Inc. Fluidic apparatus and methods useful for chemical and biological reactions
AU2018259202B2 (en) 2017-04-23 2022-03-24 Illumina Cambridge Limited Compositions and methods for improving sample identification in indexed nucleic acid libraries
DK3615691T3 (en) 2017-04-23 2021-07-26 Illumina Inc Compositions and methods for improving sample identification in indexed nucleic acid libraries
CN111094584B (en) 2017-04-23 2024-11-26 伊鲁米那股份有限公司 Compositions and methods for improving sample identification in indexed nucleic acid libraries
US10161003B2 (en) 2017-04-25 2018-12-25 Omniome, Inc. Methods and apparatus that increase sequencing-by-binding efficiency
US9951385B1 (en) 2017-04-25 2018-04-24 Omniome, Inc. Methods and apparatus that increase sequencing-by-binding efficiency
EP3619326A1 (en) 2017-05-01 2020-03-11 Illumina, Inc. Optimal index sequences for multiplex massively parallel sequencing
AU2018266377B2 (en) 2017-05-08 2024-06-20 Illumina, Inc. Universal short adapters for indexing of polynucleotide samples
IL271215B2 (en) 2017-06-07 2025-02-01 Univ Oregon Health & Science Single cell whole genome libraries for methylation sequencing
EP3642362B1 (en) 2017-06-20 2025-10-15 Illumina, Inc. Methods for addressing inefficiencies in amplification reactions
CA3070407C (en) 2017-07-18 2022-08-09 Omniome, Inc. Method of chemically modifying plastic surfaces
BR112020000826A2 (en) 2017-07-24 2020-07-21 Quantum-Si Incorporated massively parallel bio-optoelectronic instrument
WO2019027767A1 (en) 2017-07-31 2019-02-07 Illumina Inc. Sequencing system with multiplexed biological sample aggregation
CN118086479A (en) 2017-08-01 2024-05-28 深圳华大智造科技有限公司 Nucleic acid sequencing methods
KR102307473B1 (en) 2017-08-01 2021-10-01 일루미나, 인코포레이티드 Hydrogel Beads for Nucleotide Sequencing
US11352668B2 (en) 2017-08-01 2022-06-07 Illumina, Inc. Spatial indexing of genetic material and library preparation using hydrogel beads and flow cells
EP3545106B1 (en) 2017-08-01 2022-01-19 Helitec Limited Methods of enriching and determining target nucleotide sequences
AU2018317826B2 (en) 2017-08-15 2022-11-24 Pacific Biosciences Of California, Inc. Scanning apparatus and methods useful for detection of chemical and biological analytes
US11447818B2 (en) 2017-09-15 2022-09-20 Illumina, Inc. Universal short adapters with variable length non-random unique molecular identifiers
WO2019079182A1 (en) 2017-10-16 2019-04-25 Illumina, Inc. Semi-supervised learning for training an ensemble of deep convolutional neural networks
KR102662206B1 (en) 2017-10-16 2024-04-30 일루미나, 인코포레이티드 Deep learning-based splice site classification
EP3697932A1 (en) 2017-10-19 2020-08-26 Omniome, Inc. Simultaneous background reduction and complex stabilization in binding assay workflows
US11561196B2 (en) 2018-01-08 2023-01-24 Illumina, Inc. Systems and devices for high-throughput sequencing with semiconductor-based detection
CA3065934A1 (en) 2018-01-08 2019-07-11 Illumina, Inc. High-throughput sequencing with semiconductor-based detection
KR102689425B1 (en) 2018-01-15 2024-07-29 일루미나, 인코포레이티드 Deep learning-based variant classifier
JP7527961B2 (en) 2018-01-29 2024-08-05 ザ・ブロード・インスティテュート・インコーポレイテッド CRISPR effector system-based diagnostics
BR112020015905A2 (en) 2018-02-06 2020-12-15 Omniome, Inc. COMPOSITIONS AND TECHNIQUES FOR NUCLEIC ACID INITIATOR EXTENSION
EP4083225A1 (en) 2018-02-13 2022-11-02 Illumina, Inc. Dna sequencing using hydrogel beads
RU2751359C2 (en) 2018-02-16 2021-07-13 Иллюмина, Инк. Charge labelled nucleotides and methods for application thereof
IL271411B2 (en) 2018-03-09 2024-03-01 Illumina Inc Generalized stochastic super-resolution sequencing
KR102383799B1 (en) 2018-04-02 2022-04-05 일루미나, 인코포레이티드 Compositions and methods for preparing controls for sequence-based genetic testing
WO2019200338A1 (en) 2018-04-12 2019-10-17 Illumina, Inc. Variant classifier based on deep neural networks
WO2019203986A1 (en) 2018-04-19 2019-10-24 Omniome, Inc. Improving accuracy of base calls in nucleic acid sequencing methods
SG11201911961RA (en) 2018-04-20 2020-01-30 Illumina Inc Methods of encapsulating single cells, the encapsulated cells and uses thereof
JP7554117B2 (en) 2018-04-26 2024-09-19 パシフィック・バイオサイエンシズ・オブ・カリフォルニア・インク． Methods and compositions for stabilizing nucleic acid-nucleotide-polymerase complexes - Patents.com
EP4306532A3 (en) 2018-05-15 2024-04-10 Illumina, Inc. Chemical cleavage and deprotection
US11981891B2 (en) 2018-05-17 2024-05-14 Illumina, Inc. High-throughput single-cell sequencing with reduced amplification bias
CN110785499B (en) 2018-05-25 2024-12-03 伊鲁米那股份有限公司 Circulating RNA signature specific for preeclampsia
JP2021525078A (en) 2018-05-31 2021-09-24 オムニオム インコーポレイテッドＯｍｎｉｏｍｅ， Ｉｎｃ． Increased signal vs. noise in nucleic acid sequencing
US11180794B2 (en) 2018-05-31 2021-11-23 Omniome, Inc. Methods and compositions for capping nucleic acids
KR102507415B1 (en) 2018-06-04 2023-03-07 일루미나, 인코포레이티드 High-throughput single-cell transcriptome libraries and methods of making and of using
AU2019288394B2 (en) 2018-06-22 2025-01-30 Quantum-Si Incorporated Integrated photodetector with charge storage bin of varied detection time
US12073922B2 (en) 2018-07-11 2024-08-27 Illumina, Inc. Deep learning-based framework for identifying sequence patterns that cause sequence-specific errors (SSEs)
CN113056327A (en) 2018-07-23 2021-06-29 Dna斯克瑞普特公司 Massively parallel enzymatic synthesis of nucleic acid strands
CA3107165A1 (en) 2018-07-24 2020-01-30 Omniome, Inc. Serial formation of ternary complex species
WO2020022891A2 (en) 2018-07-26 2020-01-30 Stichting Vumc Biomarkers for atrial fibrillation
EP3833761A1 (en) 2018-08-07 2021-06-16 The Broad Institute, Inc. Novel cas12b enzymes and systems
JP7431802B2 (en) 2018-08-15 2024-02-15 イルミナ インコーポレイテッド Compositions and methods for improving library enrichment
US11519033B2 (en) 2018-08-28 2022-12-06 10X Genomics, Inc. Method for transposase-mediated spatial tagging and analyzing genomic DNA in a biological sample
EP3853358A1 (en) 2018-09-17 2021-07-28 Omniome, Inc. Engineered polymerases for improved sequencing
WO2020072816A1 (en) 2018-10-03 2020-04-09 The Broad Institute, Inc. Crispr effector system based diagnostics for hemorrhagic fever detection
NZ759665A (en) 2018-10-15 2022-07-01 Illumina Inc Deep learning-based techniques for pre-training deep convolutional neural networks
MY202795A (en) 2018-10-26 2024-05-22 Illumina Inc Modulating polymer beads for dna processing
CN112673098B (en) 2018-10-31 2023-01-06 亿明达股份有限公司 Polymerases, compositions and methods of use
WO2020093261A1 (en) 2018-11-07 2020-05-14 深圳华大智造极创科技有限公司 Method for sequencing polynucleotides
JP2022513031A (en) 2018-11-14 2022-02-07 ディーエヌエー スクリプト Terminal deoxynucleotidyl transferase variant and its use
WO2020101795A1 (en) 2018-11-15 2020-05-22 Omniome, Inc. Electronic detection of nucleic acid structure
NL2022043B1 (en) 2018-11-21 2020-06-03 Akershus Univ Hf Tagmentation-Associated Multiplex PCR Enrichment Sequencing
EP4477758A3 (en) 2018-11-30 2025-01-15 Illumina, Inc. Analysis of multiple analytes using a single assay
EP3891304A1 (en) 2018-12-04 2021-10-13 Omniome, Inc. Mixed-phase fluids for nucleic acid sequencing and other analytical assays
WO2020117968A2 (en) 2018-12-05 2020-06-11 Illumina, Inc. Polymerases, compositions, and methods of use
EP3891305A1 (en) 2018-12-05 2021-10-13 Illumina Cambridge Limited Methods and compositions for cluster generation by bridge amplification
CN113767177B (en) 2018-12-10 2025-01-14 10X基因组学有限公司 Generation of capture probes for spatial analysis
GB201820341D0 (en) 2018-12-13 2019-01-30 10X Genomics Inc Method for transposase-mediated spatial tagging and analysing genomic DNA in a biological specimen
GB201820300D0 (en) 2018-12-13 2019-01-30 10X Genomics Inc Method for spatial tagging and analysing genomic DNA in a biological specimen
EP3894593B1 (en) 2018-12-13 2024-10-02 DNA Script Direct oligonucleotide synthesis on cdna
JP7542444B2 (en) 2018-12-14 2024-08-30 イルミナ ケンブリッジ リミテッド Reduced phasing by unlabeled nucleotides during sequencing.
WO2020126595A1 (en) 2018-12-17 2020-06-25 Illumina Cambridge Limited Primer oligonucleotide for sequencing
EP3899040B8 (en) 2018-12-17 2025-06-11 Illumina Cambridge Limited Method of polynucleotide sequencing
SG11202012807YA (en) 2018-12-18 2021-01-28 Illumina Cambridge Ltd Methods and compositions for paired end sequencing using a single surface primer
ES2965222T3 (en) 2018-12-19 2024-04-11 Illumina Inc Methods to improve the clonality priority of polynucleotide pools
JP7153140B2 (en) 2018-12-19 2022-10-13 エフ．ホフマン－ラ ロシュ アーゲー 3' protected nucleotide
WO2020132350A2 (en) 2018-12-20 2020-06-25 Omniome, Inc. Temperature control for analysis of nucleic acids and other analytes
US11293061B2 (en) 2018-12-26 2022-04-05 Illumina Cambridge Limited Sequencing methods using nucleotides with 3′ AOM blocking group
WO2020141143A1 (en) 2019-01-03 2020-07-09 Dna Script One pot synthesis of sets of oligonucleotides
US11649485B2 (en) 2019-01-06 2023-05-16 10X Genomics, Inc. Generating capture probes for spatial analysis
US11926867B2 (en) 2019-01-06 2024-03-12 10X Genomics, Inc. Generating capture probes for spatial analysis
CN112930405B (en) 2019-01-11 2025-01-28 Illumina剑桥有限公司 Composite surface-bound transposome complex
WO2020165137A1 (en) 2019-02-12 2020-08-20 Dna Script Efficient product cleavage in template-free enzymatic synthesis of polynucleotides.
US11499189B2 (en) 2019-02-14 2022-11-15 Pacific Biosciences Of California, Inc. Mitigating adverse impacts of detection systems on nucleic acids and other biological analytes
KR20210132104A (en) 2019-02-19 2021-11-03 울티마 제노믹스, 인크. Linkers and Methods for Optical Detection and Sequencing
EP3927467A4 (en) 2019-02-20 2022-12-14 Pacific Biosciences of California, Inc. Scanning apparatus and methods for detecting chemical and biological analytes
MX2021003746A (en) 2019-03-01 2021-06-23 Illumina Inc High-throughput single-nuclei and single-cell libraries and methods of making and of using.
NL2023311B9 (en) 2019-03-21 2021-03-12 Illumina Inc Artificial intelligence-based generation of sequencing metadata
NL2023312B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based base calling
NL2023316B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based sequencing
NL2023314B1 (en) 2019-03-21 2020-09-28 Illumina Inc Artificial intelligence-based quality scoring
WO2020191390A2 (en) 2019-03-21 2020-09-24 Illumina, Inc. Artificial intelligence-based quality scoring
US11783917B2 (en) 2019-03-21 2023-10-10 Illumina, Inc. Artificial intelligence-based base calling
US11210554B2 (en) 2019-03-21 2021-12-28 Illumina, Inc. Artificial intelligence-based generation of sequencing metadata
NL2023310B1 (en) 2019-03-21 2020-09-28 Illumina Inc Training data generation for artificial intelligence-based sequencing
CN118931711A (en) 2019-05-15 2024-11-12 青岛华大智造科技有限责任公司 Single-channel sequencing device and sequencing method
US11593649B2 (en) 2019-05-16 2023-02-28 Illumina, Inc. Base calling using convolutions
US11423306B2 (en) 2019-05-16 2022-08-23 Illumina, Inc. Systems and devices for characterization and performance analysis of pixel-based sequencing
EP3976820A1 (en) 2019-05-30 2022-04-06 10X Genomics, Inc. Methods of detecting spatial heterogeneity of a biological sample
US11644406B2 (en) 2019-06-11 2023-05-09 Pacific Biosciences Of California, Inc. Calibrated focus sensing
KR20220034716A (en) 2019-07-12 2022-03-18 일루미나 케임브리지 리미티드 Compositions and methods for preparing nucleic acid sequencing libraries using CRISPR/CAS9 immobilized on a solid support
BR112021012751A2 (en) 2019-07-12 2021-12-14 Illumina Cambridge Ltd Nucleic acid library preparation using electrophoresis
WO2021011803A1 (en) 2019-07-16 2021-01-21 Omniome, Inc. Synthetic nucleic acids having non-natural structures
US10656368B1 (en) 2019-07-24 2020-05-19 Omniome, Inc. Method and system for biological imaging using a wide field objective lens
CA3145783A1 (en) 2019-07-30 2021-02-04 Tillmann HEINISCH Template-free enzymatic synthesis of polynucleotides using poly(a) and poly(u) polymerases
EP4007816A1 (en) 2019-08-01 2022-06-08 DNA Script Increasing long-sequence yields in template-free enzymatic synthesis of polynucleotides
EP4047098A4 (en) 2019-08-20 2023-06-07 EGI Tech (Shen Zhen) Co., Limited Method for sequencing polynucleotides on basis of optical signal dynamics of luminescent label and secondary luminescent signal
US20220315970A1 (en) 2019-09-09 2022-10-06 Dna Script Template-Free Enzymatic Polynucleotide Synthesis Using Photocleavable Linkages
TW202124406A (en) 2019-09-10 2021-07-01 美商歐姆尼歐美公司 Reversible modification of nucleotides
US20220290245A1 (en) 2019-09-11 2022-09-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Cancer detection and classification
CN114729389B (en) 2019-09-23 2024-03-08 Dna斯克瑞普特公司 Increasing long sequence yield in template-free enzymatic synthesis of polynucleotides
EP4045683B1 (en) 2019-10-18 2025-02-19 Pacific Biosciences of California, Inc. Methods for capping nucleic acids
EP4055185A1 (en) 2019-11-08 2022-09-14 10X Genomics, Inc. Spatially-tagged analyte capture agents for analyte multiplexing
WO2021092433A2 (en) 2019-11-08 2021-05-14 10X Genomics, Inc. Enhancing specificity of analyte binding
US20210139867A1 (en) 2019-11-08 2021-05-13 Omniome, Inc. Engineered polymerases for improved sequencing by binding
JP2023501651A (en) 2019-11-13 2023-01-18 ディーエヌエー スクリプト Highly efficient template-free enzymatic synthesis of polynucleotides
CA3131748A1 (en) 2019-11-22 2021-05-27 Sarah E. SHULTZABERGER Circulating rna signatures specific to preeclampsia
DE202019106695U1 (en) 2019-12-02 2020-03-19 Omniome, Inc. System for sequencing nucleic acids in fluid foam
DE202019106694U1 (en) 2019-12-02 2020-03-19 Omniome, Inc. System for sequencing nucleic acids in fluid foam
EP4010489A1 (en) 2019-12-04 2022-06-15 Illumina, Inc. Preparation of dna sequencing libraries for detection of dna pathogens in plasma
WO2021118349A1 (en) 2019-12-10 2021-06-17 Prinses Máxima Centrum Voor Kinderoncologie B.V. Methods of typing germ cell tumors
CN114787346A (en) 2019-12-12 2022-07-22 Dna斯克瑞普特公司 Chimeric terminal deoxynucleotidyl transferase for template-free enzymatic synthesis of polynucleotides
CN115135770A (en) 2019-12-16 2022-09-30 Dna斯克瑞普特公司 Template-free enzymatic synthesis of polynucleotides using disproportionation-free terminal deoxynucleotidyl transferase variants
EP4077344B1 (en) 2019-12-18 2025-07-23 F. Hoffmann-La Roche AG Methods of sequencing by synthesis using a consecutive labeling scheme
BR112021019640A2 (en) 2019-12-19 2022-06-21 Illumina Inc High-throughput single cell libraries and methods of preparation and use
CN115038794A (en) 2019-12-23 2022-09-09 10X基因组学有限公司 Compositions and methods for using fixed biological samples in partition-based assays
CN114885610B (en) 2019-12-23 2025-09-05 10X基因组学有限公司 Methods for spatial profiling using RNA-templated ligation
US12365942B2 (en) 2020-01-13 2025-07-22 10X Genomics, Inc. Methods of decreasing background on a spatial array
EP4090942A4 (en) * 2020-01-14 2024-02-28 Pacific Biosciences of California, Inc. Nucleic acid sequencing cartridges, packaged devices, and systems
US12405264B2 (en) 2020-01-17 2025-09-02 10X Genomics, Inc. Electrophoretic system and method for analyte capture
US11732299B2 (en) 2020-01-21 2023-08-22 10X Genomics, Inc. Spatial assays with perturbed cells
US11702693B2 (en) 2020-01-21 2023-07-18 10X Genomics, Inc. Methods for printing cells and generating arrays of barcoded cells
US20210230681A1 (en) 2020-01-24 2021-07-29 10X Genomics, Inc. Methods for spatial analysis using proximity ligation
US11821035B1 (en) 2020-01-29 2023-11-21 10X Genomics, Inc. Compositions and methods of making gene expression libraries
US12076701B2 (en) 2020-01-31 2024-09-03 10X Genomics, Inc. Capturing oligonucleotides in spatial transcriptomics
US12110541B2 (en) 2020-02-03 2024-10-08 10X Genomics, Inc. Methods for preparing high-resolution spatial arrays
US11898205B2 (en) 2020-02-03 2024-02-13 10X Genomics, Inc. Increasing capture efficiency of spatial assays
US20230054204A1 (en) 2020-02-04 2023-02-23 Pacific Biosciences Of California, Inc. Flow cells and methods for their manufacture and use
US11732300B2 (en) 2020-02-05 2023-08-22 10X Genomics, Inc. Increasing efficiency of spatial analysis in a biological sample
WO2021158925A1 (en) 2020-02-07 2021-08-12 10X Genomics, Inc. Quantitative and automated permeabilization performance evaluation for spatial transcriptomics
US11835462B2 (en) 2020-02-11 2023-12-05 10X Genomics, Inc. Methods and compositions for partitioning a biological sample
US12281357B1 (en) 2020-02-14 2025-04-22 10X Genomics, Inc. In situ spatial barcoding
US12399123B1 (en) 2020-02-14 2025-08-26 10X Genomics, Inc. Spatial targeting of analytes
US11807851B1 (en) 2020-02-18 2023-11-07 Ultima Genomics, Inc. Modified polynucleotides and uses thereof
MX2022010276A (en) 2020-02-20 2022-09-19 Illumina Inc MANY-TO-MANY BASE CALL BASED ON ARTIFICIAL INTELLIGENCE.
US20210265016A1 (en) 2020-02-20 2021-08-26 Illumina, Inc. Data Compression for Artificial Intelligence-Based Base Calling
US20210265015A1 (en) 2020-02-20 2021-08-26 Illumina, Inc. Hardware Execution and Acceleration of Artificial Intelligence-Based Base Caller
US12354008B2 (en) 2020-02-20 2025-07-08 Illumina, Inc. Knowledge distillation and gradient pruning-based compression of artificial intelligence-based base caller
US11891654B2 (en) 2020-02-24 2024-02-06 10X Genomics, Inc. Methods of making gene expression libraries
US20230089448A1 (en) 2020-02-25 2023-03-23 Dna Script Method And Apparatus for Enzymatic Synthesis of Polynucleotides
US11926863B1 (en) 2020-02-27 2024-03-12 10X Genomics, Inc. Solid state single cell method for analyzing fixed biological cells
WO2021178467A1 (en) 2020-03-03 2021-09-10 Omniome, Inc. Methods and compositions for sequencing double stranded nucleic acids
US11768175B1 (en) 2020-03-04 2023-09-26 10X Genomics, Inc. Electrophoretic methods for spatial analysis
US20230159903A1 (en) 2020-04-20 2023-05-25 Dna Script Terminal Deoxynucleotidyl Transferase Variants and Uses Thereof
WO2021216708A1 (en) 2020-04-22 2021-10-28 10X Genomics, Inc. Methods for spatial analysis using targeted rna depletion
WO2021221500A1 (en) 2020-04-27 2021-11-04 Agendia N.V. Treatment of her2 negative, mammaprint high risk 2 breast cancer.
US11188778B1 (en) 2020-05-05 2021-11-30 Illumina, Inc. Equalization-based image processing and spatial crosstalk attenuator
WO2021225886A1 (en) 2020-05-05 2021-11-11 Omniome, Inc. Compositions and methods for modifying polymerase-nucleic acid complexes
WO2021231477A2 (en) 2020-05-12 2021-11-18 Illumina, Inc. Generating nucleic acids with modified bases using recombinant terminal deoxynucleotidyl transferase
WO2021236625A1 (en) 2020-05-19 2021-11-25 10X Genomics, Inc. Electrophoresis cassettes and instrumentation
EP4153776B1 (en) 2020-05-22 2025-03-05 10X Genomics, Inc. Spatial analysis to detect sequence variants
EP4414459B1 (en) 2020-05-22 2025-09-03 10X Genomics, Inc. Simultaneous spatio-temporal measurement of gene expression and cellular activity
WO2021242834A1 (en) 2020-05-26 2021-12-02 10X Genomics, Inc. Method for resetting an array
WO2021247543A2 (en) 2020-06-02 2021-12-09 10X Genomics, Inc. Nucleic acid library methods
US12265079B1 (en) 2020-06-02 2025-04-01 10X Genomics, Inc. Systems and methods for detecting analytes from captured single biological particles
EP4600376A3 (en) 2020-06-02 2025-10-22 10X Genomics, Inc. Spatial transcriptomics for antigen-receptors
US12031177B1 (en) 2020-06-04 2024-07-09 10X Genomics, Inc. Methods of enhancing spatial resolution of transcripts
WO2021252375A1 (en) 2020-06-08 2021-12-16 The Broad Institute, Inc. Single cell combinatorial indexing from amplified nucleic acids
EP4421186B1 (en) 2020-06-08 2025-08-13 10X Genomics, Inc. Methods of determining a surgical margin and methods of use thereof
WO2021252617A1 (en) 2020-06-09 2021-12-16 Illumina, Inc. Methods for increasing yield of sequencing libraries
US12435363B1 (en) 2020-06-10 2025-10-07 10X Genomics, Inc. Materials and methods for spatial transcriptomics
EP4165207B1 (en) 2020-06-10 2024-09-25 10X Genomics, Inc. Methods for determining a location of an analyte in a biological sample
CA3182608A1 (en) 2020-06-16 2021-12-23 Carl Martin Systems, apparatus and kits for enzymatic polynucleotide synthesis
CN120174072A (en) 2020-06-22 2025-06-20 伊鲁米纳剑桥有限公司 Nucleosides and nucleotides with 3' acetal capping groups
ES2994976T3 (en) 2020-06-25 2025-02-05 10X Genomics Inc Spatial analysis of dna methylation
KR20230037503A (en) 2020-06-30 2023-03-16 일루미나, 인코포레이티드 Sequencing by catalytically controlled synthesis to generate traceless DNA
US20230242967A1 (en) 2020-07-02 2023-08-03 Illumina, Inc. A method to calibrate nucleic acid library seeding efficiency in flowcells
US12209280B1 (en) 2020-07-06 2025-01-28 10X Genomics, Inc. Methods of identifying abundance and location of an analyte in a biological sample using second strand synthesis
US11981960B1 (en) 2020-07-06 2024-05-14 10X Genomics, Inc. Spatial analysis utilizing degradable hydrogels
US11761038B1 (en) 2020-07-06 2023-09-19 10X Genomics, Inc. Methods for identifying a location of an RNA in a biological sample
CN116018412A (en) 2020-07-08 2023-04-25 Illumina公司 Beads as transposome vectors
EP4182472A1 (en) 2020-07-15 2023-05-24 DNA Script Massively parallel enzymatic synthesis of polynucleotides
IL300112A (en) 2020-08-06 2023-03-01 Illumina Inc Preparation of rna and dna sequencing libraries using bead-linked transposomes
CA3191159A1 (en) 2020-08-18 2022-02-24 Illumina, Inc. Sequence-specific targeted transposition and selection and sorting of nucleic acids
US11981958B1 (en) 2020-08-20 2024-05-14 10X Genomics, Inc. Methods for spatial analysis using DNA capture
AU2021339945A1 (en) 2020-09-11 2023-03-02 Illumina Cambridge Limited Methods of enriching a target sequence from a sequencing library using hairpin adaptors
ES2993269T3 (en) 2020-09-18 2024-12-26 10X Genomics Inc Sample handling apparatus and image registration methods
CA3193386A1 (en) 2020-09-22 2022-03-31 Mikhael SOSKINE Stabilized n-terminally truncated terminal deoxynucleotidyl transferase variants and uses thereof
US11926822B1 (en) 2020-09-23 2024-03-12 10X Genomics, Inc. Three-dimensional spatial analysis
MX2023004461A (en) 2020-10-21 2023-05-03 Illumina Inc Sequencing templates comprising multiple inserts and compositions and methods for improving sequencing throughput.
WO2022090057A1 (en) 2020-10-26 2022-05-05 Dna Script Novel variants of endonuclease v and uses thereof
WO2022090323A1 (en) 2020-10-29 2022-05-05 Dna Script Enzymatic synthesis of polynucleotide probes
US11827935B1 (en) 2020-11-19 2023-11-28 10X Genomics, Inc. Methods for spatial analysis using rolling circle amplification and detection probes
EP4121555A1 (en) 2020-12-21 2023-01-25 10X Genomics, Inc. Methods, compositions, and systems for capturing probes and/or barcodes
CA3204784A1 (en) 2021-01-13 2022-07-21 Alex Nemiroski Surface structuring with colloidal assembly
US20240117416A1 (en) 2021-01-29 2024-04-11 Illumina, Inc. Methods, compositions and kits to improve seeding efficiency of flow cells with polynucleotides
FI4288562T3 (en) 2021-02-04 2025-02-17 Illumina Inc Long indexed-linked read generation on transposome bound beads
WO2022174054A1 (en) 2021-02-13 2022-08-18 The General Hospital Corporation Methods and compositions for in situ macromolecule detection and uses thereof
EP4421491A3 (en) 2021-02-19 2024-11-27 10X Genomics, Inc. Method of using a modular assay support device
WO2022197752A1 (en) 2021-03-16 2022-09-22 Illumina, Inc. Tile location and/or cycle based weight set selection for base calling
ES3008686T3 (en) 2021-03-18 2025-03-24 10X Genomics Inc Multiplex capture of gene and protein expression from a biological sample
AU2022245985A1 (en) 2021-03-22 2023-09-21 Illumina Cambridge Limited Methods for improving nucleic acid cluster clonality
KR20230163434A (en) 2021-03-29 2023-11-30 일루미나, 인코포레이티드 Compositions and methods for assessing DNA damage and normalizing amplicon size bias in libraries
WO2022212269A1 (en) 2021-03-29 2022-10-06 Illumina, Inc. Improved methods of library preparation
JP2024512917A (en) 2021-03-30 2024-03-21 イルミナ インコーポレイテッド Improved methods for isothermal complementary DNA and library preparation
EP4314283A1 (en) 2021-03-31 2024-02-07 Illumina, Inc. Methods of preparing directional tagmentation sequencing libraries using transposon-based technology with unique molecular identifiers for error correction
IL307378A (en) 2021-04-02 2023-11-01 Illumina Inc Machine-learning model for detecting a bubble within a nucleotide-sample slide for sequencing
EP4314314A1 (en) 2021-04-02 2024-02-07 DNA Script Methods and kits for enzymatic synthesis of g4-prone polynucleotides
EP4305196B1 (en) 2021-04-14 2025-04-02 10X Genomics, Inc. Methods of measuring mislocalization of an analyte
US12217829B2 (en) 2021-04-15 2025-02-04 Illumina, Inc. Artificial intelligence-based analysis of protein three-dimensional (3D) structures
US12444482B2 (en) 2021-04-15 2025-10-14 Illumina, Inc. Multi-channel protein voxelization to predict variant pathogenicity using deep convolutional neural networks
US12070744B2 (en) 2021-04-22 2024-08-27 Illumina, Inc. Valve assemblies and related systems
WO2022236054A1 (en) 2021-05-06 2022-11-10 10X Genomics, Inc. Methods for increasing resolution of spatial analysis
WO2022235163A1 (en) 2021-05-07 2022-11-10 Agendia N.V. Endocrine treatment of hormone receptor positive breast cancer typed as having a low risk of recurrence
WO2022240766A1 (en) 2021-05-10 2022-11-17 Pacific Biosciences Of California, Inc. Dna amplification buffer replenishment during rolling circle amplification
US20220356519A1 (en) 2021-05-10 2022-11-10 Pacific Biosciences Of California, Inc. Single-molecule seeding and amplification on a surface
WO2022243480A1 (en) 2021-05-20 2022-11-24 Illumina, Inc. Compositions and methods for sequencing by synthesis
EP4582555A3 (en) 2021-06-03 2025-10-22 10X Genomics, Inc. Methods, compositions, kits, and systems for enhancing analyte capture for spatial analysis
EP4355476A1 (en) 2021-06-15 2024-04-24 Illumina, Inc. Hydrogel-free surface functionalization for sequencing
US20220411864A1 (en) 2021-06-23 2022-12-29 Illumina, Inc. Compositions, methods, kits, cartridges, and systems for sequencing reagents
EP4364149A1 (en) 2021-06-29 2024-05-08 Illumina, Inc. Machine-learning model for generating confidence classifications for genomic coordinates
WO2023278184A1 (en) 2021-06-29 2023-01-05 Illumina, Inc. Methods and systems to correct crosstalk in illumination emitted from reaction sites
CN117730372A (en) 2021-06-29 2024-03-19 因美纳有限公司 Signal to noise metric for determining nucleotide base detection and base detection quality
WO2023278609A1 (en) 2021-06-29 2023-01-05 Illumina, Inc. Self-learned base caller, trained using organism sequences
US12423815B2 (en) 2021-07-13 2025-09-23 Illumina, Inc. Methods and systems for real time extraction of crosstalk in illumination emitted from reaction sites
WO2023003757A1 (en) 2021-07-19 2023-01-26 Illumina Software, Inc. Intensity extraction with interpolation and adaptation for base calling
US11455487B1 (en) 2021-10-26 2022-09-27 Illumina Software, Inc. Intensity extraction and crosstalk attenuation using interpolation and adaptation for base calling
CN117813391A (en) 2021-07-23 2024-04-02 因美纳有限公司 Method for preparing substrate surface for DNA sequencing
US20230021577A1 (en) 2021-07-23 2023-01-26 Illumina Software, Inc. Machine-learning model for recalibrating nucleotide-base calls
EP4377960A1 (en) 2021-07-28 2024-06-05 Illumina, Inc. Quality score calibration of basecalling systems
EP4381514A1 (en) 2021-08-03 2024-06-12 Illumina, Inc. Base calling using multiple base caller models
US12077789B2 (en) 2021-08-14 2024-09-03 Illumina, Inc. Polymerases, compositions, and methods of use
EP4388127A1 (en) 2021-08-17 2024-06-26 Illumina, Inc. Methods and compositions for identifying methylated cytosines
CN118103750A (en) 2021-08-31 2024-05-28 伊鲁米纳公司 Flow cell with enhanced aperture imaging resolution
EP4509614A3 (en) 2021-09-01 2025-05-14 10X Genomics, Inc. Methods, compositions, and kits for blocking a capture probe on a spatial array
JP2024535758A (en) 2021-09-07 2024-10-02 深▲セン▼華大智造科技股▲ふん▼有限公司 Method for analyzing the sequence of a target polynucleotide
EP4400602A4 (en) 2021-09-07 2025-09-17 Mgi Tech Co Ltd Method for analyzing the sequence of a target polynucleotide
CN117561573A (en) 2021-09-17 2024-02-13 因美纳有限公司 Automatic identification of the source of faults in nucleotide sequencing from base interpretation error patterns
KR20240072970A (en) 2021-09-21 2024-05-24 일루미나, 인코포레이티드 Graph reference genome and base determination approaches using imputed haplotypes.
WO2023049215A1 (en) 2021-09-22 2023-03-30 Illumina, Inc. Compressed state-based base calling
WO2023056328A2 (en) 2021-09-30 2023-04-06 Illumina, Inc. Solid supports and methods for depleting and/or enriching library fragments prepared from biosamples
US12480157B2 (en) 2021-09-30 2025-11-25 Illumina, Inc. Polynucleotide sequencing
EP4419705A1 (en) 2021-10-20 2024-08-28 Illumina, Inc. Methods for capturing library dna for sequencing
EP4174189A1 (en) 2021-10-28 2023-05-03 Volker, Leen Enzyme directed biomolecule labeling
WO2023081485A1 (en) 2021-11-08 2023-05-11 Pacific Biosciences Of California, Inc. Stepwise sequencing of a polynucleotide with a homogenous reaction mixture
US20250002879A1 (en) 2021-11-10 2025-01-02 Dna Script NOVEL TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE (TdT) VARIANTS
EP4430175A2 (en) 2021-11-10 2024-09-18 DNA Script Novel terminal deoxynucleotidyl
EP4419707A1 (en) 2021-11-10 2024-08-28 10X Genomics, Inc. Methods, compositions, and kits for determining the location of an analyte in a biological sample
WO2023085932A1 (en) 2021-11-10 2023-05-19 Omnigen B.V. Prediction of response following folfirinox treatment in cancer patients
WO2023102118A2 (en) 2021-12-01 2023-06-08 10X Genomics, Inc. Methods, compositions, and systems for improved in situ detection of analytes and spatial analysis
JP2024543762A (en) 2021-12-02 2024-11-26 イルミナ インコーポレイテッド Generating cluster-specific signal corrections for determining nucleotide base calls
EP4441711A1 (en) 2021-12-20 2024-10-09 10X Genomics, Inc. Self-test for pathology/histology slide imaging device
EP4453524A1 (en) 2021-12-23 2024-10-30 Illumina, Inc. Systems and related temperature calibration methods
WO2023122363A1 (en) 2021-12-23 2023-06-29 Illumina Software, Inc. Dynamic graphical status summaries for nucelotide sequencing
US20230215515A1 (en) 2021-12-23 2023-07-06 Illumina Software, Inc. Facilitating secure execution of external workflows for genomic sequencing diagnostics
US20230207050A1 (en) 2021-12-28 2023-06-29 Illumina Software, Inc. Machine learning model for recalibrating nucleotide base calls corresponding to target variants
AU2022425440A1 (en) 2021-12-29 2024-07-11 Illumina, Inc. Automatically switching variant analysis model versions for genomic analysis applications
US20240294967A1 (en) 2022-01-20 2024-09-05 Illumina, Inc. Methods of detecting methylcytosine and hydroxymethylcytosine by sequencing
BE1030246B1 (en) 2022-02-04 2023-09-04 Leen Volker POLYMER ASSISTED BIOMOLECULE ANALYSIS
WO2023164492A1 (en) 2022-02-25 2023-08-31 Illumina, Inc. Machine-learning models for detecting and adjusting values for nucleotide methylation levels
JP2025507713A (en) 2022-02-25 2025-03-21 イルミナ インコーポレイテッド Calibration Sequences for Nucleotide Sequencing
WO2023183937A1 (en) 2022-03-25 2023-09-28 Illumina, Inc. Sequence-to-sequence base calling
IL315876A (en) 2022-04-07 2024-11-01 Illumina Inc Altered cytidine deaminases and methods of use
EP4515547A1 (en) 2022-04-26 2025-03-05 Illumina, Inc. Machine-learning models for selecting oligonucleotide probes for array technologies
WO2023209606A1 (en) 2022-04-29 2023-11-02 Illumina Cambridge Limited Methods and systems for encapsulating lyophilised microspheres
WO2023220627A1 (en) 2022-05-10 2023-11-16 Illumina Software, Inc. Adaptive neural network for nucelotide sequencing
WO2023224488A1 (en) 2022-05-19 2023-11-23 Agendia N.V. Dna repair signature and prediction of response following cancer therapy
WO2023224487A1 (en) 2022-05-19 2023-11-23 Agendia N.V. Prediction of response to immune therapy in breast cancer patients
EP4532769A2 (en) 2022-06-03 2025-04-09 Illumina, Inc. Circulating rna biomarkers for preeclampsia
JP2025526537A (en) 2022-06-09 2025-08-15 イルミナ インコーポレイテッド Dependence of base calling on flow cell tilt
IL317960A (en) 2022-06-24 2025-02-01 Illumina Inc Improving split-read alignment by intelligently identifying and scoring candidate split groups
CN119698662A (en) 2022-06-27 2025-03-25 因美纳有限公司 Generate and implement structural variation graph genomes
US20230420075A1 (en) 2022-06-27 2023-12-28 Illumina Software, Inc. Accelerators for a genotype imputation model
WO2024006705A1 (en) 2022-06-27 2024-01-04 Illumina Software, Inc. Improved human leukocyte antigen (hla) genotyping
WO2024015962A1 (en) 2022-07-15 2024-01-18 Pacific Biosciences Of California, Inc. Blocked asymmetric hairpin adaptors
EP4562638A1 (en) 2022-07-26 2025-06-04 Illumina, Inc. Rapid single-cell multiomics processing using an executable file
JP2025534191A (en) 2022-09-29 2025-10-15 イルミナ インコーポレイテッド Targeted variant reference panel for target variant attribution
EP4595059A1 (en) 2022-09-30 2025-08-06 Illumina, Inc. Machine-learning model for refining structural variant calls
US20240141427A1 (en) 2022-09-30 2024-05-02 Illumina, Inc. Polymerases, compositions, and methods of use
EP4594481A1 (en) 2022-09-30 2025-08-06 Illumina, Inc. Helicase-cytidine deaminase complexes and methods of use
WO2024073043A1 (en) 2022-09-30 2024-04-04 Illumina, Inc. Methods of using cpg binding proteins in mapping modified cytosine nucleotides
WO2024073047A1 (en) 2022-09-30 2024-04-04 Illumina, Inc. Cytidine deaminases and methods of use in mapping modified cytosine nucleotides
CN119096301A (en) 2022-10-05 2024-12-06 因美纳有限公司 Integrating variant calls from multiple sequencing pipelines using machine learning architectures
EP4482987A2 (en) 2022-10-06 2025-01-01 Illumina, Inc. Probes for improving coronavirus sample surveillance
EP4599080A2 (en) 2022-10-06 2025-08-13 Illumina, Inc. Probes for improving environmental sample surveillance
WO2024077152A1 (en) 2022-10-06 2024-04-11 Illumina, Inc. Probes for depleting abundant small noncoding rna
EP4602608A1 (en) 2022-10-11 2025-08-20 Illumina, Inc. Detecting and correcting methylation values from methylation sequencing assays
WO2024083883A1 (en) 2022-10-19 2024-04-25 Dna Script Methods and products for removal of uracil containing polynucleotides
WO2024118903A1 (en) 2022-11-30 2024-06-06 Illumina, Inc. Chemoenzymatic correction of false positive uracil transformations
US20240177802A1 (en) 2022-11-30 2024-05-30 Illumina, Inc. Accurately predicting variants from methylation sequencing data
EP4630540A1 (en) 2022-12-05 2025-10-15 DNA Script Variants of poly(a) polymerase and uses thereof
WO2024129672A1 (en) 2022-12-12 2024-06-20 The Broad Institute, Inc. Trafficked rnas for assessment of cell-cell connectivity and neuroanatomy
WO2024129969A1 (en) 2022-12-14 2024-06-20 Illumina, Inc. Systems and methods for capture and enrichment of clustered beads on flow cell substrates
EP4634403A1 (en) 2022-12-16 2025-10-22 Illumina, Inc. Boranes on solid supports
WO2024137774A1 (en) 2022-12-22 2024-06-27 Illumina, Inc. Palladium catalyst compositions and methods for sequencing by synthesis
CN119095983A (en) 2022-12-22 2024-12-06 伊路米纳有限公司 Transition metal catalyst compositions and methods for sequencing by synthesis
EP4642931A1 (en) 2022-12-27 2025-11-05 Illumina, Inc. Methods of sequencing using 3´ allyl blocked nucleotides
EP4642920A1 (en) 2022-12-31 2025-11-05 DNA Script Variable viscosity inks for inkjet delivery of enzyme reagents
EP4646491A1 (en) 2023-01-06 2025-11-12 Illumina, Inc. Reducing uracils by polymerase
EP4652292A1 (en) 2023-01-16 2025-11-26 DNA Script Inkjet-assisted enzymatic nucleic acid synthesis
EP4655411A2 (en) 2023-01-26 2025-12-03 DNA Script Enzymatic synthesis of polynucleotide probes
US20240266003A1 (en) 2023-02-06 2024-08-08 Illumina, Inc. Determining and removing inter-cluster light interference
AU2024221664A1 (en) 2023-02-17 2025-01-02 Illumina, Inc. Cell-free dna signals as biomarkers of preeclampsia
US20240327909A1 (en) 2023-03-30 2024-10-03 Illumina, Inc. Compositions and methods for nucleic acid sequencing
WO2024206848A1 (en) 2023-03-30 2024-10-03 Illumina, Inc. Tandem repeat genotyping
IL317962A (en) 2023-05-03 2025-02-01 Illumina Inc Machine learning model for recalibrating genotype calls from existing sequencing data files
WO2024249200A1 (en) 2023-05-26 2024-12-05 Illumina, Inc. Methods for preserving methylation status during clustering
WO2024249940A1 (en) 2023-05-31 2024-12-05 Illumina, Inc. Improving structural variant alignment and variant calling by utilizing a structural-variant reference genome
WO2024249973A2 (en) 2023-06-02 2024-12-05 Illumina, Inc. Linking human genes to clinical phenotypes using graph neural networks
WO2024254003A1 (en) 2023-06-05 2024-12-12 Illumina, Inc. Identification and mapping of methylation sites
WO2024256604A1 (en) 2023-06-15 2024-12-19 Dna Script Salt addition during enzymatic polynucleotide synthesis
WO2025006432A1 (en) 2023-06-26 2025-01-02 Pacific Biosciences Of California, Inc. Compositions and methods for nucleic acid extension
WO2025006565A1 (en) 2023-06-27 2025-01-02 Illumina, Inc. Variant calling with methylation-level estimation
WO2025006487A1 (en) 2023-06-30 2025-01-02 Illumina, Inc. Using flowcell spatial coordinates to link reads for improved genome analysis
WO2025006874A1 (en) 2023-06-30 2025-01-02 Illumina, Inc. Machine-learning model for recalibrating genotype calls corresponding to germline variants and somatic mosaic variants
WO2025010160A1 (en) 2023-07-06 2025-01-09 Pacific Biosciences Of California, Inc. Methods and compositions for stabilizing concatemers
GB202312147D0 (en) 2023-08-08 2023-09-20 Syndex Bio Ltd Methylation method
WO2025054389A1 (en) 2023-09-07 2025-03-13 Illumina, Inc. Identification of methylated cytosine using landmarks
WO2025058517A1 (en) 2023-09-12 2025-03-20 Levels Diagnostics Holding B.V. Biomarkers for typing a sample of an individual for hepatocellular carcinoma.
WO2025059045A1 (en) 2023-09-12 2025-03-20 Illumina, Inc. Systems and methods for determining linkage of sequence reads on a flow cell
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025072368A1 (en) 2023-09-28 2025-04-03 Illumina, Inc. Capture and selective release of biological material
WO2025072800A2 (en) 2023-09-28 2025-04-03 Illumina, Inc. Altered cytidine deaminases and methods of use
WO2025072870A1 (en) 2023-09-29 2025-04-03 Illumina, Inc. Tracking and modifying cluster location on nucleotide-sample slides in real time
WO2025072833A1 (en) 2023-09-29 2025-04-03 Illumina, Inc. Predicting insert lengths using primary analysis metrics
WO2025081064A2 (en) 2023-10-11 2025-04-17 Illumina, Inc. Thermophilic deaminase and methods for identifying modified cytosine
WO2025088024A1 (en) 2023-10-24 2025-05-01 Dna Script Novel terminal deoxynucleotidyl transferase (tdt) variants and uses thereof
WO2025090883A1 (en) 2023-10-27 2025-05-01 Illumina, Inc. Detecting variants in nucleotide sequences based on haplotype diversity
WO2025106431A1 (en) 2023-11-17 2025-05-22 Illumina, Inc. Determining structural variants
WO2025106629A1 (en) 2023-11-17 2025-05-22 Illumina, Inc. Structural variant detection using spatially linked reads
WO2025117738A1 (en) 2023-11-28 2025-06-05 Illumina, Inc. Methods of improving unique molecular index ligation efficiency
EP4567128A1 (en) 2023-12-07 2025-06-11 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Improved method and means for spatial nucleic acid detection in-situ
WO2025129074A2 (en) 2023-12-14 2025-06-19 Illumina, Inc. Indexing techniques for tagmented dna libraries
WO2025129133A1 (en) 2023-12-15 2025-06-19 Illumina, Inc. Minimal residual disease (mrd) models for determining likelihoods or probabilities of a subject comprising cancer
WO2025132603A1 (en) 2023-12-18 2025-06-26 Dna Script Novel variants of endonuclease v for cleavage of labelled dna
WO2025132627A1 (en) 2023-12-18 2025-06-26 Dna Script Stabilized variants of highly active endonuclease v for cleavage of labelled dna
US20250201346A1 (en) 2023-12-18 2025-06-19 Illumina, Inc. Using machine learning models for detecting minimum residual disease (mrd) in a subject
WO2025137222A1 (en) 2023-12-19 2025-06-26 Illumina, Inc. Methylation detection assay
WO2025136105A1 (en) 2023-12-20 2025-06-26 Stichting Amsterdam UMC Intestinal tissue-adherent microbial signatures predictive of response to anti-tnf-alpha in crohn's disease
WO2025137268A1 (en) 2023-12-20 2025-06-26 Pacific Biosciences Of California, Inc. Methods and compositions for reducing gc bias
US20250210137A1 (en) 2023-12-20 2025-06-26 Illumina, Inc. Directly determining signal-to-noise-ratio metrics for accelerated convergence in determining nucleotide-base calls and base-call quality
WO2025137647A1 (en) 2023-12-21 2025-06-26 Illumina, Inc. Enhanced mapping and alignment of nucleotide reads utilizing an improved haplotype data structure with allele-variant differences
WO2025136717A1 (en) 2023-12-22 2025-06-26 Illumina, Inc. Improving mapping resolution using spatial information of sequenced reads
WO2025144716A1 (en) 2023-12-28 2025-07-03 Illumina, Inc. Nucleotides with enzymatically cleavable 3'-o-glycoside blocking groups for sequencing
WO2025160089A1 (en) 2024-01-26 2025-07-31 Illumina, Inc. Custom multigenome reference construction for improved sequencing analysis of genomic samples
WO2025174774A1 (en) 2024-02-12 2025-08-21 Illumina, Inc. Determining offline corrections for sequence specific errors caused by low complexity nucleotide sequences
WO2025174708A1 (en) 2024-02-13 2025-08-21 Illumina, Inc. Design and method for cross-sequencing platform compatibility of flow cells
WO2025184226A1 (en) 2024-02-28 2025-09-04 Illumina, Inc. Nucleotides with terminal phosphate capping
WO2025184234A1 (en) 2024-02-28 2025-09-04 Illumina, Inc. A personalized haplotype database for improved mapping and alignment of nucleotide reads and improved genotype calling
WO2025189105A1 (en) 2024-03-08 2025-09-12 Illumina, Inc. Size thresholding of dna fragments
WO2025188906A1 (en) 2024-03-08 2025-09-12 Illumina, Inc. Modified adenosine nucleotides
WO2025193747A1 (en) 2024-03-12 2025-09-18 Illumina, Inc. Machine-learning models for ordering and expediting sequencing tasks or corresponding nucleotide-sample slides
WO2025198469A1 (en) 2024-03-18 2025-09-25 Agendia N.V. Prediction of response to immune therapy in triple negative breast cancer patients.
WO2025207886A1 (en) 2024-03-28 2025-10-02 Illumina, Inc. Kits and methods for on-flow cell library preparation and methylation detection
WO2025230914A1 (en) 2024-04-29 2025-11-06 Illumina, Inc. Nucleotides with enzyme-triggered self-immolative linkers for sequencing by synthesis
WO2025240241A1 (en) 2024-05-13 2025-11-20 Illumina, Inc. Modifying sequencing cycles during a sequencing run to meet customized coverage estimations for a target genomic region
WO2025240924A1 (en) 2024-05-17 2025-11-20 Illumina, Inc. Blind equalization systems for base calling applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863849A (en) * 1985-07-18 1989-09-05 New York Medical College Automatable process for sequencing nucleotide
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
US4962037A (en) * 1987-10-07 1990-10-09 United States Of America Method for rapid base sequencing in DNA and RNA
US4971903A (en) * 1988-03-25 1990-11-20 Edward Hyman Pyrophosphate-based method and apparatus for sequencing nucleic acids
GB8910880D0 (en) * 1989-05-11 1989-06-28 Amersham Int Plc Sequencing method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9106678A1 *

Also Published As

Publication number Publication date
CA2044616A1 (en) 1991-04-27
WO1991006678A1 (en) 1991-05-16

Similar Documents

Publication Publication Date Title
EP0450060A1 (en) Dna sequencing
Metzker et al. Termination of DNA synthesis by novel 3'-modifieddeoxyribonucleoside 5'-triphosphates
US5547835A (en) DNA sequencing by mass spectrometry
EP2321429B1 (en) Methods and kits for nucleic acid sequencing
Matteucci et al. Synthesis of deoxyoligonucleotides on a polymer support
US6573374B1 (en) Nucleotides labelled with an infrared dye and their use in nucleic acid detection
EP0640146B1 (en) Dna sequencing method
JP3013156B2 (en) Use of a DNA polymerase having 3'-specific proofreading activity
US5908926A (en) 5'to 3' nucleic acid synthesis using 3'-photoremovable protecting group
US5547839A (en) Sequencing of surface immobilized polymers utilizing microflourescence detection
WO2008037568A2 (en) Reversible terminators for efficient sequencing by synthesis
KR20010099663A (en) A Method for Analyzing Polynucleotides
Rosenthal et al. Automated sequencing of fluorescently labelled DNA by chemical degradation
AU694940C (en) DNA sequencing by mass spectrometry
JPH04503460A (en) DNA sequencing
Caruthers Sequencing and Synthesis of Nucleic Acids
Narang The Total Synthesis
Lowe ACID REPEAT SEQUENCES BY $8 $8 2i DISCONTINUOUS PRIMER EXTENSION

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT NL

17P Request for examination filed

Effective date: 19910925

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940501